Dietary Habits and Participant-Led Adaptations to Diet for Pain Management in Fibromyalgia Sufferers: A Cross-Sectional Study

Simone Roberts

Submitted to the University of Hertfordshire in partial fulfillment of the requirements of the degree of MSc by Research September 2020

Acknowledgements

I would like to thank the following people for their support in undertaking this research degree. My supervisory team Dr Katerina Vafeiadou, Dr Rosalind Fallaize (RD) and Dr Simon Baines, whose patience and understanding have given me the confidence and skills to complete this project. Jane McClinchy (RD), who was the driving force behind my decision to start this endeavor and inspires dietitians to take part in research. regardless of where they are in their career. Lewis Harrison-Barker, for his endless support and encouragement. The wonderful people at Hertfordshire Independent Living Service, but particularly Sarah, Alethea (RD) and Katherine and my amazing team Phoebe (RD), Kolsum, Nicola, Dionne and Karen, who remind me that we are always looking to make a positive impact on people's lives. My scout family, Kayleigh, Amy, Peter, Jon, Jennie, Daisy, Robin, Lottie and Ollie for keeping me sane and reminding me that I all I have to do is my best. To the participants who took the time to complete the survey. I would like to acknowledge the contribution of the staff and participants of the EPIC-Norfolk Study. EPIC-Norfolk has been supported by the Medical Research Council programme grants (G9502233, G0401527, G1000143) and Cancer Research UK programme grants (SP2024/0201, SP2024/0204, C865/A2883, C864/A8257, C864/A14136).

Abstract

Fibromyalgia is a disorder characterised by chronic widespread pain that has been present for more than 3 months and can be elicited by palpitation of specific touch points. It is associated with a wide range of co-morbidities including chronic fatigue and gastrointestinal disorders. Although widely accepted by wider populations to have an impact on the condition, there is limited nutritional information and associated evidence to cater specifically for the disease with widespread anecdotal and non-professional websites providing sources for dietary change. The aim of the study is to investigate the association between dietary intake and quality on pain and symptoms, in individuals with fibromyalgia.

Method

A cross sectional study was conducted. We explored the association between pain and symptoms in fibromyalgia, (Revised Fibromyalgia Impact Questionnaire, FIQR; General Anxiety Disorder, GAD-7 and Patient Health Questionnaire, PHQ-9) and markers of metabolic health (anthropometry) against dietary intake (EPIC Food Frequency Questionnaire, FFQ), diet quality (Healthy Eating Index 2015, HEI-2015) and self-reported dietary changes.

Results

Participants were adults (n = 381) with fibromyalgia and were recruited using social media platforms including Facebook, Twitter and specific online fibromyalgia support groups. Higher pain and symptom scores (FIQR) were associated with higher BMI, higher energy intake and lower diet quality (p's <0.05). Participants with lower pain scores (FIQR <49) had significantly close adherence to dietary recommendations across 7 out of 11 components of diet quality (total fruit, whole fruits, dairy, protein, fatty acids, refined grains, saturated fats), iron intakes (p=0.18) and vitamin D (p<0.001), with significantly lower carbohydrate intake (P=0.019). No significant results were noted for other selected nutrients (Ca, Mg). Participants who report engaging with dietary modification presented with significantly lower for FIQR, BMI and energy intake (p's <0.05).

Conclusion

This study suggests a link between diet quality, dietary intakes and pain in fibromyalgia. Lower diet quality, greater BMI and higher energy intake was related to higher pain and symptoms whilst reported dietary modification resulted in lower pain and symptoms, alongside lower BMIs. Iron and vitamin D consumption were higher in participants with lower pain. Future research is needed to assess the impact of specific nutrients as well as whole dietary change on pain and symptoms in fibromyalgia via nutritional intervention studies for this patient group.

Ethics

The study has been approved by the Health, Science, Engineering & Technology ECDA, (protocol number LMS/PGR/UH/03765).

1 2	Table of Contents Tables and Figures							
2		Abbreviations						
4		Introduction						
5			e Review					
J	5.1		otoms and diagnosis					
	5.1		Previous and current criteria in the UK					
	5.1		Challenges in diagnosing fibromyalgia					
	5.2		es of fibromyalgia and co-morbidities					
	5.2	.1	Excess body weight	13				
	5.2	.2	Psychological disorders and depression	14				
	5.2		Environmental Triggers					
	5.2		Genetic Associations					
	5.2 5.2		Biochemical Associations					
	5.3		Neuro-inflammation					
	5.3		Pharmacological approaches					
	5.4		Pharmacologic Treatments					
	5.4		Physical Activity					
	5.4		Cognitive Behavioural Therapy (CBT)					
	5.4		Education					
	5.5	Role	of diet in fibromyalgia	22				
	5.6	Dieta	ry components associated with improvements in pain and symptom targets	23				
5.6.1 Hypocaloric		.1	Hypocaloric diets	23				
	5.6		Gluten free					
	5.6		Vegan and Vegetarian Diets					
	5.6		Low Carbohydrate/Ketogenic Diets					
	5.7		dual nutrients that impact pain and symptoms of fibromyalgia					
	5.7		Vitamin D					
	5.7 5.7		Magnesium Calcium					
	5.7		Iron					
	5.8							
6	Ain	Patient led dietary manipulations						
7	Ма	terials	s and Methods	30				
	7.1	Subje	ects	30				
	7.2	•	/ design					
	7.3	-	and symptom assessment					
	7.4		ry Assessment					
	7.5		Quality Score					
	7.6		ession and Anxiety					
		-	-					
	7.7		opometric measurements					
	7.8		ssment of self-reported dietary change					
~	7.9		stical analysis					
8								
	8.1	Partic	cipant characteristics	35				

	8.2	Association between fibromyalgia symptoms, BMI and energy intake	39
	8.3	Association between fibromyalgia symptoms and diet quality	40
	8.4	Association between fibromyalgia symptoms and nutrient intake	42
	8.5	Self-reported impact of dietary changes on fibromyalgia	44
9	Di	scussion	47
1	9.1	Implications for clinical practice	51
9	9.2	Strengths and Limitations	52
9	9.3	Conclusion	53
10	Fu	uture research and recommendations	53
11	Bi	bliography	54
12	Ap	opendix	73
	-		

2 Tables and Figures

Table 1: Anatomic location of tender points according to the American College of Rheumatology 1990 classification for fibromyalgia.
11 Table 2. Participant characteristics (n=381) and characteristics per gender for males
(n=50) and females (=331). 35 Table 2 Dertisinent cells reported prescriptions by drug elegoification
Table 3 Participant self-reported prescriptions by drug classification.37 Table 4. Association between pain and symptoms (FIQR score), BMI and self- reported
energy (kcal) intake
Table 5. Association between pain and symptoms (FIQR score) and HEI in individuals with fibromyalgia (n=381).
39 Table 6. % of participants meeting DRVs for nutrients (not selected) per dichotomous
groups, adjusted for gender and age
Table 7. Mean FIQR, energy and BMI scores and the change for the primary group(n=330) and subgroup with self-reported dietary change (n=51).44
Figure 1 . Selection of participants for study participation
Figure 2. Frequency of reported co-morbidities (n=279)
39 Figure 4. Association between pain and symptoms (FIQR score) and HEI score parameters.
41
Figure 5. Percentage of participants meeting recommended dietary reference values (DRVs) for selected nutrients, according to pain and symptoms (FIQR score), (n=381).
42 Figure 6. Impact of self-reported dietary changes on pain scores
 44 Figure 7. Participants self-reported media accessed to support dietary change 45

3 Abbreviations

AEA	Aerobic exercise
ANOVA	Analysis of variance
AWMF	Association of Medical Scientific Societies in Germany
BMI	Body mass index
Са	Calcium
CBT	Cognitive behavioural therapy
CD	Coeliac disease
CFS	Chronic Fatigue Syndrome
СНО	Carbohydrate
CNS	Central nervous system
CRP	C-reactive protein
DA	Dopamine
DRVs	Dietary Reference Values
EULAR	European League Against Rheumatism
Fe	Iron
FFQ	Food frequency questionnaire
FIQ	Fibromyalgia Impact Questionnaire
FIQR	Revised Fibromyalgia Impact Questionnaire
GABA	Gamma aminobutyric acid
GAD-7	Generalised Anxiety Disorder Assessment
HEI	Healthy Eating Index, 2015
HLA	Human leukocyte antigen (HLA)
HPA	Hypothalamic-Pituitary-Adrenal axis
IBS	Irritable bowel syndrome
ICD	International Classification of Diseases
IL- 2	Interleukin - 2
IL- 6	Interleukin - 6
IL- 8	Interleukin - 8
Kcal	Kilocalories
Kg	Kilogram

Μ	Metre
Mg	Magnesium
Na⁺	Sodium
NE	Norepinephrine
NICE	National Institute for Health and Care Excellence
NKLCD	Non-ketogenic, low CHO diet
NSAIDs	Non-steroidal anti-inflammatory drugs
PHQ-9	Patient Health Questionnaire (PHQ)-9
QOL	Quality of life
RCT	Randomised controlled trails
SACN	Scientific Advisory Committee on Nutrition
SNRI	Serotonin-norepinephrine reuptake Inhibitor.
SS	Symptom severity
SSRIs	Selective Serotonin Reuptake Inhibitor
TCAs	Tricyclic antidepressants
TeCAs	Tetracyclic antidepressants
TRP	Transient receptor potential
TSH	Thyroid Stimulating Hormone
TSPO	Translocator proteins
WHO	World Health Organisation
WPI	Widespread Pain Index
5-HT	Serotonin

4 Introduction

It is estimated that around 3 million people in the UK suffer from fibromyalgia syndrome (Jones et al., 2015) and world population rates are suggested to be around 3.98% in women and 2.40% in men (Heidari, Afshari & Moosazadeh, 2017). The disease is characterised by whole body pain, increased sensitivity and lethargy (Wolfe et al., 2010). Symptoms include sleep disturbances, irritable bowel syndrome, increased fatigue and altered or reduced mental processes; anxiety and depression (Rahman, Underwood & Carnes, 2014). Chronic and often widespread pain is the most reported symptom in fibromyalgia, however, there is a lack of visible physiological abnormalities and biochemical responses to explain these manifestations (Elmas et al., 2016). Hyperalgesia, where there is increased reaction to painful stimuli and allodynia, pain caused by normally nonpainful stimuli are common symptoms (Littlejohn & Guymer, 2018). Patients display enhanced sensitivity to external stimuli including thermal changes (Littlejohn & Guymer, 2018). This often leads to a lack of medical understanding and patients being offered limited or no medical support (Sluka & Clauw, 2016). Furthermore, measurement of pain is not objective as all tools available rely on the ability for the participant to self-report (Brian et al., 2019).

Fibromyalgia is more often reported by females than males to a ratio of 2:1, however this may be due to underreporting or a lack of medical diagnosis (Rahman et al., 2014). Social stigma relating to expectation of pain management and perception that the disease only effects females, may also contribute to limited health professional contact by men (Paulson, Danielson, & Söderberg, 2002; Miró, Martínez, Sánchez, Prados, & Lupiáñez, 2015). Diagnosis appears not to be affected by ethnicity, geographical location or economic status, suggesting that fibromyalgia is a global condition (McBeth & Jones, 2007).

In 2018, Silva et al., undertook a systematic review of dietary interventions specific to fibromyalgia and were only able to identify 7 unique studies. Despite improvements highlighted in 5 of these studies the knowledge base is too small to make any final conclusions or provide dietary advice. In lieu of condition specific guidance, population

level guidance can provide a starting point to good dietary practice. This guidance provided by government public health departments and SACN is the only evidence base currently available to support those with fibromyalgia. There is limited and often conflicting nutritional research to demonstrate the benefits of dietary intervention on pain and symptoms in fibromyalgia, despite interventions showing success in comparable conditions, lending itself to research opportunities.

5 Literature Review

5.1 Symptoms and diagnosis

5.1.1 Previous and current criteria in the UK

The disease originally recognised by medical professionals in 1990 was classified as widespread pain in combination with tenderness at 11 or more of 18 specified tender point sites, **Table 1** (Wolfe, et al, 1990). In 2010, Wolfe et al. proposed new criteria to diagnose fibromyalgia that assesses widespread pain, using a widespread pain index (WPI), alongside symptom severity (SS); diagnosis is confirmed by a WPI ≥7 AND SS \geq 5 or a WPI 3–6 AND SS \geq 9 lasting more than three months with no alternative medical explanations. The WPI measures all-over pain and tenderness on both sides of the body (Wolfe, 2003) with the SS scale considering fatigue, cognitive symptoms and waking unrefreshed. The new diagnostic criteria may be undertaken by nonprofessionals and is the current diagnostic tool used in the UK (Wolfe et al., 2010). The FIQR tool was created in 2005 and validated in 2009 as an update to the original tool (FIQ), published in 1991 (Burckhardt, Clark & Bennett, 1991) with the assistance of a focus group of women with fibromyalgia. Changes in the tool removed the VAS scoring system in favour of numeric ratings and included the addition of environmental, memory, balance and tenderness questions in response to updated research (WHO, 2001; Bennett, 2007; Mease et al., 2007; Jones et al., 2009)

Table 1: Anatomic location of tender points according to the American College of

 Rheumatology 1990 classification for fibromyalgia.

Anterior tender points	Posterior tender points
------------------------	-------------------------

Low Cervical: bilateral at C5-C7.	Occiput; bilateral at the suboccipital muscle insertions.
Second rib: bilateral at the second costochondral junctions.	Trapezius; bilateral at the midpoint of the upper border.
Great trochanter; bilateral posterior to the trochanteric prominence.	Supraspinatus; bilateral above the scapular spine near the medial border.
Knees; bilateral at the medial fat pad proximal to the joint line	Lateral epicondyle; bilateral, 2cm distal to the epicondyles.
	Gluteal; bilateral, upper outer quadrants of bittocks in anterior fold of the muscle

5.1.2 Challenges in diagnosing fibromyalgia

Complications in the diagnosis of fibromyalgia arise from the common symptoms it shares with other conditions and thus, diagnosis is often confirmed by exclusion of other complaints (Arnold, Clauw & McCarberg, 2011). For example, similar symptoms are seen in several rheumatic diseases such as: rheumatoid arthritis, ankylosing spondylitis, Lyme disease and lupus, however in contrast to fibromyalgia these conditions effect the joints and not the soft tissue (Elmas et al., 2016). Further comparisons are found between fibromyalgia and autoimmune disorders leading to hyper and hypothyroidism and inflammatory conditions such as polymyalgia and metabolic myopathies, myofascial pain syndromes and chronic fatigue syndrome (CFS) (Goldberg, Bradley, Arnold, Glass, & Clauw, 2005; Kaltsas G, & Tsiveriotis K., 2017). In a systematic review of 52 studies on fibromyalgia and 95 on CFS, Teodoro, Edwards and Isaacs (2018) conclude that the conditions share cognitive symptoms, particularly with attentional dysfunction but question if current research is sufficient to suggest they are standalone conditions. Patients currently use both pharmacological and non-pharmacological approaches to manage the symptoms of fibromyalgia (Macfarlane et al., 2016).

5.2 Causes of fibromyalgia and co-morbidities

There is currently no defined cause for the development of fibromyalgia (Furness et al., 2018) and the aetiology of the condition has been the subject of many debates amongst

professionals (Wolfe et al., 2019). Excess body weight, environmental triggers that lead to prolonged increases in stress levels, genetic considerations, biochemical dysfunctions and neural inflammation have all been attributed to disease development (Backryd, et al, 2017; Bennett et al., 2007) The disease is recognised as one that is challenging to diagnose (Wolfe & Walitt, 2013), often due to physician bias, social stigma leading to changes in patient behaviours and perception of the disease (Bidari, Parsa, Ghalehbaghi, 2018).

5.2.1 Excess body weight

There is evidence to suggest that excess body weight has a negative influence on pain levels in fibromyalgia, although there is no evidence to suggest that obesity is a cause for disease manifestation (Yunus, Arslan and Aldag, 2002). A study by Lerner et al., (2008) reported of 100 patients randomly selected from 550 fibromyalgia sufferers, 28% were overweight and 45% obese, significantly higher than population average of approximately 26% (House of Commons, 2018). An internet survey of 2596 fibromyalgia patients yielded similar results with 70% of respondents reporting a body mass index (BMI) > 25kg/m² and 43% a BMI > 30kg/m² (Bennett et al., 2007). Significant correlations between BMI, quality of life and tenderness thresholds were seen when undertaking health assessment questionnaires, directly associating BMI with symptoms (Neurmann et al., 2008). A negative correlation was experienced between BMI, pain threshold and quality of life (QOL) factors whilst a positive correlation between BMI, fatigue and pain (Yunus, Arslan, & Aldag, 2002).

Shapiro, Anderson, & Danoff-Burg, (2005) found significant improvements in symptoms, pain interference and QOL measures in patients undertaking a weight loss program. The reasons for this may be attributed to decreased energy requirements (Hall et al., 2012) and a reduced pressure on joints (Messier, Gutekunst, Davis & DeVita, 2005). A positive correlation between weight loss and improvements in depressive symptoms suggest reducing excess body weight may attribute to symptom improvements (Alhalel,

Schueller, O'Brien, 2018; Faulconbridge et al., 2009). A reduction in BMI may be the primary cause of pain management in this disease, beyond dietary modification (Timmerman, Calfa & Stuifbergen, 2013). The impact of participant BMI in studies is not always considered. Some research suggests this excess body weight limits the effectiveness of undertaking nutritional research (Fenton et al., 2016).

5.2.2 Psychological disorders and depression

Psychological disorders, particularly depression and anxiety are commonly seen in patients with fibromyalgia (Furness et al., 2018; Hawkins, 2013). Participants with fibromyalgia are 3.04 times more likely to suffer from depressive symptoms than those without the disease (Zamini, Alizadeh and Zamini, 2019). It has been suggested that fibromyalgia and depression may represent two manifestations of affective spectrum disorder, a group of psychiatric and medical conditions that share similar pathophysiology, pharmaceutical interventions, namely antidepressants and neurotransmission pathways (Gracely, Ceko & Bushnell, 2012). Depressive symptoms are frequently reported and significant numbers of individuals with fibromyalgia are diagnosed with a psychiatric comorbidity, including bipolar, major depressive disorders and anxiety (Morgan & Raper, 2005; Singh & Kaul, 2018, Steiner et al., 2017).

There is clear evidence linking chronic pain and depression (Sheng, Liu, Wang, Cui & Zhang, 2017), both sharing similar pathophysiology, and the World Health Organisation suggests that 75% of patients with depression in primary care, report symptoms of pain (Lepine & Briley, 2004). Co-existence of the diseases appears to increase overall symptom severity (Sheng, et al., 2017). A World Health organisation (WHO) study involving screening either random or consecutive patient samples for depression, in 14 countries over a 1-year period from May 1991, found that of 1146 patients that met the criteria for major depression only 69% presented with symptoms, suggesting potential under-reporting of the condition (Simon, et al., 1999). Common underlying molecular mechanisms across conditions include dysfunctions of monoamine neurotransmitters, including serotonin (5-HT), dopamine (DA), and norepinephrine (NE), indicating why tricyclics like Amitriptyline, that inhibit 5-HT and NE reuptake, may work across

conditions (Kremer, Salvat, Muller, Yalcin & Barrot, 2016). Sensory pathways in brain regions involved in pain modulation, including the hippocampus, amygdala and prefrontal cortex are also involved in mood management (Meerwijk, Ford & Weiss, 2013). Although there are some suggestions that chronic pain and depression are linked on a biochemical level, limited efficacy of current treatments means more exploration into non-pharmaceutical approaches including nutrition-based therapy are required to treat pain symptoms (Brian et al., 2018).

5.2.3 Environmental Triggers

Environmental triggers may be involved in the pathophysiology of fibromyalgia. These triggers include mechanical or physical trauma and psychosocial stressors (Clauw, 2014). Patients report the onset of fibromyalgia following a bereavement or other traumatic experience, accident resulting in injury and even childbirth (Furness et al, 2018). An internet questionnaire undertaken by Bennett, et al., (2007) of 2596 fibromyalgia suffers found that 73% attributed the onset of the disease to emotional trauma or chronic stress (41.9%). Acute illness (26.7%) or physical injury, including surgery were also reasons strongly attributed to disease development. A further 20.6% of responses cited emotional and/or physical abuse, childhood sexual abuse or the menopause. 98.4% of respondents had a formal diagnosis from a medical professional. A potential neuro-endocrine link between stress and fibromyalgia involving the Hypothalamic-Pituitary-Adrenal (HPA) axis disturbances and deranged cortisol levels, is attributed to early life stressors (Harris et al., 2005), however these disturbances are only reported within one hour of waking, leading to suggestions further research is required to understand this mechanism.

5.2.4 Genetic Associations

There is a strong familial aggregation in fibromyalgia sufferers suggesting that a genetic element may be involved in the development of the disease (Arnold et al., 2004). Furthermore, mood disorders, such as major depressive disorder and bipolar, may share the same genetic influence (Broad et al., 2009). Lower back pain, frequently seen in fibromyalgia and chronic widespread pain share common genetic factors and are associated with increased BMI (Malkin et al., 2014). Arnold et al., (2013) used suggestive wide genome linkage of fibromyalgia to the chromosome 17p11.2-q11.2 region. This region coincides with transient receptor potential TRP vanilloid 2, (TRPV2) gene. Transient receptor potential channels are a group of unique ion channels that serve as cellular sensors for a wide array of physical and chemical stimuli (Ramsey, Delling & Clapham, 2006). The TRP family, including TRPV1, TRPV4, and the ankyrin transmembrane protein TRPA1, are thought to contribute to pain by transmitting noxious thermal, mechanical and chemical sensitivities (Premkumar & Abooj, 2013) and more specifically pathological pain associated with inflammatory and neuropathic states. TRPV2 may play a role in mediating pain but its role in fibromyalgia is not currently understood (Broad et al., 2009).

5.2.5 Biochemical Associations

Biochemical systems in the body may mediate symptom intensity in patients with fibromyalgia, including dysfunctional neuronal signalling leading to nociceptive signalling and inflammation (Sluka & Clauw, 2016). Elevated levels of pro-inflammatory linterleukin-8 (IL-8) in cerebrospinal fluid can result in nociception-driven amplification of neural signaling, increasing pain hypersensitivity in the central nervous system (Backryd, Tanum & Lind et al., 2017; Kadetoff, Lampa, Westman, Andersson & Kosek, 2012; Wolfe, 1990). In turn this leads to increased nociceptive processing, creating somatic symptoms affecting mood, memory and fatigue (Sluka & Clauw, 2016). Further evidence to support this theory relates to allodynia and hyperalgesia, often experienced in fibromyalgia, alongside CNS mediated symptoms such as fatigue, memory and sleep disorders (Littlejohn & Guymer, 2018). Fundamental problems with sensory processing in the CNS result in pain amplification. Functional imaging studies report imbalances in both glutamate and GABA neurotransmitters levels, found in patients with fibromyalgia, that have a direct effect on the transmission of pain in these patients (Clauw, 2014; Harris & Clauw, 2012).

Biochemical alterations may lead to increased inflammation, however there is some dispute to its existence in fibromyalgia (Tanaka, Narazaki, & Kishimoto, 2014). Metyas,

Solyman and Arkfeld (2015), argue however that fibromyalgia patients should be split into subgroups which acknowledge those patients that have inflammation present but no other existing comorbidities. Alterations in pro-inflammatory cytokines have been detected in both serum and biopsies of patients. Ernberg et al., (2018) reported that baseline levels of interleukin – 2 (IL-2), responsible for white blood cell regulation; interleukin – 6 (IL-6), stimulation of acute phase responses; TNF- α , involved in systemic inflammation; CXCL10, chronic hepatitis C infection and eotaxin, produced in the lungs of asthmatics, were higher in FM than in healthy controls. IL-1 β responsible for the hostresponse and resistance to pathogens, was recorded in lower levels (Lopez-Castejon & Brough, 2011; Sprott Souzan Salemi et al., 2003; Tanaka, Narazaki, & Kishimoto, 2014). Serum inflammatory markers for interleukin-6 (IL-6) and C-reactive protein (CRP) are elevated in obese patients with fibromyalgia (Blüher et al., 2005). Evidence suggests that whilst inflammation is not currently considered a diagnostic criterium for fibromyalgia, further research should be undertaken to establish the role in the disease.

5.2.6 Neuro-inflammation

New evidence suggests that there is a link between neuroinflammation and the development of fibromyalgia. Albrechta et al., (2019) report neurochemical changes in patients with fibromyalgia when compared with healthy participants. These changes, mediated by activation of glial cells, were measured using PET radiopharmaceuticals binding to Translocator proteins (TSPO), a marker for inflammation. TSPO is overexpressed in activated glial cells and increased numbers were observed in patients with fibromyalgia when compared to healthy patients (Littlejohn & Guymer, 2018). More importantly, no discrimination was seen in TSPO elevation between brain regions suggesting a correspondence to the complex symptom patterns of fibromyalgia. A direct correlation was found between comparative levels of TSPO in the cingulate gyrus, an area of the brain associated with emotional processing and reported levels of chronic fatigue, further indicating an association between neuroinflammation and fibromyalgia symptoms (Backryd, et al., 2017). Yasui et al., (2019) observed microglial activation in the absence of peripheral nerve damage and inflammation in a stress induced

environment using an animal model of fibromyalgia. This suggests that microglial activation may play a role in the pain initiation in patients with chronic pain.

5.3 Symptom management

5.3.1 Pharmacological approaches

Current symptom management is primarily based on pharmaceutical interventions (Sugerman, 2014). Tricyclics (antidepressants) work to increase levels of norepinephrine and serotonin, where deficiencies in these neurotransmitters have been linked to depressive symptoms (Moret & Briley, 2011). These drugs block the action of acetylcholine, a regulator of neuronal activity throughout the peripheral and central nervous system, overexpression of which may lead both to increased depression symptoms and CNS sensitivity (Harmer, Duman & Cowan 2017, Higley & Piccioto, 2014). Gabapentinoids (ligands) act as selective blockers of calcium channels that contain the $\alpha 2\delta$ -1 (Sills, 2006), which contribute to neuropathic pain (Chen et al., 2018). Serotonin norepinephrine reuptake inhibitors (SNRIs) are indicated to manage depression, anxiety and chronic pain by inhibiting the reuptake of both serotonin and norepinephrine, implicated as principal mediators of endogenous analgesic mechanisms in the descending pain pathways (Lamont, Tranquilli & Grimm, 2000). Commonly, physicians prescribe, or patients purchase over the counter pain relievers like aspirin and ibuprofen both indicated to manage pain (Sugerman, 2014). Although some medication may have multiple applications, patients often find that they require multiple prescriptions to manage the various elements of their own condition (Kwiatek, 2017). Patients often report negative side effects to medication, commonly citing weight gain (Domecq et al, 2015).

Amitriptyline, more commonly used to treat symptoms of depression, is the first line treatment for fibromyalgia and is recommended in many guidelines including European League Against Rheumatism (EULAR) and the Association of Medical Scientific Societies in Germany (AWMF) however it is not currently licensed to treat neuropathic pain in the UK (Hauser et al., 2008; Kia & Choy, 2017; Macfarlane et al., 2016). Amitriptyline inhibits both serotonin and noradrenaline reuptake, suppressing the role of these neurotransmitters, in the modulation of neural activity and neuropsychological processes, that impacts endogenous pain inhibitory mechanisms (Lawson, 2017). However, studies are limited and there is potential that only a minority of patients have satisfactory symptom relief (25%) and significant numbers of patients experience adverse effects (64%), including weight gain (Arnold et al., 2013; Kwiatek, 2017; Moore, Derry, Aldington, Cole, & Wiffen, 2013). Patients often report weight gain as a major side effect of Amitriptyline with an average of 1.8kg increase (Domecq et al., 2015). One explanation may be as a result of the influence of Amitriptyline on leptin resistance, causing an increase in serum leptin levels that increase susceptibility to weight gain (Fleisch et al., 2007).

Milnacipran, is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), originally developed for the treatment of depression and licensed to treat fibromyalgia in some countries including the USA (Cording, Derry, Phillips, Moore & Wiffen, 2015). Milnacipran appears to resolve the issue of weight gain and may promote weight loss. Serotonin and norepinephrine reuptake inhibitors (SNRIs) are effective in the treatment of depression and their use in fibromyalgia is currently a focus of research (Arnold, Palmer, Hufford, & Chen, 2012). Physical symptoms of pain are often characterised alongside major depressive disorder and anxiety disorders, therefore a link between the management of both diseases may be implicated (Marks et al., 2009). Animal studies indicate that noradrenaline plays an important role in the inhibition of neuropathic pain, through the α_2 -adrenergic receptors in the dorsal horn of the spinal cord and reuptake inhibition enhances analgesic effects, indicating effectiveness against allodynia and hyperalgesia associated with neuropathic pain (Kimura, Saito & Obata, 2012; Paquerin, Conkiln & Eisenach, 2003), suggesting the efficacy of antidepressants in treating neural pain, relies in the increase in noradrenaline in the spinal cord (Obata, 2017). SNRIs are also successful in treating depressive symptoms. A systemic review and meta-analysis by Cipriani et al., (2018) reports off 522 clinical trials all 21 antidepressants identified were more effective than placebo.

Pharmacological therapies are often insufficient and ineffective in combating pain in fibromyalgia (Domecq et al., 2015). A multi-disciplinary approach involving medications alongside non-pharmacological interventions is suggested by the European League Against Rheumatism (EULAR), due to the polysymptomatic nature of the condition (Carville, et al., 2008). Nutrition is an important alternative approach and when used in combination with medications has shown some success in alleviating symptoms and in some cases resulted in the total removal of all pharmaceuticals (Senna et al., 2012).

5.4 Non-Pharmacologic Treatments

A lack of success with conventional treatments has grown the need for alternative and complementary measures to target fibromyalgia symptoms (Abeles, Solitar, Pillinger & Abeles, 2008). Physical activity levels, cognitive behavioural therapy, alternative medicines, patients and clinician education all appear to have an influence on pain, depression and other symptoms.

5.4.1 Physical Activity

Exercise and strengthening activities in fibromyalgia are used as a form of therapy to relieve symptoms (Hauser et al., 2010). In comparison to no exercise, improvements in wellbeing, tender point reactions to pain stimulation and pain are reported, however the effects on fatigue and stiffness are unknown, in aerobic exercise (AE) (Busch, Barber, Overend, Peloso & Schachter, 2007). Strength training has shown a greater effect on pain reduction and overall wellbeing, but evidence is of low quality, due to limited reported details, preventing further evaluation (Busch, Schachter, Peloso & Bombardier, 2002). Hauser et al., (2010) compared 28 randomised controlled trails (RCTs) for AE against controls and seven RCTs comparing different methods of AE. Positive results were seen in pain, fatigue, depressive symptoms and QOL measures and post treatment pain was reduced with both land and pool-based exercise. Jones & Lipton (2009) found similar conclusions for yoga, tai chi and other movement-based exercise. A Cochrane review in 2017 by Geneen et al., concluded that whilst some evidence is available to support the use of exercise as a method of chronic pain relief, studies are of poor quality due to limited participant numbers (<50) and results were not conclusive,

possibly due to the mix of activities undertaken. Therefore, it is unclear if physical exercise is of benefit to all patients with fibromyalgia.

5.4.2 Cognitive Behavioural Therapy (CBT)

Stress is symptom of fibromyalgia and increased levels of stress may correlate with increased pain levels (Bennet et al., 2007). Some evidence suggests that stress is a primary factor in the onset of the syndrome (Furness et al, 2018). CBT therapy, a type of talking therapy that supports individuals to change how they think and behave, may provide coping strategies to manage stress levels and therefore reduce overall pain symptoms but is more effective for female patients due to increased ability to empathise (Lim et al., 2018). Furthermore, no limitations have been seen in CBT delivered via electronic communication (Webb, Joseph, Yardley & Mitchie, 2010), opening up possible treatments for fibromyalgia suffers who are limited with physical movement (Geneen et al, 2017). A multi-disciplinary, patient centred approached has shown success in reducing overall pain levels in sufferers, suggesting that cognitive, behavioural therapies may be effective in the treatment of fibromyalgia pain (Bourgault et al., 2015).

5.4.3 Education

Education both for patients and medical professionals has shown improvements in management of fibromyalgia symptoms (Micheaslon et al., 2005; Musekamp, Gerlich, Ehlebracht-König, Faller, & Reusch 2016). Annemarns et el., (2008) reported that disease diagnosis alone, and the tools provided to manage the condition, resulted in improved symptom management for patients, reducing anxiety by the absence of a lifethreatening condition. Moseley and Butler, (2015) suggest educating medical professionals is key to supporting pain management. Inaccurate diagnosis of fibromyalgia is in part due to a dissimilarity between current International Classification of Diseases (ICD) and criteria-based diagnoses of fibromyalgia (Wolfe et al. 2019). Clinician bias, understanding and the validity of diagnosis are key contributors that prevent disease diagnosis and denial of correct treatment methods (Micheaslon et al., 2005). Clinician education programs aim to use biological understanding of pain to

devise new treatments for pain management (Moseley & Butler, 2015). A focus on the biopsychosocial nature of chronic pain has highlighted the importance of treating psychological implications, where no physical manifestations may be present (Rafaelli & Arnaudo, 2017).

5.5 Role of diet in fibromyalgia

Nutrition plays a key role in health and dietary modification and has been a factor in managing many chronic diseases like obesity, type 2 diabetes and stroke (Schluze, Matinez-Gonzalez, Fung, Lichtestein & Forouhi, 2018). Nutritional studies that quantify the effect of dietary factors on health outcomes may influence dietary guidelines or create change in public health policy (Schoenfeld & John, 2013). The World Health Organisation (WHO, 2004) support the use of diet as a factor in the prevention of noncommunicable disease. Although some studies look at individual micronutrients (Skerrett & Willett, 2010), a methodical approach to dietary patterns suggest that a focus on diet has a wider impact on disease than a single nutrient (Schulze & Hoffman, 2006). Food patterns, the frequency food and drink items are consumed and the portions, diversity, or combination of different foods and drinks in an individuals' diet may give a wider understanding of the effects of nutrition (Leech, Worsley, Timperio & McNaughton, 2015). Modifications, additions and exclusions of macronutrients (proteins, fats and carbohydrates); micronutrients (vitamins and minerals) and combinations of changes can all have an implication on health outcomes in disease (Silva et al., 2012).

There are no current guidelines that support the use of nutritional intervention in fibromyalgia management, despite significant results seen both for pain management and quality of life scores (Holton et al., 2012; Silver & Gebler, 2016). Brian et al., 2019 undertook a meta-analysis of twenty-three intervention studies, that included a nutritional strategy to reduce pain. Participants included adults (>18 years old) who had a history of chronic pain. The authors concluded that nutritional interventions, including vegan and vegetarian diets, exclusion of gluten, low fat and fasting therapy, can be

effective for chronic pain; however, the evidence is limited, varied and in some cases difficult to implement (Brain et al., 2019). Participant adherence to dietary manipulation may be varied and impacted by dietary choice such as food type and quantity or socioeconomic factors such as time, cost and societal demands, often limiting the value of research (Irwin, Desbrow, Khalesi & McCartney, 2019). This is further confounded by the vast array of comorbidities associated with the disease including gastrointestinal, psychological and reproductive complaints (Kaltsas & Tsiveriotis, 2017). Each of these additional concerns often has its own nutritional guidelines which contrast with each other, often leading to further confusion for suffers.

5.6 Dietary components associated with improvements in pain and symptom targets

5.6.1 Hypocaloric diets

Weight reduction influences improvements in pain, sleep quality and depression symptoms of fibromyalgia (Senna, Sallam, Ashour & Elaman, 2012) suggesting a hypocaloric weight loss plan could lead to potential improvements in symptoms for obese patients, including QOL, depression, sleep quality and tender point count (Senna, et al., 2012). Weight loss was linked to lower levels of interleukin-6 and CRP, both implicated in inflammation and an increase in the anti-inflammatory cytokine Interleukin10 (Schrepf et al., 2017). A 12-week calorie restricted diet (800kcal/day) led to 30% symptom improvement where <10% weight loss was seen in patients with a mean BMI of 40kg/m² (Michealsen, et al, 2013). Weight loss in obese patients has further implications in general health and the management of several potential co-morbidities (Timmerman, Calfa & Stuifbergen, 2014).

5.6.2 Gluten free

Gluten free diets involve the removal of dietary wheat, rye, barley and oats (Lewis, Haridy & Newnham, 2017) and is regularly prescribed for patients with coeliac disease (CD). Non-coeliac gluten sensitivity has been identified in patients with fibromyalgia, without a diagnosis of CD (Sapone et al., 2012). Approximately half of patients with gluten sensitivity carry the human leukocyte antigen (HLA) DQ2 or DQ8 heterodimers, in comparison to almost all CD patients (Fry, Seah, McMimm & Hoffbrand 2011).

Symptoms similar to those found in fibromyalgia include chronic fatigue, 'foggy mind', muscle cramps, and joint pain (Troncone & Jabri, 2011). Isasi et al, (2014) found improvements in 22 female patients with fibromyalgia without CD, undertaking a gluten free diet, 15 reporting full remission from all symptoms alongside improvements in depression, gastrointestinal symptoms and fatigue. Furthermore, Isasi et al., (2014) found the presence of intraepithelial lymphocytosis in participants with fibromyalgia but without CD. Intraepithelial lymphocytosis, an increased number of intra-epithelial lymphocytes, a recognised finding in latent coeliac disease (Fry, et al., 2011; Rodrigo et al., 2013), suggests that a gluten free diet may have some benefits in the control of fibromyalgia symptoms in some patients.

5.6.3 Vegan and Vegetarian Diets

A vegetarian diet involves excluding animal meat products from an individual's diets, and a vegan diet is the complete exclusion of all animal products including by-products such as honey and dairy (Satija et al., 2017). Kaartinen et al., (2000) explored the effects of a vegan diet on 18 fibromyalgia patients, over three months, against a control group of 15 patients. Improvements were seen in pain levels, joint stiffness and sleep quality, however as a reduction in BMI was also seen, there is a lack of clarity to the actual cause of symptomatic improvement (Shapiro, Anderson & Danoff-Berg, 2005). Azad et al., (2000) concluded that despite a decrease in overall pain scores seen in patients with fibromyalgia undertaking a vegetarian diet, the resulting improvement was less than the use of Amitriptyline, and no other symptomatic improvement was seen, therefore suggesting this diet is of low value to alleviate symptoms. The quality of foods consumed as part of a plant-based diet may vary, refined grains and sugar sweetened beverages may impact on obesity levels known to cause increased pain in the disease (Satija et al., 2017), therefore the quality of a vegetarian or vegan diet should be considered when supporting this intervention.

5.6.4 Low Carbohydrate/Ketogenic Diets

Ketogenic diets, primarily consisting of high fat, moderate levels of protein and a very low carbohydrate intake, have been used as an anti-convulsant therapy for seizures, which share physiological symptoms of neuronal excitability with pain (D'Andrea, Romão, Pires do Prado, Krüger, Pires, & da Conceição, 2019). Macronutrient's components of this particular diet are approximately split as >70% fat, and <50g/d carbohydrates, with protein making up the remainder (Ludwig, 2020). Low CHO diets, <10% of total calorie intake, result in a reduction of reactive oxygen species in the brain, seen in rodent models, resulting in a reduction in inflammation (Kim, 2012). With the suggested implication of neuroinflammation effecting fibromyalgia, these changes may result in improved symptoms for patients. A comparative study of 33 women with fibromyalgia following either a western style diet (control group), or a non-ketogenic, low CHO diet (NKLCD) found a positive effect on energy levels and fibromyalgia symptoms in the NKLCD group (Ernst & Shelley-Tremblay, 2013). The level of adherence to the NKLCD was considered but the levels of macronutrient intake was set by the participants and therefore unregulated, so there are several limitations to the authors conclusions. A more robust study would be needed to conclude the benefits of this intervention.

5.7 Individual nutrients that impact pain and symptoms of fibromyalgia

5.7.1 Vitamin D

Vitamin D deficiency is prevalent amongst worldwide populations and estimates suggest that almost 50% of people are affected (Nair & Maseeh, 2012). Vitamin D₃ is produced in the skin from exposure to ultra-violet radiation, emitted from sunshine and dietary sources of Vitamin D₃ include oily fish such as salmon, mackerel and tuna (SACN, 2016). Vitamin D deficiency may result in abnormal absorption of dietary calcium and phosphorus, affecting bone metabolism and density (SACN, 2016). Vitamin D also plays a role in immune system regulation, as an active co-factor in multiple sclerosis, type 1 DM, IBS and rheumatoid arthritis (Plotnikoff, & Quigley, 2003; Atherton et al, 2009). Olama et al. (2013) and Okyay et al., (2016) linked vitamin D deficiency with increased pain scores (measured using the VAS scale), and depression scores in premenopausal

women with fibromyalgia. Furthermore, Okyay et al., (2016) and Altindag et al., (2014) report a correlation between lower QOL scores and decreased vitamin D levels using FIQR. A randomized control trial comparing Vitamin D supplementation (150,000 IU vitamin D₃, oral) with placebo, over 6 weeks, found significant reductions in pain in the treatment group, an effect that was magnified over the treatment period (Schreuder, Bernsen & van der Woulden, 2012). This suggests that vitamin D deficiency may play a role in several symptomatic controls for the disease.

5.7.2 Magnesium

Magnesium (Mg) plays a role in enzymatic reactions and intracellular physiological functions (Grases et al., 2006). Deficiency in Mg may lead to disorders of the neuromuscular, cardiac or nervous system (Jahnen-Dechent & Ketteler, 2012). Green vegetables, nuts, seeds, and unprocessed cereals are rich sources of magnesium (Costello, Wallace & Rosanoff, 2016). Common side effects of hypomagnesemia include muscle weakness, cramps and increased sensitivity of the nervous system (Grober, Schmidt, & Kister, 2015). Magnesium deficiency plays a role in psychiatric symptoms, including depression, although the action of magnesium is not currently understood, it is hypothesised that magnesium effects oxidation reduction and ionic regulation in the brain, leading to a reduction in depressive symptoms (Serefko et al., 2013; Eby, Eby & Murk, 2011). Furthermore, acute stress leads to excretion of Mg through activation of the HPA axis (Grases et al., 2006). Kasim (2017) found significantly lower serum levels in five Iragi women with fibromyalgia, and Engen et al., (2015) found improvements in scores on the Fibromyalgia Impact Questionnaire on a four-week feasibility study with transdermal magnesium spray. However, a cross sectional study by Sakarya, et al. (2011), found no significant differences in serum Mg levels between patients with fibromyalgia and healthy controls. RCTs exploring the impact of magnesium on patients with fibromyalgia are limited, with participant numbers less than 100 (Joustra et al., 2017). Larger studies may support a better understanding of the impact magnesium has on the disease.

5.7.3 Calcium

Calcium and magnesium have closely related metabolic properties (King, 2009). Like magnesium, calcium has been connected with symptoms and pain in fibromyalgia (Andretta, et al 2019). Kim et al., (2011) compared the hair minerals of females with fibromyalgia with a control group and found significantly lower levels of calcium, as well as magnesium and iron. However, Andretta et al., (2019) reported no difference in serum calcium levels between participants with fibromyalgia and their control group but did highlight substantially lower intakes of dietary calcium. However, this calcium intake was positively correlated to pain threshold, suggesting that lower dietary intakes of calcium may impact on pain in the disease. A review and meta-analysis by Joustra et al. (2017), identified 1 RCT for fibromyalgia and calcium intake, however the study quality was ranked as poor and no clinical improvements were seen with supplementations, suggesting further, more robust RCTs may be required.

5.7.4 Iron

There is a suggested association between ferritin levels and the prevalence of fibromyalgia (Ortancil, et al, 2010). Furthermore, fibromyalgia has been shown to be more prevalent in individuals with iron deficiency anemia (Pamuk et al, 2008). Animal models have linked iron-deficiency with a reduction in pain threshold and increases in pain sensation (Dowling et al., 2009). Additionally, iron deficiency, without the presence of anemia has been linked with weakness, fatigue and difficulty concentrating, pathophysiology seen in fibromyalgia (Soppi, 2018). A double blinded, randomized control trial in 2017 by Boomershine, Kocj and Morris found improvements in fibromyalgia symptom severity in comparison to placebo when supplementing with ferric carboymaltose at 15 mg/kg, over a period of 42 days, suggesting iron may play a role in disease severity.

Despite specific study examples both epidemiological and RCTs, a meta-analysis, of 5 RCTs and 40 observational studies by Joustra et al., (2017), reported no evidence to support the hypothesis that deficiencies in vitamins and minerals play a role in the

pathophysiology of fibromyalgia, so further research is required to understand the role both in the disease and as a part of wider dietary intake.

5.8 Patient led dietary manipulations

Disordered eating patterns alongside gastrointestinal dysfunction are more common in patients with fibromyalgia than healthy adults (Silva et al., 2012; Slim, Calandre & Viladermros, 2015). Patients are often influenced by information found via online sources, often non-scientific in basis, often due to a lack of sources from medical professionals (Arrenz, Canela & Rafecas, 2010). Imbalances in nutritional status are reported amongst patient groups (Rossi et al, 2015). A plethora of research suggests benefits of following nutrition-based interventions for symptomatic improvement in both fibromyalgia and gastrointestinal dysfunction (Silva et al., 2012). However, dietary changes which are mediated by negative symptomatic reactions to specific food groups, often lead to exclusion of dietary components. These changes are rarely undertaken on the basis of evidence-based practice or professional advice but more commonly on the advice of other individuals with the disease (Arrenz, Canela & Rafecas, 2012; Bennet, 2007; Lopez-Rodriguez, Molina, Medina, Sola & Muelle, 2015; Morris, Bowen & Morris, 2005). The sources accessed to guide these dietary changes are often unclear.

Self-medication is commonly seen in fibromyalgia. A study by Wahner-Roedler et al., (2005), reported 98% of outpatients attending a fibromyalgia clinic had used alternative therapy, not prescribed by a medical professional, including dietary therapy, physical relaxation techniques and exercise. A Facebook group poll by Bowden (2019), in the UK Fibromyalgia Private group resulted in 419 responses with 18 nutritional triggers for fibromyalgia (appendix B). Of these 15.27% suggested aspartame was responsible for making their symptoms worse, 13.37% suggesting refined carbohydrates, understood as; white flour, white bread, white rice, pastries and biscuits and 11.22% suggesting alcohol is the cause. There was no indication of the number of participants to this poll, however the number of potential causes does indicate that suffers of fibromyalgia

themselves have a wide range of concerns with nutritional intake and limited advice to follow.

Despite continued research there is still confusion in both the diagnosis and treatment of fibromyalgia (Bidari, Parsa, Ghalehbaghi, 2018). Patients often suffer with a range of symptoms and co-morbidities meaning treatment must be multi-model and flexible to changes in disease state (Wolfe et al., 2019). A lack of change in pain levels means patients offer see no improvements in quality-of-life markers (Micheaslon et al., 2005). Lack of patient satisfaction in medical led treatments results in the growth of anecdotal evidence (Mazanderani, Locock & Powell, 2012). Non-pharmaceutical treatments based on nutrition have been found to show some improvements, but the range of suggestions leads to continued confusion for patients (Shao et al, 2017). Furthermore, these interventions lack sufficient evidence from randomized controlled trials to establish efficacy (De Silva, El-Metwally, Ernst, Lewith & Macfarlane, 2010). Understanding the role patient led changes in diet has on pain levels in conjunction with food frequency may lead to better understanding and more patient led treatments for fibromyalgia.

6 Aims and objectives

The effect of diet on fibromyalgia symptoms is not widely researched but a frequent topic discussed in social media groups. This guidance is often unregulated, and, in some cases, dietary restrictions may result in negative health outcomes. This project aims to explore the association between dietary choices, including food and nutrient types, quantity and quality, and pain and symptoms in individuals with fibromyalgia. This research will use a series of validated tools to investigate the relationship between reported dietary intake, dietary quality, anthropometric measurements and specific nutrients on pain and symptoms for individuals with fibromyalgia.

The specific objectives are:

1. Elucidate the link between diet quality and fibromyalgia symptoms.

- 2. Investigate the association between nutrient intake and fibromyalgia symptoms.
- 3. Explore any self-reported impact of dietary changes on fibromyalgia.

7 Materials and Methods

This cross-sectional study used an online survey to assess the impact of diet on fibromyalgia symptoms in adults (aged > 18 years) with fibromyalgia. The study protocol was approved by the Health, Science, Engineering & Technology ECDA, at the University of Hertfordshire (protocol number LMS/PGR/UH/03765).

7.1 Subjects

Participants were recruited via social media platforms including Facebook, Instagram and Twitter between March and October 2019. Four international fibromyalgia support groups were identified on Facebook and members were invited to complete the study. All participants provided informed consent via the online survey platform (Qualtrics). Participants in the study were required to meet the following inclusion criteria: 1) Must be over the age of 18 years, 2) Must suffer from fibromyalgia (medical or self-diagnosis) which was assessed via a screening questionnaire.

7.2 Study design

The online survey was launched in March 2019 and ran for a period of 6 months. A link to the survey was included in the adverts posted on social media pages on Facebook, Twitter and specific support groups for fibromyalgia. Participants first completed consent, which assessed eligibility. Those undertaking the survey were asked to complete validated questionnaires for pain and symptom assessment, and dietary intake. Participants were also instructed to provide self-recorded height (m) and weight (kg). Further questions assessing comorbidities, including depression and anxiety, prescribed medication, dietary changes and dietary sources of information were also included. Participants who responded positively to having manipulated their dietary

intake in order manage fibromyalgia symptoms, were asked to provide details on these including where they obtained information to make these decisions.

7.3 Pain and symptom assessment

Pain and symptom assessment were undertaken using the validated Revised Fibromyalgia Impact Questionnaire (FIQR) (Bennett et al., 2009). The FIQR tool requires the respondent to report pain and symptoms over a previous seven-day period, via a Likert scale. The responses indicate the difficulty in completing specific activities over 3 domains that assess for physical limitations, pain levels and mental wellbeing. All questions are graded on a 0–10 numeric scale. The final score across the 21 questions ranges from 0 to 100, weighted 30% to function, 50% to symptoms and 20% to overall impact and provides a subjective response to the impact fibromyalgia has on an individual's lifestyle in the absence of objective validated tools.

7.4 Dietary Assessment

The, semi-quantitative, validated European Prospective Investigation into Cancer and Nutrition Norfolk Food Frequency Questionnaire (EPIC-Norfolk FFQ), version 6 (CAMB/PQ/6/1205) was used to estimate participants usual food intake during the previous year in two parts. Part one asked participants to indicate their usual rate of consumption for 130 foods or food types in nine frequencies: never or less than once a month, 1–3 times a month, once a week, 2–4 times a week, 5–6 times per week, once a day, 2–3 times per day, 4–5 times per day, and 6+ times per day. Part two included additional questions on brand and type of cereal, fat, milk, cooking methods and eating habits based on responses in part 1. These additional questions allow the software to calculate total fat and fatty acid consumption. Data were analysed using FETA (Φ εrα) to produce nutritional information at both macro and micronutrient level, for each participant (Mulligan et al., 2014). Participants were provided with instructions on how to complete the FFQ (Appendix B).

7.5 Diet Quality Score

Diet quality score was assessed from the completed FFQs. The Healthy Eating Index

(HEI) assesses an individual's dietary intake against suggested guidelines by the Dietary Guidelines for Americans (U.S. Department of Health and Human Services and U.S. Department of Agriculture, 2015). Each dietary group is provided with a minimum (0) or maximum (5 or 10) score based on cup equivalent and ounce equivalent portions and their positive or negative effects on health outcomes or adherence to recommendations. HEI categories in red are negatively associated to HEI score. Data is energy adjusted per 1000kcal intake or % energy.

Healthy Eating Index, 2015 (HEI, 2015) were calculated for each participant based on their FFQ. The HEI includes 13 component food groups, including (1) total fruit; (2) whole fruit; (3) total vegetables; (4) greens and beans; (5) whole grains; (6) dairy; (7) total protein foods; (8) seafood and plant proteins; and (9) fatty acids. The final four components should be consumed in moderation (10) refined grains; (11) sodium; (12) added sugars and (13) saturated fat and are therefore scored negatively. The range of points per component varies between 0-5 and 0-10 (fruit, vegetable and protein components, five points; remainder 10 points) and the 13 components are totalled to produce a total maximum score of 100 (Krebs-Smith et al., 2018). Fatty acid total in the HEI is calculated by the addition of polyunsaturated fats and monounsaturated fats divided by saturated fatty acids.

7.6 Depression and Anxiety

The Patient Health Questionnaire (PHQ) is a self-administered diagnostic instrument for common mental disorders, also used in primary care and a reliable and valid measure of depression severity (Kroenke, Spitzer, & Williams, 2001). The tool uses 4 response frequencies (Not at all; Several days; More than half the days and nearly every day) to measure a score out of 27 that rates levels of depression (Depression Severity: 0-4 none, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe). Scores above 4 are medically recognised as a depression diagnosis.

Generalized Anxiety Disorder 7 (GAD-7) is a self-reported questionnaire for screening and measuring severity of generalized anxiety disorder (GAD). GAD-7 is a series of seven questions to measure the severity of GAD according to reported response categories (Spitzer, Kroenke, Williams, & Löwe, 2006). It uses the same 4 frequencies as the PHQ-9 tool, with overall measures out of 21 (Anxiety Severity: 0-4 none, 5-9 mild, 10-14, moderate, 15-21 severe).

7.7 Anthropometric measurements

Self-reported anthropometric measurements weight (kg) and height (m) were used to calculate participants BMI. Participants were provided with instructions to complete these measures for reporting consistency.

7.8 Assessment of self-reported dietary change

Self-reported dietary change was assessed via multiple-choice questions to ascertain the type of diet change, impact on pain and evidence sources. They survey asked participants to report total pain out of 10 before dietary change and after. This allowed participants to identify individual nutrients or food groups and score them independently. Respondents were asked to indicate the ease at which these changes have been maintained via open-ended comments (appendix B).

7.9 Statistical analysis

Data are shown as means +/- SD. Outcome measures were normally distributed with outliers excluded for energy. Participants reporting a daily energy intake greater than 4500 kcal, which is considered implausibly high, were excluded from the analysis (Herbert et al., 2001). Gender-based differences in age, weight (kg), BMI (kg/m²), FIQR, PHQ-9 and GAD-7 were analysed using independent samples t-test. The association between pain and symptoms, and BMI and energy, were evaluated using 1) Pearson's Rank correlation coefficients and 2) ANOVA (with post-hoc Bonferroni tests) following the separation of participants into quintiles based on their FIQR score; models were adjusted for gender (where significant).

To assess the association between pain and symptoms, and diet quality and adherence to dietary reference values, participants were separated into dichotomous groups, representing low (<49) and high (>49) FIQR scores. Independent samples t-test was used to analyse HEI component scores. Chi-squared tests were used to assess dietary reference values and the participant adherence to nutrient intake targets. Previous research suggests that the nutrients magnesium (Mg), vitamin D, calcium (Ca), iron (Fe), sodium (Na+) and vitamin B12 have an association with the pain and symptoms of fibromyalgia (Altindag et al., 2014; Okyay et al., 2016; Andretta et al, 2019). Questions in domain 3 of the FIQR tool can independently score for energy levels and guality of sleep. We used these questions to additionally, investigate the association of Magnesium with fatigue measures, as evidence has suggested that low intakes of Mg may be associated with lethargy (Kirkland, Sarlo & Holton, 2018; Andretta et al., 2019). A one-way analysis of variance (ANOVA) was conducted to ascertain if there is an association between meeting dietary reference values for magnesium and increased scores for these criterium. Participants were divided into 3 groups based on their vitamin D intake (Group 1: <2ug, Group 2: 2-5ug, Group 3: >5ug). ANOVA was conducted to explore the impact of vitamin D consumption on FIQR score. Reported pain scores before and after specific food or food group modification were assessed using an independent samples t-test.

A p-value of <0.05 was considered statistically significant. Data were analysed using SPSS, version 25 (IBM Corp, 2017).

8 Results

8.1 Participant characteristics

In total, 414 participants registered for the study, 381 (92%) completed the survey in full (86.9% female). The majority of participants were UK residents (97.4%), (USA n=4: Egypt, Australia, Malaysia and New Zealand n=1) with a confirmed diagnosis of fibromyalgia from a medical professional (95.5%). Baseline characteristics of participants as a total group and per gender are shown in **Table 2** for age, weight, weight status (BMI), total FIQR, GAD-7 and PHQ-9 score.




Figure 1. Selection of participants for study participation.

The mean age and self-reported weight of male participants was significantly higher than females (p's<0.005). With regard to pain and symptom scores (FIQR), females reported 33% higher scores than males (p<0.001). There were no significant differences in BMI, depression or anxiety scores between males and females.

	AI particip		Male Mean		Female	9	¹ P value
	Mean	SD		SD	Mean	SD	
Age	44	13.65	48	11.73	43	13.84	.033
Weight kg	81.23	18.67	87.49	16.07	80.34	18.88	.011
BMI kg/m²	30.3	7.01	28.8	6.05	30.5	7.13	.121
Underweight (<18.49kg/m ^{2, %})	4.5		0.0		5.1		
Healthy Weight (<18.5-24.99kg/m ² , %)	19.2		24		18.4		
Overweight (<25- 29.99kg/m², %)	26		46		23.3		
Obese (<30-39.99kg/m², %)	42.3		24		45.0		
Morbidly obese (>40kg/m ² , %)	8		6.0		8.2		
FIQR	50.19	19.89	35.14	13.76	52.46	19.70	<.001
GAD-7	8.40	5.53	9.66	5.24	8.21	4.84	.052
PHQ-9	9.91	4.91	10.64	4.96	9.80	5.61	.316

Table 2. Participant characteristics (n=381) and characteristics per gender for males (n=50) and females (=331).

Data is presented as means +/-SD.

¹Data analysed using independent samples T-test

FIQR – Revised Fibromyalgia Impact Questionnaire

GAD-7 - General Anxiety Disorder Assessment

PHQ-9 – Patient Health Questionnaire

In total, 73% of participants reported additional co-morbidities alongside their fibromyalgia, with some reporting multiple conditions. The spread of self-reported comorbidities is presented in **Figure 2**. Each disease category is represented using a different colour, with specific conditions indicated by boxes. The larger boxes represent a larger reported sample. The majority of additional health concerns were reported as mental health (26.5%), gastrointestinal (16.8%) and muscular-skeletal symptoms (17.1%). Cancer, liver disease, hyperthyroidism and kidney disease appeared only once in the participant survey.




Figure 2. Frequency of reported co-morbidities (n=279).

Data are presented as sample numbers. Each coloured box represents a disease category, with specific medical conditions extrapolated. OCD -Obsessive Compulsive Disorder; CD - Crohn's Disease; CFS - Chronic Fatigue Syndrome; T2DM - Type 2 diabetes mellites; HIV - Human Immunodeficiency Virus; HT - Hyperthyroidism; HN – Hypertension; IBS – Irritable Bowel Syndrome **Table 3** describes the total number of prescriptions per drug classification reported by the participant group. In total, 61% (n=231) of participants reported medication prescribed specifically for the treatment of fibromyalgia. The majority (72.3%) reported a single prescription for fibromyalgia, with the remainder reporting multiple medications (maximum of 4). The most common prescription was antidepressants (72.4%) with others for pain management (26.3%), nutrition (1%) and non-classified medications (0.3%). Of the drug class antidepressants, the most prescribed were tricyclic antidepressants (TCAs, 43%), including amitriptyline (n=125) and Imipramine (n=1), and serotonin and norepinephrine reuptake inhibitors (SNRIs, 14%), including Duloxetine (n = 30), Milnacipran (n=12) and Paroxetine (7). Gabapentinoids (14%), including Pregabalin (n=30) and Gabapentin (n=11), and opiates (8.2%), including Tramadol (n= 18) and Codeine (n = 6), were the most commonly prescribed pain relievers. Nutritional supplements accounted for only 1% of all prescribed medication, which included Vitamin D (n=2) and Ferrous Sulphate (n = 1) for iron deficiency.

10	Bie 9 ranticipant sen repented prescriptions by	urug uu	3311041011.
	Drug Classification	Total	%
	TCAs	126	43
	SNRIs	45	15.4
	Gabapentinoids	41	14
	Opiates	24	8.2
	TeCAs	21	7.3
	SSRIs	20	6.8
	Glucocorticoids	6	2.0
	Supplements	3	1.0
	NSAIDs	3	1.0
	Analgesics	2	0.7
	Skeletal muscle relaxant	1	0.3
	Antihistamines	1	0.3

	Table 3 Partici	pant self-reported	prescriptions b	y drug classification.
--	-----------------	--------------------	-----------------	------------------------

TCAs – tricyclic antidepressants

SNRIs - Serotonin and norepinephrine reuptake inhibitors

SSRIs - Selective serotonin reuptake inhibitor

TeCAs - Tetracyclic antidepressants

NSAIDS – Non-steroidal anti inflammatory

8.2 Association between fibromyalgia symptoms, BMI and energy intake

The relationship between fibromyalgia symptoms, and BMI and energy were evaluated using Pearson product-moment correlation coefficient. There was a strong positive correlation between the variables BMI and FIQR, (r = .63, p < 0.001) and a small positive correlation between energy intake and FIQR (r = .28, p = < 0.001)

The results in **Table 4** show the mean BMI and energy intake (kcal) according to quintiles of FIQR score. A significant association was observed for both variables (P=<0.05) (**Table 3**). BMI was significantly higher in Q3, Q4 and Q5 than Q1. BMI scores for participants in Q4 and Q5 were significantly higher than all other quintile groups. A significantly higher energy intake was seen in Q3, Q4 and Q5 when compared with Q1 and Q2.

Table 4. Association between pain and symptoms (FIQR score), BMI and self-reported energy (kcal) intake.

	Q1 <31	(n=83)		32 - 44 = 70)	Q3 45 - 55 (n = Q4 56 - 69 (n=78) Q5 70+ (n=73)					+ (n=73)	P- value	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD		
BMI	25.3с-е	4.76	26.4d,e	4.73	28.9 a,d,e	6.11	33.8 a-c,e	5.44	37.7 a-d	5.65	<.001	
Energy intake (kcal)	1874 _{h-j}	776.11	1842h-j	627.38	2177 ^{f,g}	803.85	2221f,g	865.86	2415f,g	958.83	<.001	

Data is presented as means +/- SD. Data analysed using one-way analysis of variance, significant at P<.05. Post hoc analysis using Bonferroni. Data were split into quintiles.

BMI post-hoc analysis ^astatistical significance with Q1, ^bstatistical significance with Q2 ^c statistical significance with Q3, ^dstatistical significance with Q4, ^eStatistical significance with Q5 Energy intake post-hoc analysis ^fstatistical significance with Q1, ^gstatistical significance with Q2, ^hstatistical significance with Q3, ⁱstatistical significance with Q3, ^jstatistical significance with Q5

The impact of BMI on pain and symptoms (FIQR) was further explored by analysing the percentage of participants in each quintile group in relation to their BMI group. **Figure 3** shows the total number of participants in each BMI classification per FIQR quintile. Underweight participants were the majority in Q3 (35.3%) with a similar sample in Q1 (29.4%) and Q2 (23.5%). The majority (>80%) of individuals with a healthy BMI had low FIQR scores (Q1,59%; Q2,24.5%). Overweight participants reported FIQR scores predominantly in Q2 (37%), Q3 (27%) and Q1 (24%). However, 36% of obese participants (30-39.99kg/m²) reported FIQR scores between 56-69 (Q4) and 29.8%

above 70 (Q5), indicating higher pain and symptom scores. Similarly, morbidly obese participants (>40kg/m²) had scores predominantly in Q5 (63.3%).




Figure 3. Association between pain and symptoms (FIQR score) and participants BMI weight classification.

Data presented as participant numbers per BMI category. Underweight (<18.49kg/m²), Healthy Weight (<18.5-24.99kg/m²), Overweight (<25-29.99kg/m²), Obese (<30-39.99kg/m²), Morbidly obese (>40kg/m²). Data were separated into quintiles according to FIQR score.

8.3 Association between fibromyalgia symptoms and diet quality

The relationship between fibromyalgia symptoms and diet quality, assessing using the healthy eating index (HEI), were evaluated using Pearson product-moment correlation coefficient, with a small negative correlation observed between FIQR and total HEI score (r = -0.13, p=.0.002). The mean scores for the HEI and HEI components are shown in **Table 5**; participants were divided into dichotomous groups based on the median FIQR score. **Figure 4** shows the percentage of total points received for each component score on a radar plot, with 100% indicating a perfect score.

	Total group (n = 381)	SD	Low FIQR (n=191)	SD	High FIQR (n=190)	SD	¹ P
HEI	49.43	9.89	49.95	10.07	48.90	9.70	.299
Total fruit ²	3.09	1.67	3.30	1.60	2.88	1.71	.014
Whole fruits ³	3.78	1.63	3.98	1.50	3.57	1.73	.016
Total Veg ⁴	3.36	1.49	3.48	1.44	3.23	1.54	.108
Green and beans ⁴	4.31	1.16	4.41	1.07	4.22	1.24	.119
Whole grains	6.41	4.25	6.65	4.16	6.17	4.34	.268
Dairy ⁵	1.33	1.24	1.52	1.38	1.13	1.04	.002
Protein ⁴	3.06	0.80	3.21	0.90	2.91	0.65	<.001
Seafood and plant proteins ^{4,6}	0.67	0.85	0.71	0.75	0.63	0.86	.370
Fatty Acids ⁷	1.07	2.51	1.50	2.98	0.63	1.84	.001
Refined Grains ⁸	4.20	4.57	4.72	4.64	3.68	4.46	.025
Sodium ⁸	5.59	2.78	5.66	2.89	5.52	2.65	.612
Added sugars ⁸	9.33	1.77	9.49	1.57	9.17	1.94	.082
Saturated fats ⁸	3.24	2.97	3.65	3.05	2.84	2.83	.007

Date is presented as means +/-SD.

¹Data analysed using independent samples t-test, significant at P < .05.

Data were dichotomised according to median FIQR score, 49. Data is energy adjusted per 1000kcal intake or % energy. Intakes between the minimum and maximum standards are scored proportionately.

²Includes 100% fruit juice.

³Includes all forms except juice.

4Includes legumes (beans and peas).

⁵Includes all milk products, such as fluid milk, yogurt, and cheese, and fortified soy beverages.

⁶Includes seafood; nuts, seeds, soy products (other than beverages), and legumes (beans and peas).

⁷ Ratio of poly- and mono-unsaturated fatty acids (PUFAs and MUFAs) to saturated fatty acids (SFAs).

⁸ Moderation components, **higher** scores reflect **lower** intakes

The Healthy Eating Index (HEI) assesses an individual's dietary intake against suggested guidelines by the

Dietary Guidelines for Americans (U.S. Department of Health and Human Services and U.S. Department of Agriculture, 2015). Each dietary group is provided with a minimum (0) or maximum (5 or 10) score based on cup equivalent and ounce equivalent portions and their positive or negative effects on health outcomes or adherence to recommendations. HEI categories in blue are negatively associated to HEI score.

An independent t-test was undertaken to evaluate the difference in HEI scores according to dichotomous FIQR groups. Participants with lower pain scores (FIQR <49) scored significantly higher across 7 out of 11 components (**Table 5**). Whilst there was no significant difference in overall HEI, participants with lower FIQR scores had significantly higher intakes of total fruits (p=0.014), whole fruits (P=0.016), dairy (P=0.002), protein (P<0.001) and fatty acids (P=0.001). Similarly, significantly lower intakes of the moderation components refined grains (P=0.025) and saturated fats (p=0.007) were seen in participants reporting lower fibromyalgia symptoms, when compared with those reporting higher levels of pain.




Figure 4. Association between pain and symptoms (FIQR score) and HEI score parameters.

Radar plot showing HEI-2015 scores for low FIQR scores (n=191) and high FIQR scores (n=190). The outer wheel represents the maximum adherence to dietary guidelines (100%) for each component, whilst the center of the circle represents the minimum score (0%). The majority of components represent higher scores with higher consumption, whereas moderation components; saturated fat, sodium, added sugars and refined grains are inversely scored (higher scores = lower consumption). Differences in HEI-2015 components were analysed using independent samples t-tests. P values transposed from table 5.

8.4 Association between fibromyalgia symptoms and nutrient intake

Figure 5 represents the percentage of participants meeting their dietary reference values (DRVs) for selected micronutrients, in relation to their dichotomous FIQR group.

A significantly higher number of participants with high FIQR scores met their dietary reference values for iron intake than those participants with lower scores (P=.018). However, no significant results were noted for calcium, B12, Mg or Na+ intake between these groups. No significance was seen for energy scores or rested scores between participants meeting and not meeting their DRVs for dietary magnesium.

There was a statistical difference between vitamin D groups (p<0.001). In total, 38.8% (n= 147) of participants reported a mean dietary intake of vitamin D between 2-5ug, with 14.2% (n=54) exceeding this. Between group means suggest significantly higher intakes of Vitamin D in group 2 (2-5ug Vitamin D/day) (3.22 ± 0.78 SD) than group 1 (<2ug vitamin D/day) (M=1.42 ± 0.43 SD), however there was no statistically significant difference in mean Vitamin D intake between group 3 (>5ug Vitamin D/day) (M = 5.97 ± 0.82 SD) and the other groups.




Figure 5. Percentage of participants meeting recommended dietary reference values (DRVs) for selected nutrients, according to pain and symptoms (FIQR score), (n=381). Dietary reference values (DRVs) per gender and age group for adults (PHE, 2018). Data were analysed using chi squared test. Significance was only seen in iron intakes.

The data in **Table 6** describes macronutrients and micronutrients, with no previous clear link to fibromyalgia. The data displayed is for participants who are meeting DRVs for these nutrients, separated into dichotomous groups based on FIQR score. Participants with high pain and symptom scores (FIQR) were more likely to meet or exceed recommended dietary intakes for carbohydrates than those with lower scores (p= 0.019). No statistical significance was seen between groups for other recorded micro or macro nutrients.

Nutrient	v FIQR<49 (n=191)	FIQR = <u>></u> 49 (n=190)	P^1
Protein (g)	91.9	92.6	0.719
CHO (g)	20.9	32.1	0.019
Total fat (g)	51.8	44.2	0.166
Ascorbic Acid (mg)	94.8	96.3	0.628
Calcium (mg)	68.6	65.8	0.637
Chlorine (mg)	80.1	86.3	0.138
Cobalamin (mcg)	96.9	94.2	0.316
Copper (mg)	49.2	49.5	1
lodine (mcg)	31.4	37.9	0.222
Niacin (mg)	90.1	90.5	1
Phosphorus (mg)	100	100	1
Potassium (mg)	37.7	47.4	0.071
Pyridoxine (mg)	90.6	94.7	0.174
Retinol equivalents (mcg)	26.7	20.5	0.194
Riboflavin (mg)	84.3	86.3	0.680
Selenium (mcg)	40.3	46.8	0.237
Sodium	85.1	84.3	0.576
Thiamine (mg)	92.7	95.3	0.397
Total Folate (mcg)	71.2	76.8	0.255
Zinc (mg)	68.1	74.7	0.184
Vitamin B12	94.2	97.0	0.314

Table 6. percentage of participants meeting DRVs for nutrients (not selected) per
 dichotomous groups adjusted for gender and age.

¹Data analysed using chi-squared test.

Continuity correlation used for statistical significance, table size 2x2.

Self-reported impact of dietary changes on fibromyalgia 8.5

The results in Table 6 describe the mean and SD for FIQR, energy and BMI for participants who did not report dietary modification (primary dataset) and those who did self-report dietary modifications (sub-group). Significant differences were seen between the primary group and subgroup (self-reporting dietary change) in FIQR score, energy intake and BMI. There overall mean pain and symptom (FIQR) score was 9.24 points lower in this sub-group in comparison to those who did not report change (P<0.001). Furthermore, there was a significantly lower overall calorie intake (-441, P<0.001) and BMI (-4.04kg/m², P<0.001) in the self-reported dietary modification group compared to the primary group.

	Primary	(n=330)	Subgroup	o (n = 51)				
	Mean	SD	Mean S		Difference in mean	Р		
FIQR	51.6	19.78	42.33	18.84	-9.24	<.001		
Kcal	2198	868	1757	579	-441	<.001		
BMI	30.9	6.90	26.83	6.66	-4.04	<.001		


Table 7. Mean FIQR, energy and BMI scores and the change for the primary group (n=330) and subgroup with self-reported dietary change (n=51).


Samples analysed using independent samples t-test, significant at P<.05

Figure 6 represents the self-reported dietary changes undertaken to manage fibromyalgia by participants in the subgroup. The changes are categorised into whole dietary changes, dietary inclusions and exclusions, with the effect on pain score considered. 74% of subgroup participants self-reported a complete dietary change intended to manage their fibromyalgia symptoms; these included vegetarian diets (35%), including pescatarian and ovo-lacto vegetarians, ketogenic diet (18%), vegan diet (11%) or Hashimoto diet (10%). Carbohydrates were targeted (removed or reduced) by 43% of participants. The exclusion of alcohol and fish were also associated with the highest reductions in mean reported pain, (83.9% and 88.9% reduction respectively) whilst garlic and onion (44% reduction) and dairy (68.4% reduction) represented the lowest impact on pain levels pre- and post-dietary change.



Figure 6. Impact of self-reported dietary changes on pain scores. Indicated by whole diet change (green), foods removed (blue), foods added (orange). Larger font size indicates higher frequency of reported change (font scaled by 15 + 1 per variable). Darker colours indicate larger changes in pain scores. The types of media accessed to support dietary changes, specifically aimed to impact fibromyalgia are shown in **Figure 7**. The majority of responses (n=39, 76.5%) reported obtaining information from social media or websites with very few (n=5, 9.8%) accessing a professional for support.





9 Discussion

In the present cross-sectional study, in 381 adults, we observed that fibromyalgia sufferers with greater diet quality reported significantly lower pain and symptom scores (FIQR). Participants with lower FIQR scores (<49) scored significantly higher across 7 out of 11 HEI components including the moderation components, refined grains and saturated fat. We also observed higher BMI and overall energy intake in participants reporting greater pain severity, and the lowest symptom severity in those with a healthy weight. Higher energy intakes resulted in greater BMI and FIQR scores. Unique to this study is the employment of a whole diet approach to assessing diet quality through the use of the healthy eating index (HEI, 2015).

In addition to reporting lower intakes of sodium and added sugar and higher intakes of total vegetables and whole grains, fibromyalgia suffers with low FIQR scores reported significantly higher intakes of total and whole fruit, dairy, protein and fatty acids and significantly lower intakes of refined grains and saturated fat, and hence a higher adherence to healthy eating guidelines. Fruit and vegetable intake is widely recognised to support disease prevention, as well as promoting good mental health (Głąbska, Guzek, Groele & Gutkowska, 2020; Wallace et al., 2020) and higher intakes have been linked with pain reduction (Ferraz, et al., 2020). Some fruits, including berries and pomegranates have analgesic properties due to polyphenolic flavonoids and supplementation has shown positive effects on pain (Basu, Schell & Schofield, 2019; Ferraz, et al., 2020). Additionally, fruits and vegetables support bowel health as source of dietary fibre which may mediate IBS associated with fibromyalgia (EI-Salhy, Ystad, Mazzawi, & Gundersen, 2017; Yang et al., 2017). Saturated fat has been linked to cardiovascular disease, increased cholesterol and cognitive impairment (Briggs, Petersen & Kris-Etherton, 2017). Animal studies suggest high intakes of saturated fat may have negative impacts on pain (Tian et al., 2018) stimulating hyperalgesia, although no supporting human studies. No specific research into refined grains has been undertaken in fibromyalgia. Caution should be applied to nutritional studies in fibromyalgia as sample sizes are often small and adherence to dietary intervention is

rarely evaluated, resulting in potential bias (Pagliai et al. 2020). A whole dietary approach, whilst not without challenges may provide a better understanding of dietary impact on the disease.

The HEI allows us to collectively assess dietary adherence between groups to identify distinctions with some acknowledged exclusions, including sodium added post food preparation (Kirkpatrick et al., 2018). It is important to note that mean HEI for this group (49.5±9.89) falls within the range for similar studies. Low HEI scores, such as those seen in the Food4me obesity cohort (49.2±9.9)(Fallaize et al., 2018) have been associated with higher adiposity, total cholesterol, cardiovascular disease and most importantly premature death (George et al., 2014; Li, et al, 2019; Maskarinec et al., 2020) In addition, higher diet quality scores are associated with significant reductions in all-cause mortality, including common comorbidities associated with fibromyalgia. (Petermann-Rocha, Gray, Pell, et al., 2020; Schwingshackl et al., 2018; Sotos-Prieto et al., 2017). As in other fibromyalgia studies, a large number of our participants reported co-morbidities or multimorbidity (73%), which may impact on their nutritional requirements. Studies looking at specific chronic disease include an American population study which aimed to explore the role of diet quality on spinal pain found significantly lower adherence to dietary guidelines in those with spinal pain than without (51.97±0.65 vs 54.31±0.39) (Zick, Murphy & Calocino, 2020). Similarly, a cross sectional study to understand the role of diet quality in rheumatoid arthritis, resulted in a mean score of 58.7+15.9 (Berube et al., 2017), suggesting diet quality plays a role in the mediation of pain not limited to fibromyalgia.

The observations of higher BMI and overall energy intake in participants reporting greater pain severity, and the lowest symptom severity in those with a healthy weight has been reported previously (Bennet et al., 2007; Paglial 2020). Individuals with chronic pain may choose food for analgesic effect (de Freitas et al., 2012; O'Loughlin, Toby, Bewton-John, 2019). Research suggests food is used as a coping mechanism for pain, with participants reporting relief, although temporary, from energy dense, high fat, high sugar food sources (Amy Janke & Kozak, 2012; Chrisholm et al., 2016;). This

propensity for energy dense foods, may result in a cycle of weight gain, further impacting chronic pain and symptoms (Choi et al., 2014; Janke et al., 2016). Reliance on food for relief may be described as behavioural addiction, and relevant support pathways may be needed for weight management (Bonder, Davis, Kuk & Loxton, 2018; Schulte, Potenza & Gearhardt, 2017; Taylor, Curtis & Davis, 2010). Limited physical activity, due to pain may lead to increased body weight (Geenen et al, 2017, Hitt et al, 2007; Summer, Wren & Keffe, 2011). Restricted diets with increased physical activity, with the aim of weight loss, have shown significant improvements in pain, quality of life, depression and anxiety (Shapiro et al., 2005), however as they study was only 20 weeks long, the longevity of these interventions are not fully explored.

In the present study 38.6% of participants reported Vitamin D intakes below the UK average, with lower intakes significantly associated with higher pain and symptom scores (PHE, 2020). This association was only significant in individuals with less than 5ug dietary intake per day, half the UK recommended dose of 10ug (SACN, 2016), although we cannot exclude vitamin D sourced from sunlight. It is proposed that low vitamin D intake can lead to increased pain levels and is a common feature in arthritis, muscle pain and chronic widespread pain (Helde-Frankling & Bjorkhem-Bergman, 2017; Wu et al., 2018). A 2017 meta-analysis concluded that there is credible evidence that Vitamin D intake can impact fibromyalgia symptoms (Makrani et al, 2017), and suggested that Vitamin D should be considered as a preventative strategy. This study was only undertaken in females.

We also observed a link between symptom scores and low iron intake. There are cross overs between the symptoms of iron deficiency and fibromyalgia, with the most prevalent being fatigue and cognitive dysfunction, often described as 'fibro-fog' (Ortancil, 2010). Whilst some studies found no link between iron intake and symptoms, (Mader et al., 2012) we observed a clear impact, with higher intakes seen in participants with lower FIQR scores. Okan et al. (2019) found a significant correlation between depression and sleep quality in fibromyalgia patients with iron deficiency when compared with controls, and supplementation has in some cases improved pain and fatigue in patients with fibromyalgia (Dowling et al., 2009). Dietary intakes for calcium, B12, Mg or Na+, were not associated with pain and symptom scores in the present analysis, which is a contradiction to previous studies but may be due to differences in study design (Kasim, 2017; Joustra et al., 2017, Andretta, et al 2019). Whilst previous studies highlight links between pain (FIQR), depression and anxiety (Furness, 2018; Zamini, Alizadeh and Zamini, 2019) it is important to note that no significance was seen in this study.

Despite a lack of robust evidence to date for diet impact on fibromyalgia symptoms, it is anecdotally acknowledged by those with fibromyalgia to manage symptoms (Lowry et al., 2020; Silva, 2019). In our study, 26% of participants self-reported making dietary changes to manage their fibromyalgia symptoms, however the period of change was not recorded, which limits the interpretation of this data and the objective element of self-reporting may result in bias. Self-reported changes included reducing carbohydrate intake (43%). It is interesting to note that the FFQ data suggests an association between significantly higher intakes of CHO and total participants with higher FIQR scores (=> 49). Similar links have been found in individuals with knee pain (Strath, et al., 2020), an intervention study where low CHO diets resulted in significantly reduced markers of pain and oxidative stress, however the quality and type of CHO's in this study were not controlled. Whole dietary change, amongst those participants making self-reported dietary changes, focused on plant-based diets. Improvements in pain levels were reported in participants excluding meat and fish, exclusion of the later having the largest reported impact on pain.

Plant based diets have been known to produce reductions in pain, inflammation and weight (Lee et al., 2016; Medawar, Huhn, Villringer & Witte, 2019; Turner Mc-Grievey et al., 2015), however, limited impact on neurological status has been reported, which may be important in fibromyalgia (Watson et al., 2010). However, these studies include low participants numbers and adherence to intervention was not fully controlled. Common between studies is a beneficial impact of weight loss suggesting impacts seen in specific nutrients or diets may be misleading. Dietary regulation is a common behaviour

change strategy used to promote weight reduction (Gudzune et al., 2015), therefore it can be argued that a reduction in total body weight may be a key factor in managing fibromyalgia symptoms.

9.1 Implications for clinical practice

The costs of medical treatment for fibromyalgia are fairly insubstantial in comparison to other diseases (Briggs, Scarborough, & Wolstenholme, 2018) and the burden of disease is mostly felt in social funding (Barry et al., 2018; Lacasse, Bourgault, & Choinière, 2016,) and less so to the NHS. A failure to diagnose has a cost of its own, in repeated GP visits and investigations (Annemans et al., 2008), which might explain the claims by Fitzcharles and Bolous (2003) that fibromyalgia is often over diagnosed. Whilst previous studies have acknowledged the need for further research into the impact of the disease, the overall economic impact is widely unknown. As such, there will continue to be a "one size fits all" approach to treatment and limitations placed on access to secondary referrals. However, with symptoms of Fibromyalgia being reflected in individuals suffering from Long Covid (Greenhalgh, Knight, A'Court, Buxton & Husain, 2020; Ladds, Rushforth, Wieringa, et al., 2020), including fatigue, neurocognitive difficulties, muscle pain and weakness, there may be some cross over in treatments developed that can reduce the symptoms in both conditions.

In this study we also investigate sources of self-prescribed advice. Our results indicate that this was obtained via peers and online forums for dietary change. The current study acknowledges the sources accessed to prompt dietary changes and highlights a lack of reliance on professional support, instead citing online community support groups and peer support. The study agrees with previous research that social media is a key area for obtaining health knowledge and has an influence in determining decisions around diet (Mazanderani, Locock & Powell, 2012; Ziebland, Lavie-Ajayi & Lucius-Hoene, 2015).

Adhering to guidelines for Vitamin D supplementation might be an area to explore to reduce overall disease severity but a clearer public health message, linked with pain

management may be required to encourage uptake. In the most recent NICE draft guidelines (NICE, 2020), the role of vitamin D was not considered in the management of chronic pain in over 16s. As fibromyalgia alone is not a referral criterion for dietetic care in the UK (BDA, 2017), it is not surprising that anecdotal evidence is most highly referenced amongst participants and suggests a flaw in the limited access to nutrition professionals for this disease. The UK Allied Health Professions Public Health Strategic Framework (2019-2024) alongside the NHS long term plan (2019) underlines the role of all AHPs, including dietitians, in the prevention and reduction of health inequalities. Under the population health strand, AHPs are tasked with supporting the self-management of long-term conditions. It could be suggested that to meet these outcomes, individuals with fibromyalgia should have access to nutrition professionals to support symptom management and to promote public health strategies including vitamin D supplementation.

9.2 Strengths and Limitations

A validated FFQ was used to assess habitual diet, having the advantage of being simple and cost-effective to assess "usual" diet over longer periods of time (Resnicow, 2000) and discriminating individuals in relation to their dietary intake. FFQs are considered a strong tool to examine relationships between intake and disease, although limitations of self-reported dietary intakes should be acknowledged (WHO, 2003). An internet-based platform was an effective method for recruiting participants with fibromyalgia, which resulted in a large sample size (Blumenberg, et al., 2019), however this design may limit depth of information, versus interviews, and the number of measures collected (Shim, Oh & Kim, 2014). Males are less likely to participate in survey-based research than women (Curtin et al., 2000; Moore & Tarnai, 2002; Singer et al., 2000) and whilst the focus of this study was not gender specific it is important to note that the majority of fibromyalgia research is undertaken using females (Segura Jiménez, 2016) and where gender has been a focus, male participation has been limited, reducing the validity of results (Aparicio, 2012).

9.3 Conclusion

This study highlights a link between diet quality, BMI and pain levels in fibromyalgia sufferers. Higher HEI scores were associated with significant improvement in pain and symptoms indicated in lower FIQR scores. There is some evidence to suggest specific micronutrients, including Vitamin D and Iron, may play a role in the mediation of pain and symptoms. Self-prescribed diets may be beneficial to individuals with fibromyalgia, including supporting weight management, however this should be confirmed with well-designed trials. The study highlights a lack of guidance on nutrition from health care professionals, resulting in individuals looking for advice from support groups and their peers, that may not always be based on sound science.

10 Future research and recommendations

Future research may benefit from further exploring the impact of diet quality on fibromyalgia symptoms in larger cross-sectional studies and RCTs, with equal gender representation. Exploration of micronutrient supplementation via RCTs may result in clearer guidance for individuals with fibromyalgia. Analysis of urine and blood results can provide more accurate results on nutritional status. Results from this and future studies should be implemented in the creation of specific nutrition guidance for individuals with chronic pain including fibromyalgia.

11 Bibliography

- Abeles, M., Solitar, B.M., Pillinger, M.H. & Abeles, A.M. (2008). Update on fibromyalgia therapy. *American Journal of Medicine*, *121*(7), 555–561
- Ablin, J. N., Shoenfeld, Y., & Buskila, D. (2006). Fibromyalgia, infection and vaccination: Two more parts in the etiological puzzle. *Journal of Autoimmunity*, 27(3), 145–152.
- Albrechta, D. S., Forsbergb, A., Sandstromc, A., Bergana, C., Kadetoffc, D., Protsenkoa, E., et al. (2019). Brain glial activation in fibromyalgia - a multi-site positron emission tomography investigation. *Brain, behavior, and immunity,* 75(1), 72–83.
- Alhalel, N., Schueller, S. M. & O'Brien, M. J. (2018). Association of changes in mental health with weight loss during intensive lifestyle intervention: does the timing matter? *Obesity science & practice*, *4*(2), 153–158.
- Altindag, O., Ögüt, E., Gur, A., Gursoy, S. & Gunay, M. (2014). Serum vitamin D level and its relation with clinical parameters in fibromyalgia as a neuropathic pain. *Orthopedic & Muscular System, 3,* 171.
- Amy Janke, E., & Kozak, A. T. (2012). "The more pain I have, the more I want to eat": obesity in the context of chronic pain. *Obesity (Silver Spring, Md.)*, 20(10), 2027–2034.
- Andretta, A., Dias Batista, E., Schieferdecker, M.E.M., Petterle, R.R. Boguszewski, C.L. & dos Santos Paiva, E. (2019). Relation between magnesium and calcium and
- parameters of pain, quality of life and depression in women with fibromyalgia. Advances in Rheumatology, 59(55), S42358.
- Annemans, L., Wessely, S., Spaepen E., Caekelbergh, K., Caubere, J.P., Le Lay, K., et al. (2008). Health economic consequences related to the diagnosis of fibromyalgia syndrome. *Arthritis & Rheumatology*, 58(3), 895-902.
- Aparicio, V.A., Ortega, F.B., Carbonell-Baeza, A, Femia, P., Tercedor, P., Ruiz, J.R., et al. (2012). Are there gender differences in quality of life and symptomatology between fibromyalgia patients? *American Journal of Men's Health, 6*(4), 314-319.
- Arnold, L. M., Hudson, J. I., Hess, E. V, Ware, A. E., Fritz, D. A., Auchenbach, M. B., et al. (2004). Family study of fibromyalgia. *Athritis & Rheumatology*, *50*(3), 944– 952.
- Arnold, L.M., Clauw, D.J. & MacCarberg, B.H. (2011). Improving the Recognition and Diagnosis of Fibromyalgia. *Mayo Clinic Proceedings* 86(5): 457–464.
- Arnold, L. M., Palmer, R. H., Hufford, M. R., & Chen, W. (2012). Effect of milnacipran on body weight in patients with fibromyalgia. *International Journal of General Medicine*, 5, 879–887.
- Arnold, L. M., Fan, J., Russell, I., Yunus, M., Khan, M., Kushner, I., et al. (2013). The Fibromyalgia Family Study: A Genome-Scan Linkage Study. *Arthritis and Rheumatism*, 65(4), 1122–1128.
- Arranz, L., Canela, M. & Rafecas, M. (2010). Fibromyalgia and nutrition, what do we know? *Rheumatology International, 30*(11), 1417-1427
- Arranz, L.I., Canela, M.A. & Rafecas, M. (2012). Dietary aspects in fibromyalgia patients: results of a survey on food awareness, allergies, and nutritional supplementation. *Rheumatology International 32*(9), 2615-2621.
- Atherton, K., Berry, D.J., Parsons, T., Macfarlane, GJ., Power, C. & Hyppönen, E. (2009). Vitamin D and chronic widespread pain in a white middle-aged British

population: evidence from a cross-sectional population survey. *Annals of the Rheumatic Diseases, 68*(6),817–822.

- Azad, K.A., Alam, M.H., Haq, S.A., Nahar, S., Chowdhury, M.A., Ali, S.M., et al. (2000). Vegetarian diet in the treatment of fibromyalgia. *Bangladesh Medical Research Council bulletin*, *26*(2), 41-7.
- Backryd, E., Tanum, L., Lind, A., Larsson, A. & Gordh, T. (2017). Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma. *Journal of Pain Research 10*, 515-525.
- Barrett, J. S. (2013) Extending our knowledge of fermentable, short-chain carbohydrates for managing gastrointestinal symptoms. *Nutrition in Clinical Practice, 28*(3), 300–306.
- Barrett, J.S. (2017). How to institute the low-FODMAP diet. *Journal of Gastroenterology* and Hepatology 32(S1), 8-10.
- Basu, A., Schell, J., & Scofield, R. H., (2018). Dietary fruits and arthritis. Food & *function*, 9(1), 70–77.
- Bell, P. G., McHugh, M. P., Stevenson, E. & Howatson, G. (2014). Cherries, exercise, recovery, and health. Scandinavian Journal Medicine & Science in Sports, 24(3), 477-490.
- Bellato, E., Marini, E., Castoldi, F., Barbasetti, N., Mattei, L., Bonasia, D. E., & Blonna, D. (2012). Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. *Pain research and treatment*, 426130.
- Bennett, R. M., Friend, R., Jones, K. D., Ward, R., Han, B. K. & Ross, R. L. (2009). The revised fibromyalgia impact questionnaire (FIQR): Validation and psychometric properties. *Arthritis Research and Therapy*, 11(4), 3–4.
- Bennett, R. M., Jones, J., Turk, D. C., Russell, I. J. & Matallana, L. (2007). An internet survey of 2,596 people with fibromyalgia. *BMC Musculoskeletal Disorders*, 8(27), 1–11.
- Berube, L.T., Kiely, M., Yazici, Y. & Woolf, K. (2017). Diet quality of individuals with rheumatoid arthritis using the Healthy Eating Index (HEI)-2010. *Nutrition and Health, 23*(1), 17-24.
- Bidari, A., Ghavidel Parsa, B. & Ghalehbaghi, B. (2018). Challenges in fibromyalgia diagnosis: from meaning of symptoms to fibromyalgia labeling. *The Korean journal of pain*, *31*(3), 147–154.
- Blüher, M., Fasshauer, M., Tönjes, A., Kratzsch, J., Schön, M. R. & Paschke, R. (2005). Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. *Experimental and Clinical Endocrinology and Diabetes*, *113*(9), 534– 537.
- Blumenberg, C., Menezes, A., Gonçalves, H., Assunção, M., Wehrmeister, F., Barros, A. (2019). How different online recruitment methods impact on recruitment rates for the web-based coortesnaweb project: a randomised trial. *BMC Medical Research Methodology*, *19*(10), 127.
- Bonder, R., Davis, C., Kuk, J.L. & Loxton, N.J. (2018). Compulsive "grazing" and addictive tendencies towards food. *European Eating Disorders Review 26*(6), 569-573.

- Boomershine, C.S., Koch, T.A. & Morris, D. (2018). A Blinded, Randomized, Placebo Controlled Study to Investigate the Efficacy and Safety of Ferric Carboxymaltose in Iron-Deficient Patients with Fibromyalgia. *Rheumatology and Therapy 5,* 271– 281.
- Boonnate, P., Waraasawapati, S., Hipkaeo, W., Pethlert, S., Sharma, A., Selmi, C., et al. (2015). Monosodium glutamate dietary consumption decreases pancreatic βcell mass in adult Wistar rats. *PLoS ONE*, *10*(6), e0131595.
- Bourgault, P., Lacasse, A., Marchand, S., Courtemanche-Harel, R., Charest, J., Gaumond, I., et al. (2015). Multicomponent interdisciplinary group intervention for self-management of fibromyalgia: A mixed methods randomized controlled trial. *PLoS ONE*, *10*(5), e0126324.
- Brain, K., Burrows, T. L., Rollo, M. E., Chai, L. K., Clarke, E. D., Hayes, C., et al. (2019). A systematic review and meta-analysis of nutrition interventions for chronic noncancer pain. *Journal of Human Nutrition and Dietetics*, *32*(2), 198–225.
- Brassard, D., Lemieux, S., Charest, A., Lapointe, A., Couture, P., Labointe, M., et al. (2018). Comparing interviewer administered and web-based food frequency questionnaires to predict energy requirements in adults. *Nutrients, 10*(9), 1292.
- Briggs, M. A., Petersen, K. S., & Kris-Etherton, P. M. (2017). Saturated Fatty Acids and Cardiovascular Disease: Replacements for Saturated Fat to Reduce Cardiovascular Risk. *Healthcare (Basel, Switzerland)*, *5*(2), 29.
- Briones-Vozmediano, E., Vives-Cases, C., Ronda-Pérez, É. & Gil-González, D. (2013). Patients' and professionals' views on managing fibromyalgia. *Pain research & management*, *18*(1), 19–24.
- British Dietetics Association. (2017). *Dietitians in Primary Care*. Retrieved August, 9, 2020 from https://www.bda.uk.com/uploads/assets/d8272cae-2214-4df6-930d24fd00536494/bdaprimarycarepaper.pdf
- Broad, L. M., Mogg, A. J., Beattie, R. E., Ogden, A.M., Blanco, M.J. & Bleakman, D. (2009). TRP channels as emerging targets for pain therapeutics. *Expert Opinion on Therapeutic Targets*, *13*(1), 69–81.
- Briggs, A., Scarborough, P., & Wolstenholme, J. (2018). Estimating comparable English healthcare costs for multiple diseases and unrelated future costs for use in health and public health economic modelling. *PloS one*, *13*(5), e0197257.
- Burckhardt, C.S., Clark, B.D. & Bennett, R.M. (1991). The fibromyalgia impact questionnaire: development and validation. *Journal of Rheumatology, 18*(1), 728–733
- Busch, A. J., Barber, K. A., Overend, T. J., Peloso, P. M., & Schachter, C. L. (2007). Exercise for treating fibromyalgia syndrome. *The Cochrane database of* systematic reviews, (4), CD003786.
- Busch, A., Schachter, C. L., Peloso, P. M., & Bombardier, C. (2002). Exercise for treating fibromyalgia syndrome. *The Cochrane database of systematic reviews*, (3), CD003786.
- Carville, S.F., Arendt-Nielsen, L., Bliddal, H., Blotman, F., Branco, J.C., Buskila, D., et al. (2008). EULAR evidence-based recommendations for the management of fibromyalgia syndrome. *Annals of the rheumatic diseases*, 67(4),536-41.
- Cashman, K.D. van den Heuvel, E.G.H.M., Schoemaker, R.J.W., Prévéraud, D.P., Macdonald, H.M. & Arcot, J. (2017). 25-hydroxyvitamin d as a biomarker of

vitamin d status and its modeling to inform strategies for prevention of vitamin d deficiency within the population. *Advances in* Nutrition, *8*(6) 947–957

- Celis-Morales, C., Livingstone, K.M., Marsaux, C.F.M., Macready, A.L., Fallaize, R., O'Donovan, C.B., et al. (2017). Effect of personalized nutrition on health-related behaviour change: evidence from the Food4Me European randomized controlled trial, *International Journal of Epidemiology*, 46(2), 578–588.
- Chen, J., Li, L., Chen, S. R., Chen, H., Xie, J. D., Sirrieh, R. E., et al. (2018). The α2δ-1NMDA Receptor Complex Is Critically Involved in Neuropathic Pain Development and Gabapentin Therapeutic Actions. *Cell reports*, 22(9), 2307– 2321.
- Choi, K. W., Somers, T. J., Babyak, M. A., Sikkema, K. J., Blumenthal, J. A., & Keefe, F. J. (2014). The relationship between pain and eating among overweight and obese individuals with osteoarthritis: an ecological momentary study. *Pain research & management*, *19*(6), e159–e163.
- Chrisholm, A., Pearce, C.J., Chinoy, H., Warren, R.B. & Bundy, C. (2016). Distress, misperceptions, poor coping and suicidal ideation in psoriatic arthritis: A qualitative study *Rheumatology* 55(1), 1047-1052,
- Cipriani, A., Ruhe, H. G., Furukawa, T. A., Tajika, A., Egger, M., Geddes, J. R., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *The Lancet*, *391*(10128), 1357–1366.
- Clauw, D. J. (2014). Fibromyalgia: A clinical review. JAMA Journal of the American Medical Association, 311(15), 1547–1555.
- Clénin G. E. (2017). The treatment of iron deficiency without anaemia (in otherwise healthy persons). Swiss medical weekly, 147, w14434.
- Cording, M., Derry, S., Phillips, T., Moore, R. & Wiffen, P.J. (2015). Milnacipran for pain in fibromyalgia in adults. Cochrane Database of Systematic Reviews, 10, CD008244.
- Costello, R., Wallace, T.C. & Rosanoff, A. (2016). Magnesium, *Advances in Nutrition*, 7(1), 199–201.
- Curtin, R., Presser, S., & Singer, E. (2000). The effects of response rate changes on the index of consumer sentiment. *Public Opinion Quarterly* 64: 413–428.
- D'Andrea, M. I., Romão, T. T., Pires do Prado, H. J., Krüger, L. T., Pires, M., & da Conceição, P. O. (2019). Ketogenic Diet and Epilepsy: What We Know So Far. *Frontiers in neuroscience*, *13*, 5.
- Da Silva, S., Sarni, R.O., de Souza, F.I., Molina, J., Terreri, M.T., Hilário, M.O., *et al.* (2012). Assessment of nutritional status and eating disorders in female adolescents with fibromyalgia. *Journal of Adolescent Health*, *51*(5), 524-527.
- Department of Health. *Dietary Reference Values for Food, Energy and Nutrients in the United Kingdom*. Report on Health and Social Subjects, No. 41. London: HSMO, 1991
- de Freitas, R.L., Kübler, J.M.L., Elias-Filho, D.H.& Coimbra N.C. (2012). Antinociception induced by acute oral administration of sweet substance in young and adult rodents: The role of endogenous opioid peptides chemical mediators and µ1-opioid receptors. *Pharmacology Biochemistry and Behavior, 101,* 265-270

- De Silva, V., El-Metwally, A., Ernst, E., Lewith, G., Macfarlane, G. J., & Arthritis Research Campaign working group on complementary and alternative medicines (2010). Evidence for the efficacy of complementary and alternative medicines in the management of fibromyalgia: a systematic review. *Rheumatology (Oxford, England)*, 49(6), 1063–1068.
- Doebl, S., Macfarlane, G. J. & Hollick, R.J. (2020). "No one wants to look after the fibro patient". Understanding models, and patient perspectives, of care for fibromyalgia: reviews of current evidence. *PAIN*, *161* (8), 1716-1725.
- Domecq, J. P., Prutsky, G., Leppin, A., Sonbol, M. B., Altayar, O., Undavalli, C., et al. (2015). Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. *The Journal of clinical endocrinology and metabolism*, *100*(2), 363–370.
- Dowling P, Klinker F, Amaya F, Paulus W, Liebetanz D (2009). Iron- deficiency sensitizes mice to acute pain stimuli and formalin- induced nociception. Journal of Nutrition 139, 2087–2092.
- Eby G.A., Eby K.L. & Murk. H. (2011). Magnesium and major depression. In: Vink R, Nechifor M, editors. *Magnesium in the Central Nervous System.* Adelaide, University of Adelaide Press.
- Elmas, O., Yildiz, S., Bilgin, S., Demirci, S., Comlekci, S., Rifat, H., et al. (2016). Physiological parameters as a tool in the diagnosis of fibromyalgia syndrome in females: A preliminary study. *Life Sciences 145*, 51-56.
- EPIC-Norfolk Food Frequency Questionnaire (FFQ) Entry and Processing Documentation (2012) Retrieved, March 23, 2019 from <u>http://hoodedclaw.srl.cam.ac.uk/epicffq/websitedocumentation_211111.html</u>.
- Ernberg, M., Christidis, N., Ghafouri, B., Bileviciute-Ljungar, I., Löfgren, M., Bjersing, J., et al. (2018). Plasma Cytokine Levels in Fibromyalgia and Their Response to 15 Weeks of Progressive Resistance Exercise or Relaxation Therapy. *Mediators of Inflammation*, 3985154, 1–14.
- Ernst, A. & Shelley-Tremblay, J. (2013). Non-Ketogenic, Low Carbohydrate Diet Predicts Lower Affective Distress, Higher Energy Levels and Decreased Fibromyalgia Symptoms in Middle-Aged Females with Fibromyalgia Syndrome as Compared to the Western Pattern Diet. *Journal of Musculoskeletal Pain*, 21(4), 365-370.
- El-Salhy, M., Ystad, S. O., Mazzawi, T., & Gundersen, D. (2017). Dietary fiber in irritable bowel syndrome (Review). *International journal of molecular medicine*, *40*(3), 607–613.
- Engen, D.J., McAllister, S.J., Whipple, O.J., Cha, S.S., Dion, L.J., Vincent, A., et al. (2015). Effects of transdermal magnesium chloride on quality of life for patients with fibromyalgia: a feasibility study. *Journal of Integrative Medicine, 13*(5), 306313.
- Enna, S.J. & McCarson, K.E. (2006). The role of GABA in the mediation and perception of pain. *Advances in pharmacology 54*, 1-27.
- European Food Safety Authority. (2013). Scientific Opinion on the re-evaluation of aspartame (E 951) as a food additive. *EFSA Journal*, *11*(12).
- Fallaize, R., Livingstone, K., Celis-Morales, C., Macready, A., San-Cristobal, R., NavasCarretero, S., et al. (2018). Association between Diet-Quality Scores,

Adiposity, Total Cholesterol and Markers of Nutritional Status in European Adults: Findings from the Food4Me Study. *Nutrients, 10,* 49.

- Faulconbridge, L. F., Wadden, T. A., Berkowitz, R. I., Sarwer, D. B., Womble, L. G., Hesson, L. A., et al. (2009). Changes in symptoms of depression with weight loss: results of a randomized trial. *Obesity*, *17*(5), 1009–1016.
- Fayaz, A., Croft, P., Langford, R. M., Donaldson, L. J. & Jones, G. T. (2016). Prevalence of chronic pain in the UK: A systematic review and meta-analysis of population studies. *BMJ Open*, 6(6), e010364.
- Fenton, T., Engel, B., Gibbs, M., Mannering. C. & Darling, A.L. (2016). A pilot study to determine if adherence to a gluten free diet reduces the symptoms of fibromyalgia. *Journal of Human Nutrition and Dietetics 29*(S1), 7-13.
- Ferraz, C. R., Carvalho, T. T., Manchope, M. F., Artero, N. A., Rasquel-Oliveira, F. S., Fattori, V., Casagrande, R., & Verri, W. A., Jr (2020). Therapeutic Potential of Flavonoids in Pain and Inflammation: Mechanisms of Action, Pre-Clinical and Clinical Data, and Pharmaceutical Development. *Molecules (Basel, Switzerland)*, 25(3), 762.
- Fishbain, D.A., Cutler, R., Rosomoff, H.L. & Rosomoff, R.S. (1997). Chronic painassociated depression: antecedent or consequence of chronic pain? A review. *The Clinical Journal of Pain 13*(2), 116–137.
- Fitzcharles, M.A. & Boulos, P. (2003). Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals. *Rheumatology* 42(2), 263-267.
- Fleisch, A. F., Agarwal, N., Roberts, M.D., Han, J.C., Theim, K.R., Vexler, A., et al. (2007). Influence of Serum Leptin on Weight and Body Fat Growth in Children at high risk of adult obesity. *The Journal of clinical endocrinology and metabolism*, 92(3), 948-54.
- Fleisch, A.F., Agarwal, N., Roberts, M. D., Han, J.C. Theim, K.R., Vexler, A., et al. (2007). High Risk for Adult Obesity, *The Journal of Clinical Endocrinology & Metabolism*, *92*(3), 948–954.
- Fry, L., Seah, P.P., McMinn, R.M. & Hoffbrand, A.V. (2011). Lymphocytic infiltration of epithelium in diagnosis of gluten-sensitive enteropathy. *British Medical Journal* 59(2),166–179
- Furness, P. J., Vogt, K., Ashe, S., Taylor, S., Haywood-Small, S. & Lawson, K. (2018).
 What causes fibromyalgia? An online survey of patient perspectives. *Health* psychology open, 5(2), 1-11.
- Garrido, M., Espino, J., Gonzale-Gomez, D., Lazano, M., Cubero, J., Torbio-Delgado, A. F., et al. (2009). A nutraceutical product based on Jerte Valley cherries improves sleep and augments the antioxidant status in humans. *e-SPEN, the European eJournal of Clinical Nutrition and Metabolism 4*(6), e321-e323.
- Geneen, L.J., Moore, R., Clarke, C., Martin, D., Colvin, L.A. & Smith, B.H. (2017). Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. Cochrane Database of Systematic Reviews, 4, CD011279.
- George, S., Ballard-Barbash, R., Manson, J., Reedy, J., Shikany, J., Subar, A., et al. (2014). Comparing indices of diet quality with chronic disease mortality risk in postmenopausal women in the women's health initiative observational study: evidence to inform national dietary guidance. *American journal of epidemiology 180*(6), 616-625.

- Głąbska D, Guzek D, Groele B, Gutkowska K. Fruit and Vegetable Intake and Mental Health in Adults: A Systematic Review. *Nutrients*. 2020; 12(1), 115.
- Gobbi, G., Atkin, T., Zytynski, T., et al. (2019) Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis. *JAMA Psychiatry*, *76*(4), 426–434.
- Gracely, R. H., Ceko, M. & Bushnell, M. C. (2012). Fibromyalgia and depression. *Pain* research and treatment, 486590.
- Grases, G., Pérez-Castelló, J. A., Sanchis, P., Casero, A., Perelló, J., Isern, B., Rigo, E., & Grases, F. (2006). Anxiety and stress among science students. Study of calcium and magnesium alterations. *Magnesium research*, *19*(2), 102–106.
- Greenhalgh, A., Knight, M., A'Court, C., Buxton, M. & Husain, L. (2020). Management of post-acute covid-19 in primary care. *British Medical Journal*, *370*, m3026.
- Grober, W., Schmidt, J. & Kister, K. (2015). Magnesium in prevention and therapy. *Nutrients, 7*(9), 8199-8226.
- Goldberg, D., Bradley, L. A., Arnold, L., Glass, J., & Clauw, D. (2005). Understanding Fibromyalgia and Its Related Disorders. *Primary Care; Clinics In Office Practice*, 5(2), 180–190.
- Gudzune, K. A., Doshi, R. S., Mehta, A. K., Chaudhry, Z. W., Jacobs, D. K., Vakil, R. M., et al. (2015). Efficacy of commercial weight-loss programs: an updated systematic review. *Annals of internal medicine*, *162*(7), 501–512.
- Habib, G. & Artul, S. (2018). Medical Cannabis for the Treatment of Fibromyalgia. Journal of Clinical Rheumatology, 24(5), 255–258.
- Hall, K. D., Heymsfield, S. B., Kemnitz, J. W., Klein, S., Schoeller, D. A. & Speakman, J. R. (2012). Energy balance and its components: implications for body weight regulation. *The American journal of clinical nutrition*, *95*(4), 989–994.
- Harmer, C. J., Duman, R. S. & Cowen, P. J. (2017). How do antidepressants work? New perspectives for refining future treatment approaches. *The lancet. Psychiatry*, *4*(5), 409–418.
- Harris, R.E., Williams, D.A., McLean, S.A., Sen, A., Hufford, M., Gendreau, R.M., et al., (2005). Characterization and consequences of pain variability in individuals with fibromyalgia. *Arthritis & Rheumatology*, 52(11), 3670-4.
- Harris, R. E. & Clauw, D. J. (2012). Imaging central neurochemical alterations in chronic pain with proton magnetic resonance spectroscopy. *Neuroscience Letters*, 520(2), 192–196.
- Häuser, W., Bernardy, K., Arnold, B., Offenbächer, M., & Schiltenwolf, M. (2009). Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. *Arthritis and rheumatism*, *61*(2), 216–224.
- Häuser, W., Klose, P., Langhorst, J., Moradi, B., Steinbach, M., Schiltenwolf, M., & Busch, A. (2010). Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. *Arthritis research & therapy*, 12(3), R79.
- Hawkins R. A. (2013). Fibromyalgia: a clinical update. *The Journal of the American Osteopathic Association*, *113*(9), 680–689.

- Hayes, S. M., Myhal, G. C., Thornton, J. F., Camerlain, M., Jamison, C., Cytryn, K. N. & Murray, S. (2010). Fibromyalgia and the therapeutic relationship: where uncertainty meets attitude. *Pain research & management*, *15*(6), 385–391.
- Hébert, J. R., Peterson, K. E., Hurley, T. G., Stoddard, A. M., Cohen, N., Field, A. E., & Sorensen, G. (2001). The effect of social desirability trait on self-reported dietary measures among multi-ethnic female health center employees. *Annals of epidemiology*, *11*(6), 417–427.
- Heidari, F., Afshari, M., & Moosazadeh, M. (2017). Prevalence of fibromyalgia in general population and patients, a systematic review and metaanalysis. *Rheumatology international*, 37(9), 1527–1539.
- Helde-Frankling, M., & Bjorkhem-Bergman, L. (2017). Vitamin D in Pain Management. International Journal of Molecular Sciences 18(10), 2170.
- Higley, M. J. & Picciotto, M. R. (2014). Neuromodulation by acetylcholine: examples from schizophrenia and depression. *Current opinion in neurobiology*, 29, 88–95.
- Hindle, L & Charlesworth, L. (2019). The UK Allied Health Professions Public Health Strategic Framework (2019-2024). Retrieved March, 24, 2020, from http://www.ahpf.org.uk/files/UK%20AHP%20Public%20Health%20Strategic%20F ramework%202019-2024.pdf
- Holton, K. F., Taren, D. L., Thomson, C. A., Bennett, R. M., & Jones, K. D. (2012). The effect of dietary glutamate on fibromyalgia and irritable bowel symptoms. *Clinical and experimental rheumatology*, *30*(6 Suppl 74), 10–17.
- House of Commons. (2018). House of Commons Obesity Statistics. *House of Commons Briefing Paper*, (3336), 1–34.
- IBM Corp. (2017). IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp
- Irwin, C., Desbrow, B., Khalesi, S. & McCartney, D. (2019). Challenges following a personalised diet adhering to dietary guidelines in a sample of Australian university students. *Nutrition and Health 25*(3), 185-194.
- Isasi, C., Colmenero, I., Casco, F., Tejerina, E., Fernandez, N., Serrano-Vela, J. I., Castro, M. J., & Villa, L. F. (2014). Fibromyalgia and non-celiac gluten sensitivity: a description with remission of fibromyalgia. *Rheumatology international*, *34*(11), 1607–1612.
- Jahnen-Dechent, W., & Ketteler, M. (2012). Magnesium basics. *Clinical kidney journal*, *5*(Suppl 1), i3–i14. <u>https://doi.org/10.1093/ndtplus/sfr163</u>
- Janke, E.A., Jones, E., Hopkins, C.M., Ruggieri, M. & Hruska, A. (2016). Catastrophizing and anxiety sensitivity mediate the relationship between persistent pain and emotional eating. *Appetite*, *103*, 64-71.
- Jensen, M. P. & Karoly, P. (2010). Handbook of Pain Assessment. In D. C. Turk & R. Melzack (Eds.), *Handbook of Pain Assessment*. New York: The Guilford Press.
- Jones, K.D., Horak, F.B., Winters-Stone, K., Irvine, J.M. & Bennett R.M. (2009). Fibromyalgia is associated with impaired balance and falls. *J Clin Rheumatology*, *15*(1), 16–21.
- Jones, K.D. & Lipton, G. (2009). Exercise interventions in fibromyalgia: clinical applications from the evidence. *Rheumatic disease clinics of North America, 35*, 373-391.

- Jones, G. T., Atzeni, F., Beasley, M., Flüß, E., Sarzi-Puttini, P. & Macfarlane, G. J. (2015). The prevalence of fibromyalgia in the general population: A comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. *Arthritis and Rheumatology*, *67*(2), 568–575.
- Joustra, M.L., Minovic, I., Janssens, K.A.M., Bakker, S.L. & Rosmalne, J.G.M. (2017). Vitamin and mineral status in chronic fatigue syndrome and fibromyalgia syndrome: A systematic review and meta-analysis. *PLOS ONE, 12*(4), e0176631.
- Kaartinen, K., Lammi, K., Hypen, M., Nenonen, M., Hanninen, O. & Rauma, A.L. (2000). Vegan diet alleviates fibromyaglia symptoms. *Scandanavian Journal of Rhyematology*, *29*(1), 308-313.
- Kadetoff, D., Lampa, J., Westman, M., Magnus, A. & Kosek, E. (2012). Evidence of central inflammation in fibromyalgia - increased cerebrospinal fluid interlekin-8 levels. *Journal of Neuroimmunology* 242(1-2), 33-38.
- Kaltsas, G. & Tsiveriotis, K. (2017). Fibromyalgia. In K. R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, K. Dungan, A. Grossman (Eds.), *Endotext*. South Dartmouth: MDT
- Kasim, A.A. (2012). Calcium, Magnesium and Phosphorous Levels in Serum of Iraqi Women with Fibromyalgia. *Iraqi Journal of Pharmaceutical Sciences*, 20(2), 3437.
- Kelly, D.S., Adkins, Y. & Laugero, K.D. (2018). A review of the health benefits of cherries. *Nutrients, 10*(3), 368.
- Kelm, M. K., Criswell, H. E. & Breese, G. R. (2011). Ethanol-enhanced GABA release: A focus on G protein-coupled receptors. *Brain Research Reviews*, *65*(2), 113–123.
- Kia, S. & Choy, E. (2017). Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. *Biomedicine*, *5*(2), 20.
- Kim, D.Y., Hao, J., Liu, R., Turner, G., Shi, F.D. & Rho, J.M. (2012).
 Inflammationmediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis. *PLoS One*, 7(5):e35476.
- Kim, C., Vincent, A., Clauw, D., Luedtke, C., Thompson, J. & Schneekloth, T. (2013). Association between alcohol consumption and symptom severity and quality of life in patients with fibromyalgia. *Arthritis Research and Therapy*, *15*(2), R42.
- Kim, Y. S., Kim, K. M., Lee, D. J., Kim, B. T., Park, S. B., Cho, D. Y., Suh, C. H., Kim, H. A., Park, R. W., & Joo, N. S. (2011). Women with fibromyalgia have lower levels of calcium, magnesium, iron and manganese in hair mineral analysis. *Journal of Korean medical science*, 26(10), 1253–1257.
- Kimura, M., Saito, S. & Obata, H. (2012). Dexmedetomidine decreases hyperalgesia in neuropathic pain by increasing acetylcholine in the spinal cord. *Neuroscience Letters*, *529*(1), 70–74.
- King DE. (2009). Inflammation and elevation of C-reactive protein: does magnesium play a key role? *Magnesium Res*earch, 22(2), 57-59.
- Kirkland, A. E., Sarlo, G. L., & Holton, K. F. (2018). The Role of Magnesium in Neurological Disorders. *Nutrients*, *10*(6), 730.
- Kirkpatrick, S.I., Reedy, J., Krebs-Smith, S.M., Pannucci, T.E., Subar, A., Wilson, M.M., et al. (2018). Applications of the Healthy Eating Index for Surveillance, Epidemiology, and Intervention Research: Considerations and Caveats. *Journal* of the Academy of Nutrition and Dietetics, 118(9), 1603-1621.

- Knudsen, N., Laurberg, P., Rasmussen, L. B., Bülow, I., Perrild, H., Ovesen, L., & Jørgensen, T. (2005). Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. *The Journal of clinical endocrinology and metabolism*, *90*(7), 4019–4024.
- Krebs-Smith, S. M., Pannucci, T. E., Subar, A. F., Kirkpatrick, S. I., Lerman, J. L., Tooze, J. A., Wilson, M. M., & Reedy, J. (2018). Update of the Healthy Eating Index: HEI-2015. *Journal of the Academy of Nutrition and Dietetics*, *118*(9), 1591–1602.
- Kremer, M., Salvat, E., Muller, A., Yalcin, I., & Barrot, M. (2016). Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights. *Neuroscience*, *338*, 183–206.
- Kroenke, K., Spitzer, R. L. & Williams, J. B. W. (2001). The PHQ-9. *Journal of General Internal Medicine*, *16*(9), 606–613.
- Kwiatek, R. (2017). Treatment of fibromyalgia. Australian Prescriber, 40(5), 179-183.
- Ladds, E., Rushforth, A., Wieringa, S., Taylor, S., Raynor, C., Husain, L., *et al.* (2020). Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients and draft quality principles for services. *BMC Health Services Research, 20*, 1144.
- Lacasse, A., Bourgault, P., & Choinière, M. (2016). Fibromyalgia-related costs and loss of productivity: a substantial societal burden. *BMC musculoskeletal disorders*, *17*, 168.
- Lamont L.A., Tranquilli W.J., Grimm K.A. (2000). Physiology of pain. Veterinary Clinics of North America: Small Animal Practice 30(4), 703-28
- Lattanzio, S. M. (2017). Fibromyalgia Syndrome: A Metabolic Approach Grounded in Biochemistry for the Remission of Symptoms. *Frontiers in Medicine*, *4*, 198.
- Lawson, K. (2017). A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia. *Biomedics* 5, 24.
- Lee, Y. M., Kim, S. A., Lee, I. K., Kim, J. G., Park, K. G., Jeong, J. Y., et al. (2016). Effect of a Brown Rice Based Vegan Diet and Conventional Diabetic Diet on Glycemic Control of Patients with Type 2 Diabetes: A 12-Week Randomized Clinical Trial. *PloS one*, *11*(6), e0155918.
- Leech, R. M., Worsley, A., Timperio, A. & McNaughton, S. A. (2015). Understanding meal patterns: definitions, methodology and impact on nutrient intake and diet quality. *Nutrition research reviews*, *28*(1), 1–21.
- Lepine, J.P. & Briley, M. (2004). The epidemiology of pain in depression. *Human Psychopharmacology*, *1*, S3-7.
- Lerner, E., Glazer, Y., Neumann, L., Bolotin, A., Buskila, D. & Shefer, A. (2008). A cross-sectional study of the relationship between body mass index and clinical characteristics, tenderness measures, quality of life, and physical functioning in fibromyalgia patients. *Clinical Rheumatology*, *27*(12), 1543–1547.
- Lewis, D., Haridy, J. & Newnham, E. D. (2017). Testing for coeliac disease. *Australian* prescriber, 40(3), 105–108.
- Li, Y., Schoufour, J., Wang, D. D., Dhana , K., Pan, A., Liu, X., et al. (2019). Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study. *British Medical Journal, 368*, 16669.

- Lim, J. A., Choi, S. H., Lee, W. J., Jang, J. H., Moon, J. Y., Kim, Y. C., et al. (2018). Cognitive-behavioral therapy for patients with chronic pain: Implications of gender differences in empathy. *Medicine*, *97*(23), e10867.
- Littlejohn, G. & Guymer, E. (2018). Central processes underlying fibromyalgia. *European Medical Journal 3*(4), 79-86.
- Lopez-Castejon, G. & Brough, D. (2011). Understanding the mechanism of IL-1β secretion. *Cytokine and Growth Factor Reviews*, 22(4), 189–195.
- Lopez-Rodriguez, M.M., Molina, J.G., Medina, I.M.F., Sola, C.F. & Muelle, A.R. (2015). Patterns of food avoidance and eating behaviour in women with fibromyalgia. *Endocrinología, Diabetes y Nutrición, 64*(9), 480-490.
- Lowe, J. C., Yellin, J., & Honeyman-Lowe, G. (2006). Female fibromyalgia patients: lower resting metabolic rates than matched healthy controls. *Medical science monitor: international medical journal of experimental and clinical research*, 12(7), CR282–CR289.
- Lowry, E., Marley, J., McVeigh, J. G., McSorley, E., Allsopp, P., & Kerr, D. (2020). Dietary Interventions in the Management of Fibromyalgia: A Systematic Review and Best-Evidence Synthesis. *Nutrients*, *12*(9), 2664.
- Ludwig, D. (2020). The Ketogenic Diet: Evidence for Optimism but High-Quality Research Needed, *The Journal of Nutrition*, *150*(6), 1354–1359.
- Macfarlane, G.J., Kronisch, C., Dean, L.E., Atzeni, F., Häuser W., Fluß E., et al. (2016). EULAR revised recommendations for the management of fibromyalgia. Annals of the rheumatic diseases, *76*(2), 318-328.
- Mader, R., Koton, Y., Buskila, D., Herer, P. & Elias M. (2012). Serum iron and iron stores in non-anemic patients with fibromyalgia. Clinical Rheumatology. 31, 595-9.
- Makrani, A.H., Afshair, M, Ghajar, M., Forooghu, Z. & Moosazadeh, J. (2017). Vitamin D and fibromyalgia: a meta-analysis. *Korean Journal of Pain, 30*(4), 250-257.
- Malkin, I., Williams, F. M. K., Lachance, G., Spector, T., Macgregor, A. J., & Livshits, G. (2014). Low back and common widespread pain share common genetic determinants. *Annals of Human Genetics*, *78*(5), 357–366.
- Mammen, G., Rueda, S., Roerecke, M., Bonato, S., Lev-Ran, S. & Rehm, J. (2018). Association of cannabis with long-term clinical symptoms in anxiety and mood disorders: A systematic review of prospective studies. *The Journal of Clinical Psychiatry*, 79(4), pii:17r11839.
- Marks, W., Fournier, N. M., & Kalynchuk, L. E. (2009). Repeated exposure to corticosterone increases depression-like behavior in two different versions of the forced swim test without altering nonspecific locomotor activity or muscle strength. *Physiology & behavior*, *98*(1-2), 67–72.
- Marum, A. P., Moreira, C., Saraiva, F., Tomas-Carus, P. & Sousa-Guerreiro, C. (2016). A low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet reduced pain and improved daily life in fibromyalgia patients. *Scandinavian Journal of Pain, 13*, 166–172.
- Maskarinec, G., Namatame, L.A., Kang, M., Buchthal, S.D., Ernst, T., Monroe, K.R. et al. (2020). Differences in the association of diet quality with body fat distribution between men and women. *European Journal of Clinical Nutrition* 74, 1434–1441

Mazanderani, F., Locock L. & Powell, J. (2012). Being differently the same: The mediation of identity tensions in the sharing of illness experiences. *Social Science & Medicine*, *74*(4), 546-553.

McBeth, J. & Jones, K. (2007). Epidemiology of chronic musculoskeletal pain. *Best Practice & Research Clinical Rheumatology*, *21*(3), 403–425.

McRae M. P. (2017). Health Benefits of Dietary Whole Grains: An Umbrella Review of Meta-analyses. *Journal of chiropractic medicine*, *16*(1), 10–18.

Mease, P., Arnold, L.M., Bennett, R., Boonen, A., Buskila, D., Carville, S., et al. (2007). Fibromyalgia syndrome. *The Journal of Rheumatology* 34, 1415–1425

- Mease, P. J., Farmer, M. V., Palmer, R. H., Trugman, J. M., Gendreau, R. M. & Wang, Y. (2013). Milnacipran combined with pregabalin in fibromyalgia: A randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin. *Therapeutic Advances in Musculoskeletal Disease*, *5*(3), 113–126.
- Medawar, E., Huhn, S., Villringer, A. & Veronica Witte, A. (2019). The effects of plantbased diets on the body and the brain: a systematic review. *Translational Psychiatry*, *9*(1), 226.
- Meerwijk, E. L., Ford, J. M. & Weiss, S. J. (2013). Brain regions associated with psychological pain: implications for a neural network and its relationship to physical pain. *Brain Imaging and Behaviour*, *7*(1),1–14.
- Messier, S. P., Gutekunst, D. J., Davis, C. & DeVita, P. (2005). Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. *Arthritis & Rheumatism, 52*(7), 2026-2032.

Metyas, S. K., Solyman, J. S., & Arkfeld, D. G. (2015). Inflammatory Fibromyalgia: Is it Real? *Current rheumatology reviews*, *11*(1), 15–17.

- Michalsen, A., Hoffmann, B., Moebus, S., Bäcker, M., Langhorst, J. & Dobos, G.J.
- (2005). Incorporation of fasting therapy in an integrative medicine ward: evaluation of outcome, safety, and effects on lifestyle adherence in a large prospective cohort study. *Complementary Medicine 11*(4), 601-7.

Miró, E., Martínez, M. P., Sánchez, A. I., Prados, G. & Lupiáñez, J. (2015). Men and women with fibromyalgia: Relation between attentional function and clinical symptoms. *British Journal of Health Psychology*, *20*(3), 632–647.

- Moore, D. L., & Tarnai, J. (2002). Evaluating nonresponse error in mail surveys. In: Groves, R. M., Dillman, D. A., Eltinge, J. L., and Little, R. J. A. (eds.), *Survey Nonresponse*, John Wiley & Sons, New York, pp. 197–211.
- Moore, R., Derry, S., Aldington, D., Cole, P., & Wiffen, P. J. (2013). Amitriptyline for neuropathic pain and fibromyalgia in adults. *Journal of Pain and Palliative Care Pharmacotherapy*, 27(2), 179–180.
- Moret, C. & Briley, M. (2011). The importance of norepinephrine in depression. *Neuropsychiatric disease and treatment*, 7(Suppl 1), 9–13.
- Morgan, L. K. & Raper, Jr., J. E. (2005). Comorbidity of Addictive and Psychiatric Disorders. *Journal of Addictive Diseases*, *12*(3), 171–185.
- Morris, C. R., Bowen, L., & Morris, A. J. (2005). Integrative therapy for fibromyalgia: possible strategies for an individualized treatment program. *Southern medical journal*, *98*(2), 177–184.

- Moseley, G. L. & Butler, D. S. (2015). Fifteen Years of Explaining Pain: The Past, Present, and Future. *Journal of Pain*, *16*(9), 807–813.
- Mulligan, A. A., Luben, R. N., Bhaniani, A., Parry-Smith, D. J., O'Connor, L., Khawaja,
 A. P., et al. (2014). A new tool for converting food frequency questionnaire data into nutrient and food group values: FETA research methods and availability.
 BMJ Open, 4(3), e004503.
- Musekamp, G., Gerlich, C., Ehlebracht-König, I., Faller, H. & Reusch, A. (2016). Evaluation of a self-management patient education program for patients with fibromyalgia syndrome: study protocol of a cluster randomized controlled trial. *BMC musculoskeletal disorders*, *17*, 55.
- Nair, R., & Maseeh, A. (2012). Vitamin D: The "sunshine" vitamin. *Journal of pharmacology & pharmacotherapeutics*, *3*(2), 118–126.
- National Health Service (2019). The NHS Long Term Plan. Retrieved March, 24, 2021 from https://www.longtermplan.nhs.uk/wp-content/uploads/2019/08/nhs-longterm-plan-version-1.2.pdf
- National Institute for Health and Care Excellence (2020). Guideline Chronic pain in over 16s: assessment and management. Draft for consultation. Retrieved 5, August 2020 from <u>https://www.nice.org.uk/guidance/GID-</u> NG10069/documents/draftguideline
- Navarro, P., Mehegan, J., Murrin, C. M., Kelleher, C. C., & Phillips, C. M. (2019). Adherence to the Healthy Eating Index-2015 across Generations Is Associated with Birth Outcomes and Weight Status at Age 5 in the Lifeways Cross-Generation Cohort Study. *Nutrients*, *11*(4), 928.
- Neurmann, L., Lener, E. & Glazer, Y. (2008). A cross-sectional study of the relationship between body mass index and clinical characteristics, tenderness measures, quality of life, and physical functioning in fibromyalgia patients. *Clinical Rheumatology* 27(12), 1543 – 1547.
- Nishida, C., Uauy, R., Kumanyika, S & Shettey, P. (2004). The joint WHO/FAO expert consultation on diet, nutrition and the prevetion of chronic diseases; process, product and policy implications. *Public Health Nutrition* 7(1A), 245-250.
- Obata H. (2017). Analgesic Mechanisms of Antidepressants for Neuropathic Pain. *International journal of molecular sciences*, *18*(11), 2483.
- Office for National Statistics. (2019). Internet access households and individuals, Great Britain: 2019. Retrieved, July 23, 2020 from <u>https://www.ons.gov.uk/peoplepopulationandcommunity/householdcharacteristics</u> /homeinternetandsocialmediausage/bulletins/internetaccesshouseholdsandindivi duals/2019
- Okan, S., Turk, A. C., Hakan, S., Filiz, O. & Okan, F. (2019). Association of ferritin levels with depression, anxiety, sleep quality, and physical functioning in patients with fibromyalgia syndrome: a cross-sectional study. *Croatian Medical Journal*, *60*, 515-520
- Okyay, R., Koçyigit, B. & Gürsoy, S. (2016). Vitamin D levels in women with fibromyalgia and relationship between pain, tender point count and disease activity. *Acta Medica Mediterranea*, *32(1)*, 243–247.

- Olama, S.M., Senna, M.K., Elarman, M.M. & Elhawary, G. (2013). Serum vitamin D level and bone mineral density in premenopausal Egyptian women with fibromyalgia. *Rheumatology International*, *33(1)*,185–192.
- O'Leary, F., & Samman, S. (2010). Vitamin B12 in health and disease. *Nutrients*, 2(3), 299–316.
- Ortancil, O., Sanli, A., Eryuskel, R., Basaran, A. & Ankarali, H. (2010). Association between serum ferritin level and fibromyalgia syndrome. *European Journal of Clinical Nutrition, 64,* 308–312.
- Ostry, A., Young, M. L. & Hughes, M. (2008). The quality of nutritional information available on popular websites: a content analysis, *Health Education Research*, 23 (4), 648–655
- Paddon-Jones, D., Short, K.R., Campbell, W.W., Volpi, E., Wolfe, R.R. (2008). Role of dietary protein in the sarcopenia of aging, *The American Journal of Clinical Nutrition*, 87(5), 1562–1566.
- Pagliai G, Giangrandi I, Dinu M, Sofi F, Colombini B. (2020). Nutritional Interventions in the Management of Fibromyalgia Syndrome. *Nutrients, 12*(9), 2525.
- Pamuk, G. E., Pamuk, O. N., Set, T., Harmandar, O., & Yeşil, N. (2008). An increased prevalence of fibromyalgia in iron deficiency anemia and thalassemia minor and associated factors. *Clinical Rheumatology*, *27*(9), 1103–1108.
- Paqueron, X., Conklin, D. & Eisenach, J.C. (2003). Plasticity in action of intrathecal clonidine to mechanical but not thermal nociception after peripheral nerve injury. Anaesthesiology, 99(1), 199–204.
- Parker, G.B., Brotchie, H. & Graham, R.K. (2017). Vitamin D and depression. *Journal of Affective Disorders*, 208, 56-61.
- Paulson, M., Norberg, A. & Danielson, E. (2002). Men living with fibromyalgia-type pain: Experiences as patients in the Swedish health care system. *Journal of Advanced Nursing, 40*(1), 87–95.
- Petermann-Rocha, F., Gray, S., Pell, J., & Celis-Morales, C. (2020). Diet-quality and its association with cardiovascular diseases and cancer incidence and all-cause mortality: A prospective cohort study from UK Biobank. *Proceedings of the Nutrition Society, 79*(OCE2), E72. doi:10.1017/S0029665120000208
- Peters, S. L., Biesiekierski, J. R., Yelland, G. W., Muir, J. G., & Gibson, P. R. (2014). Randomised clinical trial: gluten may cause depression in subjects with noncoeliac gluten sensitivity - an exploratory clinical study. *Alimentary pharmacology & therapeutics*, *39*(10), 1104–1112.
- Plotnikoff, G.A. & Quigley, J.M. (2003). Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. *Mayo Clinic Proceedings*, *78*(12),1463–1470.
- Premkumar, L. S. & Abooj, M. (2013). TRP channels and analgesia. *Life sciences*, *92*(89), 415–424.
- Public Health England. (2016). Government Dietary Recommendations: Government recommendations for energy and nutrients for males and females aged 1 18 years and 19+ years. London: Crown
- Public Health England. (2020). NDNS: results from years 9 to 11 (combined) statistical summary. London: Crown

- Raatz, S. K., Conrad, Z., Johnson, L. K., Picklo, M. J., & Jahns, L. (2017). Relationship of the Reported Intakes of Fat and Fatty Acids to Body Weight in US Adults. *Nutrients*, *9*(5), 438.
- Raffaeli, W. & Arnaudo, E. (2017). Pain as a disease: an overview. *Journal of pain research*, *10*(1), 2003–2008.
- Rahman, A., Underwood, M. & Carnes, D. (2014). Fibromyalgia. *British Medical Journal*, *348*(1), 28–32.
- Ram, M. & Shoenfeld, Y. (2008). Hepatitis B: Infection, vaccination and autoimmunity. *Israel Medical Association Journal*, *10*(1), 61–64.
- Ramsey, I.S., Delling, M. & Clapham, D.E. (2006). An introduction to TRP channels. Annual review of physiology, *68*, 619–647.
- Resnicow, K., Odom, R., Wang, T., Dudly, W.N., Mitchell, D., Vaughan, R., et al. (2000). Validation of Three Food Frequency Questionnaires and 24-Hour Recalls with
- Serum Carotenoid Levels in a Sample of African-American Adults, *American Journal of Epidemiology*, *152*(11), 1072–1080,
- Rizzo, G., Laganà, A. S., Rapisarda, A. M., La Ferrera, G. M., Buscema, M., Rossetti, P., Nigro, A., Muscia, V., Valenti, G., Sapia, F., Sarpietro, G., Zigarelli, M., & Vitale, S. G. (2016). Vitamin B12 among Vegetarians: Status, Assessment and Supplementation. *Nutrients*, 8(12), 767.
- Rodrigo, L., Blanco, I., Bobes, J., & de Serres, F. J. (2013). Remarkable prevalence of coeliac disease in patients with irritable bowel syndrome plus fibromyalgia in comparison with those with isolated irritable bowel syndrome: a case-finding study. *Arthritis research & therapy*, *15*(6), R201.
- Rossi, A., di Lollo, A.C., Guzzo, M.P., Giacornelli, C., Atenzi, F., Bazzichi, L., et al. (2015). Myalgia and nutrition: what news? Clinical and Experimental *Rheumatology, 33*(Suppl. 88), S117-S125.
- Russell, J., Perkins, A. & Michalek, J. (2009). Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: A randomized, double-blind, placebo-controlled, multicenter clinical trial. *Arthritis and Rheumatism*, *60*(1), 299–309.
- Sakarya, S. T., Akyol, Y., Bedir, A., & Canturk, F. (2011). The relationship between serum antioxidant vitamins, magnesium levels, and clinical parameters in patients with primary fibromyalgia syndrome. *Clinical rheumatology*, *30*(8), 1039–1043.
- Sapone, A., Bai, J.C., Ciacci, C., Dolinsek, J., Green, P.H., Hadjivassiliou, M., et al. (2012). Spectrum of gluten-related disorders: consensus on new nomenclature and classification. *BMC Medicine*, *10*(1),13.
- Satija, A., Bhupathiraju, S.N., Spiegelman, D., Chiuve, S.E., Manson, J.E., Willett, A., et al., (2017). Healthful and Unhealthful Plant-Based Diets and the Risk of Coronary Heart Disease in U.S. Adults. *Journal of the American College of Cardiology, 70*(4), 411- 422.
- Schmid, A., Petry, N., Walther, B., Butikofer, U., Luginbuhl, W., Gille, D., et al., (2015). Inflammatory and metabolic responses to high-fat meals with and without dairy products in men. British Journal of Nutrition (2015), 113, 1853–1861

- Schoenfeld, J.D. & John, P.A. (2013). Is everything we eat associated with cancer? A systematic cookbook review, *The American Journal of Clinical Nutrition*, *97*(1), 127–134.
- Schrepf, A., Harper, D. E., Harte, S. E., Wang, H., Ichesco, E., Hampson, J. P., et al. (2017). Endogenous opioidergic dysregulation of pain in fibromyalgia: a PET and fMRI study. *Pain*, *157*(10), 2217–2225.
- Schreuder, F., Bernsen, R. M., & van der Wouden, J. C. (2012). Vitamin D supplementation for nonspecific musculoskeletal pain in non-Western immigrants: a randomized controlled trial. *Annals of family medicine*, *10*(6), 547– 555.
- Schulte, E.M., Potenza, M.N. & Gearhardt, A.N. (2017). A commentary on the "eating addiction" versus "food addiction" perspectives on addictive-like food consumption. *Appetite*, *115*, 9-15.
- Schulze, M.B. & Hoffman, K. (2006). Methodological approaches to study dietary patterns in relation to risk of coronary heart disease and stroke. The British journal of nutrition, 95(5), 860-9.
- Schulze, M.B., Martínez-González, M.A., Fung, T.T., Lichtenstein, A.H. & Forouhi, N.G. (2018). Food based dietary patterns and chronic disease prevention. *BMJ 361,* k2396
- Schumacher H.R., Pullman-Mooar, S., Gupta, S.R., Dinnella, J.E. & Kim, R. (2013). Randomized double-blind crossover study of the efficacy of a tart cherry juice blend in treatment of osteoarthritis (OA) of the knee. Osteoarthritis and Cartilage, 21(8), 1035–1041
- Schwingshackl, L., Bogensberger, B. & Hoffmann, G. (2018). Diet Quality as Assessed by the Healthy Eating Index, Alternate Healthy Eating Index, Dietary Approaches to Stop Hypertension Score, and Health Outcomes: An Updated Systematic Review and Meta-Analysis of Cohort Studies. *Journal of the Academy of Nutrition and Dietetics*, *118*(1), 74-100.
- Scott, J. R., Hassett, A. L., Schrepf, A. D., Brummett, C. M., Harris, R. E., Clauw, D. J. & Harte, S. E. (2018). Moderate alcohol consumption is associated with reduced pain and fibromyalgia symptoms in chronic pain patients. *Pain Medicine*, *19*(12), 2515–2527.
- Scientific Advisory Committee on Nutrition (SACN). (2010). *Iron and Health*. London: TSO
- Scientific Advisory Committee on Nutrition (SACN). (2011). *Dietary Reference Values for Energy*. London: TSO
- Scientific Advisory Committee on Nutrition (SACN). (2019). Saturated Fats and Health. London: TSO
- Segura-Jiménez, V., Estévez-López, F., Soriano-Maldonado, A., Álvarez-Gallardo, I. C., Delgado-Fernández, M., Ruiz, J. R., et al. (2016). Gender Differences in Symptoms, Health-Related Quality of Life, Sleep Quality, Mental Health, Cognitive Performance, Pain-Cognition, and Positive Health in Spanish Fibromyalgia Individuals: The Al-Ándalus Project. *Pain research & management*, 5135176.

- Senna, M.K., Sallam, R.A., Ashour, H.S. & Elarman, M. (2012). Effect of weight reduction on the quality of life in obese patients with fibromyalgia syndrome: a randomized controlled trial. *Clinical Rheumatology*, *31*(11),1591-1597.
- Serefko, A., Szopa, A., Wlaz, P., Nowak, G., Rasziwon-Zaleska, M., Skalski, M., et al. (2013). Magnesium in depression. *Pharmacological Reports, 65*(3), 547-54.
- Shao, A., Drewnowski, A., Willcox, D. C., Krämer, L., Lausted, C., Eggersdorfer, M., et al. (2017). Optimal nutrition and the ever-changing dietary landscape: a conference report. *European journal of nutrition*, *56*(Suppl 1), 1–21.
- Shapiro, J. R., Anderson, D. A. & Danoff-Burg, S. (2005). A pilot study of the effects of behavioral weight loss treatment on fibromyalgia symptoms. *Journal of Psychosomatic Research*, *59*(5), 275–282.
- Sheng, J., Liu, S., Wang, Y., Cui, R., & Zhang, X. (2017). The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain. *Neural plasticity*, 2017, 9724371.
- Shim, J. S., Oh, K., & Kim, H. C. (2014). Dietary assessment methods in epidemiologic studies. *Epidemiology and health*, *36*, e2014009.
- Sills G. J. (2006). The mechanisms of action of gabapentin and pregabalin. *Current* opinion in pharmacology, 6(1), 108–113.
- Silva, A., Bernardo, A., Cardoso, J.C.A., Santos, P., Mesquita, M.F., Moreira, J.V.P.P., Silva, M.L. & Padrão, P. (2019) Dietary interventions in fibromyalgia: a systematic review. *Annals of Medicine*, *51*(sup1), 2-14
- Silver, D.S. & Gebler, L. (2016). Nutritional Management of Fibromyalgia. *Archives of Medicine 8*(2).
- Simon, G. E., VonKorff, M., Piccinelli, M., Fullerton, C., & Ormel, J. (1999). An international study of the relation between somatic symptoms and depression. *The New England journal of medicine*, *341*(18), 1329–1335.
- Singer, E., van Hoewyk, J., & Maher, M. P. (2000). Experiments with incentives in telephone surveys. *Public Opinion Quarterly* 64: 171–188.
- Singh, G. & Kaul, S. (2018). Anxiety and depression are common in fibromyalgia patients and correlate with symptom severity score. *Indian Journal of Rheumatology*, *13*(3), 168.
- Skerrett, P. J. & Willett, W. C. (2010). Essentials of healthy eating: a guide. *Journal of midwifery & women's health*, 55(6), 492–501.
- Slim, M., Calandre, E.P. & Rico-Villademoros, F. (2015). An insight into the gastrointestinal component of fibromyalgia: clinical manifestations and potential underlying mechanism. *Rheumatology International*, *35(3)*, 433-444.
- Sluka, K. A. & Clauw, D. J. (2016). Neurobiology of fibromyalgia and chronic widespread pain. *Neuroscience*, *338*, 114–129.
- Smith, J., Terpening, C., Schmidt, S. & Gums, J. (2001). Relief of fibromyalgia symptoms following dietary excitotoxins. *The Annals of Pharmacotherapy, 3*5(6), 702-708.
- Soppi E. T. (2018). Iron deficiency without anemia a clinical challenge. *Clinical case reports*, *6*(6), 1082–1086.
- Sotos-Prieto, M., Bhupathiraju, S. N., Mattei, J., Fung, T. T., Li, Y., Pan, A., Willett, W. C., Rimm, E. B., & Hu, F. B. (2017). Association of Changes in Diet Quality with

Total and Cause-Specific Mortality. *The New England Journal of Medicine*, 377(2), 143–153.

Spitzer, R. L., Kroenke, K., Williams, J. B. W. & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. *Archives of Internal Medicine*, *166*(10), 1092–1097.

- Sprott Souzan Salemi, H., Rethage, J., Salemi, S., Rethage, J., Michel, B., Gay, R., et al. (2003). skin of patients with fibromyalgia. Detection of interleukin 1beta (IL1beta), IL-6, and tumor necrosis factor-alpha in. *The Journal of Rheumatology*, *3030*(30), 146–1501.
- Staud, R. (2011). Sodium oxybate for the treatment of fibromyalgia. *Expert Opinion on Pharmacotherapy*, *12*(11), 1789–1798.
- Staudacher, H.M., Irving, P.M., Lomer, M.C.E. & Whelan, K. (2014). Mechanisms and efficacy of dietary FODMAP restriction in IBS. *Gastroenterology & Hepatology*, *11*(4), 256–66.
- Steiner, L., Bigatti, S., Slaven, J.E. & Ang, D. (2017). The Complex Relationship between Pain Intensity and Physical Functioning in Fibromyalgia: The Mediating Role of Depression. Journal of Applied Biobehavioral Research, 22(4), e12079.
- Strath, L.J., Jones, C.D., George, A.P., Lukens, S.L., Morrison, S.A., Soleymani, et al. (2020). The Effect of Low-Carbohydrate and Low-Fat Diets on Pain in Individuals with Knee Osteoarthritis. *Pain Medicine*, 21(1), 150–160.
- Sugerman, D.T. (2014). Fibromyalgia. The Journal of the American Medical Association, *311*(15), 1577.
- Swire-Thomson, B. & Lazer, D. (2020). Public Health and Online Misinformation: Challenges and Recommendations. *Annual Review of Public Health 41*, 433 – 451.
- Tanaka, T., Narazaki, M. & Kishimoto, T. (2014). IL-6 in Inflammation, Immunity, and Disease biological effect of il-6 on inflammation and immunity regulation of il-6 synthesis. *Cold Spring Harbor Perspectives in Biology*, *6*(10), a016295.
- Taylor, V. H., Curtis, C. M., & Davis, C. (2010). The obesity epidemic: the role of addiction. *CMAJ* : Canadian Medical Association journal = journal de l'Association medicale canadienne, 182(4), 327–328.
- Teodoro T., Edwards M. J. & Isaacs J. D. (2018). A unifying theory for cognitive abnormalities in functional neurological disorders, fibromyalgia and chronic fatigue syndrome: systematic review. *Journal of Neurology, Neurosurgery & Psychiatry 89*(1), 1308-1319.
- Thetford, K., Archer, S., Shayka, J., Gernhofer, N., Peters, E., Gowan, A., et al. (1999). Comparison of a food frequency questionnaire to 3-24 hour recalls in young women. *Journal of the American Dietetic Association, 99*(9), A92.
- Tian, D., Tian, M., Zhang, L., Zhao, P., Cui, Y., & Li, J. (2018). High fat diet sensitizes fibromyalgia-like pain behaviors in mice via tumor necrosis factor alpha. *PloS one*, *13*(2), e0190861.
- Tiernan, C., Imrhan, V., Prasad, C., Vijayagopal, P. & Shanil, S. (2015). Tart cherry in amelioration of pain in the elderly. *Nutrition and Aging 3*(2-4), 203-217.

Tosti, V., Bertozzi, B. & Fontana, L. (2018). Health benefits of the Mediterranean diet: metabolic and molecular mechanisms. *The Journals of Gerontology*, *73*(3), 318–326.

Trivedi, M. H. (2004). The link between depression and physical symptoms. *Primary care companion to the Journal of clinical psychiatry*, *6*(Suppl 1), 12–16.

Troncone, R. & Jabri, B. (2011). Coeliac disease and gluten sensitivity. *Journal of International Medicine*, 269(6), 582-90.

Turner-McGrievy, G.M., Davidson, C.R., Wingard, E.E., Wilcox, S. & Frongillo, E.A. (2015). Comparative effectiveness of plant-based diets for weight loss: a randomized controlled trial of five different diets. *Nutrition 31*(2), 350-358.

U.S. Department of Health and Human Services and U.S. Department of Agriculture. (2015). *Dietary Guidelines for Americans*. 8th Edition. Retrieved 5, August 2020 from <u>https://health.gov/our-work/food-and-nutrition/2015-2020dietary-guidelines/</u>

Vellisca, M. & Latorre, J. (2014). Monosodium glutamate and aspartame in perceived pain in fibromyalgia. *Rheumatology International*, *34*(7), 1011–1013.

Vos, T., Flaxman, A.D., Naghavi, M., Lozano, R., Muchaud, C., Ezzati, M., et al. (2012). Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Globel Burden of Disease Study 2010. *Lancet 380*(9859), 2163-2196.

Wallace, T.C., Bailey, R.L., Blumberg, J.B., Burton-Freeman, B., Oliver Chen, C., Crowe-White, K.M., et al., (2020). Fruits, vegetables, and health: A comprehensive narrative, umbrella review of the science and recommendations for enhanced public policy to improve intake. *Critical Reviews in Food Science* and Nutrition, 60(13), 2174-2211.

Wahner-Roedler, D. L., Elkin, P. L., Vincent, A., Thompson, J. M., Oh, T. H., Loehrer, L.
 L., Mandrekar, J. N., & Bauer, B. A. (2005). Use of complementary and alternative medical therapies by patients referred to a fibromyalgia treatment program at a tertiary care center. *Mayo Clinic proceedings*, 80(1), 55–60.

Watson, N. F., Buchwald, D., Goldberg, J., Noonan, C., & Ellenbogen, R. G. (2010). Neurologic signs and symptoms in fibromyalgia. *Arthritis and rheumatism*, *60*(9), 2839–2844.

Webb, T.L., Joseph, J., Yardley, L. & Michie, S. (2010). Using the internet to promote health behavior change: a systematic review and meta-analysis of the impact of theoretical basis, use of behavior change techniques, and mode of delivery on efficacy. Journal of Medical Internet Research, *12*(1):e4.

Wolfe, F., Smythe, H.A., Yunus, M.B., Bennet, R.M., Bombardier, C., Goldenberg, D.L., et al. (1990). The American college of rheumatology 1990 criteria for the classification of fibromyalgia. *Arthritis & Rheumatism 33*(2), 153-304.

Wolfe, F., Russell, G.A., Vipraio, G., Ross, K. & Anderson, J. (1997) Serotonin levels, pain threshold and fibromyalgia symptoms in the general population. *Journal of Rheumatology*, 24(3), 555-559.

Wolfe, F., Clauw, D.J., Fitzcharles, M.A., Goldenberg, D.L. Latz, R.S., Mease, P., Russell, A.S., et al. (2010). The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. *Arthritis Care & Research 62*(5), 600-610.

Wolfe, F. & Walitt B. (2013). Culture, science and the changing nature of fibromyalgia. *Nature Reviews Rheumatology* 9(12), 751–755.

Wolfe, f., Shmukler, J., Jamal, S., Castrejon, I., Gobson, K., Srinivasan, S., et al. (2019). Diagnosis of Fibromyalgia: Disagreement Between Fibromyalgia Criteria and Clinician-Based Fibromyalgia Diagnosis in a University Clinic. *Arthritis care & research*, 71(3), 343-351.

- World Health Organization. (2001). International Classification of Functioning, Disability and Health (ICF). Geneva: World Health Organization.
- World Health Organisation. (2003). *Diet, Nutrition and The Prevention of Chronic Diseases.* Geneva: World Health Organization.
- World Health Organisation. (2020). Body Mass Index BMI. Retrieved 7 August, 2020 from <u>https://www.euro.who.int/en/health-topics/disease-</u> prevention/nutrition/ahealthy-lifestyle/body-mass-index-bmi
- Wu, Z., Malihi, Z., Stewart, A.W., Lawes, C.M. & Scragg, R. (2018). The association between vitamin D concentration and pain: a systematic review and metaanalysis. *Public Health Nutr.* 21(11), 2022-2037
- Yang, T. Y., Chen, C. S., Lin, C. L., Lin, W. M., Kuo, C. N., & Kao, C. H. (2017). Risk for Irritable Bowel Syndrome in Fibromyalgia Patients: A National Database Study. *Medicine*, *96*(14), e6657.
- Yasui, M., Menjyo, Y., Tokizane, K., Shiozawa, A., Tsuda, M., Inoue, K. & Kiyama, H. (2019). Hyperactivation of proprioceptors induces microglia-mediated long-lasting pain in a rat model of chronic fatigue syndrome. *Journal of Neuroinflammation*, *16*, 67.
- Yunus, M. B., Arslan, S. & Aldag, J. C. (2002). Relationship between body mass index and fibromyalgia features. *Scandinavian Journal of Rheumatology*, *31*(1), 27–31.
- Zadro, J., Shirley, D., Ferreira, M., Carvalho, A.P., Lamb, S.E. Cooper, C. & Ferreira, P.H. (2017). Mapping the Association between Vitamin D and Low Back Pain: A Systematic Review and Meta-Analysis of Observational Studies. *Pain Physician*, 20(7), 611-640.
- Zamani, M., Alizadeh-Tabari, S. & Zamini, V. (2019). Systematic review with metaanalysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. *Alimentary Pharmacology & Therapeutics, 50*(2), 132-143.
- Zick, S.M., Murphy, Susan, L.M. & Colacino, J. (2020) Association of chronic spinal pain with diet quality. *PAIN Reports, 5*(5), e837.
- Ziebland, S. & Wyke, S. (2012). Health and illness in a connected world: how might sharing experiences on the internet affect people's health? *The Milbank quarterly*, *90*(2), 219–249.
- Ziebland, S., Lavie-Ajayi, M. & Lucius-Hoene, G. (2015). The role of the Internet for people with chronic pain: examples from the DIPEx International Project. *British journal of pain*, *9*(1), 62–64.

12 Appendix

Appendix A Participant Survey

ica Survey Software	15/09/2020, 06:37					
Respondent data					well on S.Bothwell k.vafeiadou@herts.	
Welcome to the research study!						
We are interested in understanding the association be		Do you consent	t to take pa	rt in this survey	?	
and participant led adaptation to diet for pain manage sufferers. You will be asked to complete a series of q		O Yes				
your fibromyalgia symptoms. You will be asked to cor	mplete a food frequency	O No				
questionnaire and information about any dietary chan relation to your fibromyalgia.						
The study should take you around 60 minutes to com	plete. Your participation	Gender				
in this research is voluntary. You have the right to with during the study, for any reason, and without any prej		I ∳				
This form will allow you to register for the survey and		Date of Birth				
be provided with a unique identification number, pass						
By clicking the button below, you acknowledge that y study is voluntary, you are 18 years of age, and that y	ou are aware that you					
may choose to terminate your participation in the stud any reason. You have been informed of storage metho		In which countr	ry do you ci	urrently reside?		
this study and any risks associated with participation.		1			0)	
your responses will be kept completely confidential. U	JH protocol				- -	
number LMS/PGR/UH/03765. Please note this appl approved by the Health, Science, Engineering & Te		Medical inform	nation			
Please note that this survey will be best displayed on computer. Some features may be less compatible for						
device.		Do you have a	diagnosis fi	rom a medical p	professional?	
If you would like to contact the Principal Investigator	in the study to discuss	t	4			
(herts.su.gutl1/563.com/Q)[didSection/Blocks/Alise/BetSur_unver(D=5V,de4x12m7uhs1Pv&Context		https://herts.au.guallrics.com/Q/Edi	-Cartine/Encles (Enc	Detter scentb-SV didst	Zm7U8h4TPv&ContextLibrary@=UI	cXRez9cOKCWyXpz
st Survey Software	15,98(1000, 06:37	Qualifics Survey Software				
a sony solem Are you prescribed medication for fibromyalgia?	15,04(1920, 5413)					
Are you prescribed medication for fibromyalgia?	150407090, 64:57	Qualifics Survey Software		her conditions.		
Are you prescribed medication for fibromyalgia?	15.00(1000, 08-07	Qualificat Servey Software		her conditions,		rees Amount (Numb of tablets,
Are you prescribed medication for fibromyalgia?	15.96(392), 66 (3 ¹	Qualificat Servey Software	pecific to ot	her conditions, Medication	Strength (each tablet or capsule)	rees Amount (Numb of tablets,
Are you prescribed medication for fibromyalgia? Ves No		Outline Borry Software No Medications sp	pecific to ot			recei Amount (Numb of tablets, capsules oft,
Are you prescribed medication for fibromyalgia? Ves No Medications specific to fibromyalgia	Amount (Number of tablets,	Curbics Borry Software No Medications sp Condi	pecific to ot			recei Amount (Numb of tablets, capsules oft,
Are you prescribed medication for fibromyalgia? Ves No	Amount (Number of tablets, capaules or tsp in	Outhous Burry Software No Medications sp Condi	pecific to ot			recei Amount (Numb of tablets, capsules oft,
Are you prescribed medication for fibromyalgia? Ves No Medications specific to fibromyalgia Strength (ea	Amount (Number of tablets, capaules or tsp in	Outhous Burry Software No Medications sp Condi 1	pecific to ot			recei Amount (Numb of tablets, capsules oft,
Are you prescribed medication for fibromyalgia? Ves No Medications specific to fibromyalgia Medication Strength (ea tablet or caps	Amount (Number of tablets, capaules or tsp in	Surfriss Borry Software No Medications sp Condi 1 2 3	pecific to ot			recei Amount (Numb of tablets, capsules oft,
Are you prescribed medication for fibromyalgia? Ves No Medications specific to fibromyalgia Medication Strength (ea tablet or caps 1 2	Amount (Number of tablets, capaules or tsp in	Quatrics Borry Software No Medications sp Condi 1 2 3 4	pecific to ot			recei Amount (Numb of tablets, capsules oft,
Are you prescribed medication for fibromyalgia? Ves No No Medications specific to fibromyalgia Medication Strength (ea tablet or caps tablet	Amount (Number of tablets, capaules or tsp in	Quatics therey to heres No Medications sp Condi 1 2 3 4 5	pecific to ot			recei Amount (Numb of tablets, capsules oft,
Are you prescribed medication for fibromyalgia? Ves No No Medications specific to fibromyalgia Medication Strength (es tablet or caps tablet	Amount (Number of tablets, capaules or tsp in	Outline being between No Medications sp Condi 1 2 3 4 5 6	becific to ot	Medication	tablet őr cápsule)	Amount (Numb of tablets, capsules of s
Are you prescribed medication for fibromyalgia? Ves. No Medications specific to fibromyalgia Medication Strength (ea tablet or caps 1 2 3 4 5	Amount (Number of tablets, capaules or tsp in	Outlies being Softers No Medications sp Condi 1 2 3 4 5 6 Do you take off	becific to ot	Medication	tablet őr cápsule)	Amount (Numb of tablets, capsules of s
Are you prescribed medication for fibromyalgia? Ves No Medications specific to fibromyalgia Medication Strength (sa tablet or caps tablet or	Amount (Number of tablets, capaules or tsp in	Outline being between No Medications sp Condi 1 2 3 4 5 6	becific to ot	Medication	tablet őr cápsule)	Amount (Numb of tablets, capsules of s
Are you prescribed medication for fibromyalgia? Ves No Medications specific to fibromyalgia Medication Strength (ea tablet or caps Medication Strength (ea tablet or caps f f f f f f f f f f f f f f f f f f f	Amount (Number of tablets, capsules or tsp in ule) 1 dey)	Custors Sonry Solvers No Medications sp Condi 1 2 3 4 5 6 Do you take off Ves	becific to ot	Medication	tablet őr cápsule)	Amount (Numb of tablets, capsules of s
Are you prescribed medication for fibromyalgia? Ves. No Medications specific to fibromyalgia Medication Strength (ea tablet or caps tablet or	Amount (Number of tablets, capsules or tsp in ule) 1 dey)	Custors Sonry Solvers No Medications sp Condi 1 2 3 4 5 6 Do you take off Ves	becific to oth	Medication	tablet őr cápsule)	Amount (Numb of tablets, capsules of s
Are you prescribed medication for fibromyalgia? Ves No Medications specific to fibromyalgia Medication Strength (ea tablet or caps Medication Strength (ea tablet or caps f f f f f f f f f f f f f f f f f f f	Amount (Number of tablets, capsules or tsp in ule) 1 dey)	No No No No No No No No No No No No No N	becific to oth ition her over the ker medicati	Medication e counter medic on information.	tablet or capsule) ations? Amount (Number of tablets, capsules or tsp in	Arnount (Numb of tablets, capsules or tsp 1 day)
Are you prescribed medication for fibromyalgia? Ves No Medications specific to fibromyalgia Medication Strength (ea tablet or caps Medication Strength (ea tablet or caps L L L L L L L L L L L L L L L L L L L	Amount (Number of tablets, capsules or tsp in 1 day) ed or unrelated to	No No No No No No No No No Medications sp Condi 1 2 3 4 5 6 No No No No No No No	becific to oth ition her over the ker medicati	Medication	tablet or capsule) tablet or capsule) tablet or capsule)	Amount (Numb of tablets, capsules of s
 Yes No Medications specific to fibromyalgia Medication Strength (ea tablet or caps 1 3 4 5 6 Do you suffer from any other medical conditions relat 	Amount (Number of tablets, capsules or tsp in 1 day) ed or unrelated to	No No No No No No No No No No No No No N	becific to oth ition her over the ker medicati	Medication e counter medic on information.	tablet or capsule) ations? Amount (Number of tablets, capsules or tsp in	Arnount (Numb of tablets, capsules or tsp 1 day)

ey Software		

15/09/2020. 08:37

Qualitics Survey Software

BMI

3

4

5

6

Height: please record this measure in metres.

Height can be calculated by removing your shoes, standing with your back to the wall and looking directly forward. The back of your feet, calves, bottom, upper back and the back of your head should all be in contact with the wall. Using a flat item rested on the crown of the head make a light mark on the wall. Measure from the ground to this mark using a tape measure.

Weight: please record this in kg.

Use a digital scale. Avoid using bathroom scales that are spring-loaded. Place the scale on firm flooring (such as tile or wood) rather than carpet. Remove shoes and heavy clothing. Stand with both feet in the centre of the scale. Please leave this section blank if you do not have access to digital scales.

FIQR

For each of the following 9 questions, check the box that best indicates how much your Fibromyalgia made it difficult to perform each of the following

n/Blocks/Ajax/GetSur..uvwylO=SV_db4x12m7UshsTPv&ContextUbraryIO=UR_cXReg8pQKCWvXp; Page 5 of 32

0 0 0 0 0 0 0 0 0 0 0

For each of the foll	owing 2 g	uestio	ns, ch	eck th	e box	that b	est de	scribe	s the	overa	
impact of your Fibr	omyalgia	over the	he last	t 7 day	/s.						
impact of your Fibr			he las	t 7 day	/S.						
impact of your Fibr	omyalgia Nev		he last	t 7 day	/5.					Ah	ways

/GetSur. urveyID+SV_db4x1Zm7UihsTPv&ContextLibraryID+UR_cXReg0gOXCWvXpz Page 8 of 32

Qualitios Survey Software 16/09/2020, 06:37 Fibromyalgla prevented me from accomplishing goals for the week 0 0 0 0 0 0 0 0 0 0 0 I was completely overwhelmed by my fibromyalgia symptoms

For each of the following 10 questions, select the box that best indicates your intensity level of these common Fibromyalgia symptoms over the past 7 days.

		0	1	2	3	4	5
Please rate the level of pain	No Pain	0	0	0	0	0	0
Please rate your level of en	ergy Lots of energy	0	0	0	0	0	0
Please rate your level of stiff	fness No stiffness	0	0	0	0	0	0
Please rate the quality of your	sleep Awoke rested	0	0	0	0	0	0
Please rate your level of depre	ssion No depression	0	0	0	0	0	0
Please rate your level of mem	ory problems Good memory	0	0	0	0	0	0
Please rate your level of an	xiety Not anxious	0	0	0	0	0	0
Please rate your level of tend	derness to touch No tenderness	0	0	0	0	0	0
Please rate your level of bal	ance problems No Imbalance	0	0	0	0	0	0
Please rate your level of se	nsitivity to loud No						

Qualifics Survey Software						16/09/2	2020, 08 37	
noises, bright lights, odors, and cold.	sensitivity	0	0	0	0	0	0	

PHQ-9 + GAD-7

Over the last 2 weeks, how often have you been bothered by any of the following problems?

	Not at all	Several days	More than half the days	Nearly every day
Little interest or pleasure in doing things?	0	0	0	0
Feeling down, depressed, or hopeless	0	0	0	0
Trouble falling or staying asleep, or sleeping much	0	0	0	0
Feeling tired or having little energy	0	0	0	0
Poor appetite or overeating	0	0	0	0
Feeling bad about yourself — or that you are a failure or have let yourself or your family down	0	0	0	0
Trouble concentrating on things, such as reading the newspaper or watching television	0	0	0	0
Moving or speaking so slowly that other people could have noticed? Or the opposite — being so fidgety or restless that you have been moving around a lot more than usual	0	0	0	0
Thoughts that you would be better off dead or of hurting yourself in some way	0	0	0	0

Over the last 2 weeks, how often have you been bothered by the following problems?

tion/Blocks/Ajax/GetSur..urvey/D+5V.db4x12m7U/hsTPv8ContextLibrary/D+UR_ckReg9gDKCwyxpg Page 8 of 32

15/09/2020 08:37

activities during the past 7 days. If you did not perform a particular activity in the last 7 days, rate the difficulty for the last time you performed the activity. If you can't perform an activity, check the last box.

	No	difficu	lty				V	ery dif	ficult		
	0	1	2	з	4	5	6	7	8	9	10
Brush or comb your hair	0	0	0	0	0	0	0	0	0	0	0
Walk continuously for 20 minutes	0	0	0	0	0	0	0	0	0	0	0
Prepare a homemade meal	0	0	0	0	0	0	0	0	0	0	0
Vacuum, scrub, or sweep floors	0	0	0	0	0	0	0	0	0	0	0
Lift and carry a bag full of groceries	0	0	0	0	0	0	0	0	0	0	0
Climb one flight of stairs	0	0	0	0	0	0	0	0	0	0	0
Change bedsheets	0	0	0	0	0	0	0	0	0	0	0
Sit in a chair for 45 minutes	0	0	0	0	0	0	0	0	0	0	0
Shop for groceries	0	0	0	0	0	0	0	0	0	0	0

75

76

Fish fingers, fishcakes Other white	0	0	0	0	0	0	0	0	С	Cream crackers, cheese	0	0	0	0	0	0	0	0	0
fish, fresh or frozen, eg. cod, haddock, plaice, sole, halibut	0	0	0	0	0	0	0	0	С	biscuits Crisp bread, eg. Ryvita	0	0	0	0	0	0	0	0	0
Oily fish, fresh or canned, eg. mackerel, kippers, tuna, salmon,	0	0	0	0	0	0	0	0	С	CEREALS (one bow!) Never or less than once/month	1-3 per month	Once a week	2-4 per week	5-6 per week	Once a day	2-3 per day	4-5 per day	6+ day
sardines, herring Shellfish, eg.										Porridge, Ready brek	0	0	0	0	0	0	0	0	0
crab, prawns, mussels	0	0	0	0	0	0	0	0	С	Breakfast cereal such as cornflakes.	0	0	0	0	0	0	0	0	0
Fish roe, taramasalata	0	0	0	0	0	0	0	0	С	corntakes, muesii etc.									
BREAD AND	SAVOURY	BISCUI	TS (one	e slice o	ır biscı	uit)				POTATOES	, RICE AND	PASTA (mediun	n servii	ng)				
	Never or less than once/month	1-3 per month	Once a week	2-4 per week	5-6 per week	Once a day	2-3 per day	4-5 per day	6+ day		Never or less than once/month	1-3 per month	Once a week	2-4 per week	5-6 per week	Once a day	2-3 per day	4-5 per day	6+ day

0 0 0 0 0 0 0 0

SV db4x12m7U8hsTPv&ContextLibrarvID+UR_cXReg9oQKCWvXpz Page 11 of 32

mashed, instant or

https://herts.au.gualtrics.com/Q/EditSi

0 0 0 0 0 0 0 0

0 0 0 0 0 0 0

Qualifics Survey Software								15/05	N2020, 06 :37
Brown bread and rolls	0	0	0	0	0	0	0	0	0
Wholemeal bread and rolls	0	0	0	0	0	0	0	0	0
Cream crackers, cheese biscuits	0	0	0	0	0	0	0	0	0
Crisp bread, eg. Ryvita	0	0	0	0	0	0	0	0	0
CEREALS (one bowl)								
	Never or less than once/month	1-3 per month	Once a week	2-4 per week	5-6 per week	Once a day	2-3 per day	4-5 per day	6+ day

0 0 0 0 0 0 0 0

ajas/GetSu..urveyiD+SV_db4x1Zm7UihsTPv&Com

textLibreryID=UR_cXReg9gQKCWvXpz Page 13 of 32

(one slice or biscuit) White bread and rolls	month		week	week	week	-	day	day	da
BREAD OR SAVOURY BISCUITS	Never or less than once a	1-3 per month	a	2-4 per	5-6 per	Once a day	2-3 per	4-5 per	6+ pe

https://heits.sw.qualtrics.com/QrZditSectlon/Blocks/Ajax/GetSur..srveyID+SV_db4x12m/UibaTP+&ContextLibraryID+UR_cXReg/8gQNCWvXpz Page 6 of 32

EXAMPLES

Qualifics Survey Software

paté, liver sausage

Fried fish in batter, as in fish and chips

White bread and rolls

0

0

0

YOUR DIET LAST YEAR For each food there is an amount shown, either a "medium serving" or a common household unit such as a slice or teaspoon. Please put choose the options which, on average, you have eaten the specified amount of each food during the past year.

FETA

Qualitics Survey Software

	Not at all	Several days	More than half the days	Nearly every day
Feeling nervous, anxious or on edge	0	0	0	0
Not being able to stop or control worrying	0	0	0	0
Worrying too much about different things	0	0	0	0
Trouble relaxing	0	0	0	0
Being so restless that it is hard to sit still	0	0	0	0
Becoming easily annoyed or irritable	0	0	0	0
Feeling afraid as if something awful might happen	0	0	0	0

	Never or less than once/month	1-3 per month	Once a week	2-4 per week	5-6 per week	Once a day	2-3 per day	4-5 per day	e d
Beef: roast steak mince, stew or casserole	0	0	0	0	0	0	0	0	(
Beefburgers	0	0	0	0	0	0	0	0	(
Pork: roast, chops, stew or slices	0	0	0	0	0	0	0	0	(
Lamb: roast, chops or stew	0	0	0	0	0	0	0	0	4
Chicken or other poultry eg. turkey	0	0	0	0	0	0	0	0	1
Bacon	0	0	0	0	0	0	0	0	1
Ham	0	0	0	0	0	0	0	0	
Corned beef, Spam, luncheon meats	0	0	0	0	0	0	0	0	
Sausages	0	0	0	0	0	0	0	0	
Savoury pies, eg. meat pie, pork pie, pasties, steak & kidney pie, sausage rolls	0	0	0	0	0	0	0	0	
Liver, liver									

MEAT AND FISH (medium serving)

15/09/2020, 06:37

18/09/2020, 06:37

Qualtrics Survey Software

15/09/2020, 05:37

Servey Souchain													0	0	0				0
tarts, crumbles, home	0	0	0	0	0	0	0	0	0	packet snacks, eg. Wotsits	0	0	0	U	0	0	0	0	0
baked Fruit pies,										Peanuts or other nuts	0	0	0	0	0	0	0	0	0
tarts, crumbles, ready made	0	0	0	0	0	0	0	0	0										
Sponge puddings,	0	0	0	0	0	0	0	0	0	SOUPS, SAU	CES, AND S	PREAD	S						
home baked	0	0	0	0	0	0	0	0	0		Never or less than once/month	1-3 per month	Once a week	2-4 per week	5-6 per week	Once a day	2-3 per day	4-5 per day	6- da
Sponge puddings, ready made	0	0	0	0	0	0	0	0	0	Vegetable soups (bowl)	0	0	0	0	0	0	0	0	C
Milk puddings, eg. rice, custard,	0	0	0	0	0	0	0	0	0	Meat soups (bowl)	0	0	0	0	0	0	0	0	C
trifle Ice cream,	0	0	0	0	0	0	0	0	0	Sauces, eg. white sauce,	-	0	0	0	0	0	0	0	-
choc ices Chocolates, single or	0	0	0	0	0	0	0	0	0	cheese sauce, gravy (tablespoon)	0	0	0	0	0	0	0	0	0
squares Chocolate										Tomato	0	0	0	0	0	0	0	0	C
snack bars eg. Mars, Crunchie	0	0	0	0	0	0	0	0	0	(tablespoon) Pickles,									
Sweets, toffees, mints	0	0	0	0	0	0	0	0	0	chutney (tablespoon)	0	0	0	0	0	0	0	0	(
Sugar added to										Marmite, Bovril (teaspoon)	0	0	0	0	0	0	0	0	(
tea, coffee, cereal (teaspoon)	0	0	0	0	0	0	0	0	0	Jam, marmalade, honey (teaspoon)	0	0	0	0	0	0	0	0	(
Crisps or other	Section/Blocks/Ajav/Get	SuurveyID=S	v_db4x1Zm7U	ihsTP+&Coni	textLibraryiD	-UR_cXRegi	на СКСЧУХ		ege 17 of 32 2020, 06:37	Peanut https://heris.eu.gualhics.com/Offici Gaathics.Burvey Schaare	ir Section/Blocks/Alex/Ge	nSu .urveyiD+	SV_db4x12m7	tUihsT₽v&C0	ntextLibraryil	D-UA_cXReg	9gDKCW/X	pz P	ige 1/
other	Section/Nocks/Ajav/Get	Su. urveyID=5	v, db4x12m7U	hhaTP+&Cont	lentübrary®	.UR_EXRegi	o O			inter (thems an qualifics convOrGe	ii Section/Biocks/Alax/Ge	rtSu . υπνεγίΟ+	SV_db4x1Zm7	ruihaTPv&Co	ntextLibraryi	D-UA_cXReg	880KCM+X		
other Intereu quatrics com/Q/Edd Survey Software butter								15/09/	2020, 06:37	Attenders an examine convolution Guatrics Survey Schware Vodka (single) Low calorie or diet fizzy soft drinks	esection/Bincks/Alax/G	rtsu .uvery10+	SV_db4st2m7	ULHSTPV&CO	ntextLibrary4	D=UR_cXReg	eeckcw+x		2070,
ather Inter availities eenvaltete Servey Sethere butter (teaspoon)							0	15/09/	6	Attenders Burry Schwart Vodka (single) Low calorie or diet fizzy soft drinks (glass) Fizzy soft drinks, eg. Coca cola, lemonade								15/09/	2070.
ather Inter availities eenvaltete Servey Sethere butter (teaspoon)	O Never or less than	0 1-3 per	O Once a	0 2-4 per	0 5-6 per	Once	0 2-3 per	4-5 per	6	Anter churn an eachtics controller Gashres Burry Milhaut Vodka (single) Low calorie or diet fizzy soft drinks (glass) Fizzy soft drinks, eg. Coca cola, lemonade (glass)	0	0	0	0	0	0	0	15/09/	2070
other atten and resolutions revolution butter (teaspoon) DRINKS Tea (cup) Coltee, Instant or	Never or less than once/month	O 1-3 per month	O Once a week	O 2-4 per week	O 5-6 per week	Once a day	O 2-3 per day	4-55 per day	2020, 04-37 O 6 7 d:	Attenders Burry Schwart Vodka (single) Low calorie or diet fizzy soft drinks (glass) Fizzy soft drinks, eg. Coca cola, lemonade	0	0	0	0	0	0	0	15/09/	2070
other strup selfnere butter (teaspoon) DRINKS Tea (cup) Coltee, Instant or ground (cup) Coffee, decaffeinated	Never or less than once/month	0 1-3 per month	Once a week	O 2-4 per week	5-6 per week	Once a day	O 2-3 per day	4-5 per day	6 C	Attention an example convolution Quarters Burvey Selfname Vodika (single) Low calorie or diet fizzy soft drinks (glass) Fizzy soft drinks, eg. Coca cola, lemonade (glass) Pure fruit	0	0	0	0	0	0	0	15/09/	2070.
ather serves setter butter (teaspoon) DRINKS Tea (cup) Coftee, instant or ground (cup) Coffee, decaffeinated (cup)	Newer or less than once/month	1-3 per month O	Once a week	2-4 per week	5-6 per week	Once a day	O 2-33 per day	4-5 per day	6 di (Autors lower behave Countries lower behave Vodika (single) Low calorie or diet fizzy soft drinks (glass) Fizzy soft drinks, eg. Coca cola, lemonade (glass) Pure fruit juice (100%) eg. orange, apple juice (glass) Fruit squash	0	0	0	0	0	0	0	15,06/	2020
other strup selfnere butter (teaspoon) DRINKS Tea (cup) Coltee, Instant or ground (cup) Coffee, decaffeinated	Newer or less than once/month	1-3 per month O	Once a week	2-4 per week	5-6 per week	Once a day	O 2-33 per day	4-5 per day	6 6 6 (Anter churn an eachirte convolution Geathers Burry Milhaut Vodka (single) Low calorie or diet fizzy soft drinks (glass) Fizzy soft drinks, eg. Coca cola, lemonade (glass) Pure fruit juice (100%) eg. orange, apple juice (glass) Fruit squash	0 0 0	0	0 0 0	0 0 0	0	0	0	0	2020.
ather atten available seevalties servey setterer butter (teaspoon) DRINKS Tea (cup) Coltee, Instant or ground (cup) Coffee, decaffeinated (cup) Coffee whitener, eg. Coffee	Never or less than once/month O	1-3 per month O	Once a week	2-4 per week	S-6 per week	Once a day O	 2-3 per day 0 0 	4-5 per day	6 6 6 (Autoritation an examinist convolution Quanticat Survey Schwart Vodika (single) Low calorie or diet fizzy soft drinks (glass) Fizzy soft drinks, eg. Coca cola, lemonade (glass) Pure fruit juice (100%) eg. orange, apple juice (glass) Fruit squash or cordial (glass) FRUIT For seasonal fi	O O O O Inuits marked		0 0 0 0		0 0 0 0 0	000000		15/09/ 0 0	2070
ather attenueutinas seev@tide servey setterer butter (teaspoon) DRINKS Tea (cup) Coltee, Instant or ground (cup) Coffee, decaffeinated (cup) Coffee, whitener, eg. Coffee teaspoon) Cocoa, hot chocolate	Newer or less than once/month O	O 1-3 per month O O O	Once a week	C 2-4 per wreek	S-6 per week	Oncee a day O	 2-3 per day 0 0 0 0 	4-5 per day	100, 04.37 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0	Attention an example convolution Quarters Burvey Methods Vodika (single) Low calorie or diet fizzy soft drinks (glass) Fizzy soft drinks, eg. Coca cola, lermonade (glass) Pure fruit juice (100%) eg. orange, apple juice (glass) Fruit squash or cordial (glass)	O O O fruits marked on Never or	0 0 0 0 0 0	O O O O See estin	0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	O O O O rage u:	0 0 0 0 0 0 0 0 0 0 0 0 0	15,000/ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	3
ather attenuestings reevolution servey software butter (teaspoon) DRINKS Tea (cup) Coltee, Instant or ground (cup) Coffee, decaffeinated (cup) Coffee, offee, eg. Coffee, eg. Coffee, eg. Coffee, eg. Coffee whitener, eg. Coffee, hot chacolate (cup) Hodicks, Ovaltine	Never or less than once/month O	1-3 per month 0 0 0	Once a week O O O	C 2-4 per week C C	0 5-6 per week 0 0 0	Once a day O	 2-3 per day 0 0 0 0 0 0 0 	4-55 per day	6 6 ((((Autoritation an examinist convolution Quanticat Survey Schwart Vodika (single) Low calorie or diet fizzy soft drinks (glass) Fizzy soft drinks, eg. Coca cola, lemonade (glass) Pure fruit juice (100%) eg. orange, apple juice (glass) Fruit squash or cordial (glass) FRUIT For seasonal fi	O O O O fruits marked on	0 0 0 0	O O O Sse estin	O O O nate yc 2-4 per	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Oncea	O O O O Sse what	15/09/	2010
ather attention and the second of the serves settines teaspoon) DRINKS DRINKS Coltees Instant or ground (cup) Coffee, whitener, eg., Coffee, whitener, eg., Coffee, (cup) Core, Coffee, whitener, eg., Coffee, (cup) Core, Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Core, Coffee, (cup) Core, Coffee, (cup) Core, Coffee, (cup) Core, Core, Coffee, (cup) Core, Coffee, (cup) Core, C	Never or less than once/month	1-3 per month 0 0	Once a week	O 2-4 per wreek O O O O	0 5-6 per week 0 0 0	Oncea day O	0 9 2-3 per day 0 0 0	4-55 per day	800, 64.37 0 6 6 (((((((((((((Anter church an examinist convolution Quarticits Burvey Mathemate Vordika (single) Low calorite or diet fizzy soft drinks, eg. Coca cola, lemonade (glass) Pure fruit juice (100%) eg. orange, apple juice (glass) Fruit squash or cordial (glass) FRUIT For seasonal fi fruit is in seasonal	fults marked on Never or less than once/month	O O O O O O O O O O O O O O O O O O O	C C C C C C C C C C C C C C C C C C C	C C C C C C C C C C C C C C C C C C C	O O O O O O O O O O O O O O O O O O O	o rage u: day	Se who	1540997	30000
ather attention and the second of the transport of the second of the transport of the second of the asymptotic of the second of the colores, instant or ground (cup) Coltes, instant or ground (cup) Coffse, whitener, eg., Coffse, whitener, eg., Coffse, whitener, eg., teaspoon) Cocos, hot checolate (cup) Wine (glass) Beer, lager or cider (half pint)	Never or less than once/month O	O 1-3 per month O O O O O O O O O O O O O	Once aweek O O O	2-4 per week 0 0 0	0 5-6 per week 0 0 0	Once a day O O O O O O O O	0 2.3 pertoday 0 0 0 0 0 0 0 0 0 0 0 0 0	4-5- per day 0	800, 64.37 0 6 6 (((((((((((((Ange divers an examine convolution Quarters Survey Sufficient Vordika (single) Low calorie or diet fizzy soft drinks (glass) Fizzy soft drinks, eg. Coca cola, lemonade (glass) Pure fruit ice (100%) eg. orange, apple juice (glass) FRUIT For seasonal fi fruit is in seasonal Apples (1 fruit) Pears (1 fruit)	o o fruits marked on Never or less than once/month	O O O O O O O O O O O O O O O O O O O	O O O See estin See estin	O O O O O O O O O O O O O O O O O O O	O O O O O O O O O O O O O O O O O O O	Concession of the second secon	O O O O Se wh	15400V	3
ather attention and the second of the serves settines teaspoon) DRINKS DRINKS Coltees Instant or ground (cup) Coffee, whitener, eg., Coffee, whitener, eg., Coffee, (cup) Core, Coffee, whitener, eg., Coffee, (cup) Core, Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Coffee, (cup) Core, Coffee, (cup) Core, Coffee, (cup) Core, Coffee, (cup) Core, Core, Coffee, (cup) Core, Coffee, (cup) Core, C	Never or less than once/month O	O 1-3 per month O O O O O O O O O O O O O	Once aweek O O O	2-4 per week 0 0 0	0 5-6 per week 0 0 0	Once a day O O O O O O O O	0 2.3 pertoday 0 0 0 0 0 0 0 0 0 0 0 0 0	4-5- per day 0	6 6 7 7 di (((((((((((((((((((Anges divers an examines convolution Quarters Survey Sufficient Vordika (single) Low calorie or diet fizzy soft drinks (glass) Fizzy soft drinks, eg. Coca cola, lemonade (glass) Pure fruit juice (100%) eg. orange, apple juice (glass) FRUIT For seasonal fi fruit is in seasonal Apples (1 fruit)	fults marked on Never or less than once/month	O O O O O O O O O O O O O O O O O O O	C C C C C C C C C C C C C C C C C C C	C C C C C C C C C C C C C C C C C C C	O O O O O O O O O O O O O O O O O O O	o rage u: day	Se who	1540997	3

Qualtrics Survey Software

16/09/2020, 06:37

Qualitrica Servey Software								15/09	2020, 06:37	Qualities Survey Software								15/09/	2020, 06:37
jacket potatoes										yogurt, fromage frais (125g	0	0	0	0	0	0	0	0	0
Chips	0	0	0	0	0	0	0	0	0	carton)									
Roast potatoes	0	0	0	0	0	0	0	0	0	Full fat or Greek yogurt	0	0	0	0	0	0	0	0	0
Potato salad	0	0	0	0	0	0	0	0	0	(125g carton)									
White rice	0	0	0	0	0	0	0	0	0	Dairy desserts	0	0	0	0	0	0	0	0	0
Brown rice	0	0	0	0	0	0	0	0	0	(125g carton)	0	0	0	0	0	0	0	0	0
White or green pasta, eg. spaghetti, macaroni, noodles	0	0	0	0	0	0	0	0	0	Cheese, eg. Cheddar, Brie, Edam (medium serving)	0	0	0	0	0	0	0	0	0
Wholemeal pasta	0	0	0	0	0	0	0	0	0	Cottage cheese, low fat soft	0	0	0	0	0	0	0	0	0
Lasagne, moussaka	0	0	0	0	0	0	0	0	0	cheese (medium serving)	0	0	0	0		0	U	0	0
Pizza	0	0	0	0	0	0	0	0	0	Eggs as boiled, fried, scrambled, etc. (one)	0	0	0	0	0	0	0	0	0
DAIRY PROD	UCTS AND	FAIS																	
	Never or less than once/month	1-3 per month	Once a week	2-4 per week	5-6 per week	Once a day	2-3 per day	4-5 per day	6+ day	Quiche (medium serving)	0	0	0	0	0	0	0	0	0
Single or sour cream (tablespoon)	O	0	0	0	0	0	0	0	0	Low calorie, low fat salad cream (tablespoon)	0	0	0	0	0	0	0	0	0
Double or clotted cream (tablespoon)	0	0	0	0	0	0	0	0	0	Salad cream, mayonnaise (tablespoon)	0	0	0	0	0	0	0	0	0
Low fat										French									
https://herts.eu.qualitries.com/Q/Ke	litSection/Blocks)Ajax/G	etSuurveyiD	- \$v_db4x1Zm	7UèsTPvàCo	nətexti. Əbrəryil	OaUW_CXR+	yegQKCWv	Xpz P	rage 13 of 32	https://werts.eu.qualtrics.com/G/E	dilSection/Block1/Ajax/6	ietSu…urveyID:	SV_db4x1Zm	1UihsTPv₿Co	steatiLibraryi	0+UR_cXRegi	900KCM/X		rge 14 of 32
Qualtrics Survey Software								15/09	/2020, 66 37	Qualizics Survey Software								15/09/	2020, 06:37
dressing (tablespoon)	0	0	0	0	0	0	0	0	0	teaspoon)									
Other salad dressing (tablespoon)	0	0	0	0	0	0	0	0	0	SWEETS AN	D SNACKS (medium	ı servin	g)					
The following	on bread or	vegetab	oles								Never or less than once/month	1-3 per month	Once a week	2-4 per week	5-6 per week	Once a day	2-3 per day	4-5 per day	6+ day
										Curant									

he following on	bread or veg	etables								once/month	month	week	week	week	day	day	day	da
Butter	Never or less than once/month	1-3 per month	Once a week	2-4 per week	5-6 per week	Once a day	2-3 per day	4-5 per day	Sweet biscuits, chocolate eg. digestive (one)	0	0	0	0	0	0	0	0	(
easpoon)	0	0	0	0	0	0	0	0	Sweet									
llock or hard hargarine, eg. tork, Krona easpoon)	0	0	0	0	0	0	0	0	biscuits plain eg. Nice, ginger (one)	0	0	0	0	0	0	0	0	
olyunsaturated hargarine, eg. lora, unflower, soya preads	0	0	0	0	0	0	0	0	Cakes eg. fruit, sponge, home baked	0	0	0	0	0	0	0	0	1
easpoon) oft argarines, cluding olive									Cakes eg. fruit, sponge, ready made	0	0	0	0	0	0	0	0	
l based and airy spreads, g. Blue Band, ivio/ Bertolli, lover easpoon)	0	0	0	0	0	0	0	0	Buns, pastries eg. scones, flapjacks, home baked	0	0	0	0	0	0	0	0	
ow fat spreads ess than 60% t), eg. Outline, old (teaspoon)	0	0	0	0	0	0	0	0	Buns, pastries eg. croissants, doughnuts, ready made	0	0	0	0	0	0	0	0	
'ery low fat pread (less han 30% fat)	0	0	0	0	0	0	0	0	Fruit pies,									

https

If YES, please list	below	
Food	Number of times eaten/week	Usual Serving Size
Food	Number of times eaten/week	Usual Serving Size
Food	Number of times eaten/week	Usual Serving Size
Food	Number of times	Usual Serving Size

1 +

Are there any OTHER foods which you ate more than once a week?

YOUR DIET LAST YEAR, continued

FETA 2

0

Carrots

Spinach Broccoli, spring

https://herts.eu.quaf

iltnas Survey Software

Beetroot

Coleslaw 0 0 0 0 0 0 0 0 Avocado 0 0 0 0 0 0 0 Baked beans 0 Dried lentils, beans, peas 0 0 0 0 0 0 0 0 0 Tofu, soya meat, TVP, Vegeburger 0 0 0 0 0 0 0 0 0

0 0 0 0 0 0 0 0 0

0 0 0

CWVXex Page 21 of 32

15/09/2020, 06:37

0 0 0 0

A STATE OF A STATE

+ +

Qualtrice Survey Software

Food

0 What type of milk did you most often use?

Please describe which milk you use most often

1 *

mentioned earlier)? 1-+

you usually eat?

Number of times eaten/week

0

ualarics.com/QrEduSection/Blocks/Ajax/GetSu..rvey/D+SV_SD4x12m/UlhtTPv&ContextLibraryID+UR_cXReg0gQKGW/Xoz Page 22 of 32

15/09/2020, 06:37

0 0

Fresh, frozen or tinned (medium serving) Never or less than once/month 1-3 Once 2-4 5-6 Once 2-3 4-5 per a per per a per per 64 month week week week day day day da

0

0

Qualifics Survey Software Bananas (1 fruit)

in any									
Grapes (medium serving)	0	0	0	0	0	0	0	0	C
Melon (1 slice)	0	0	0	0	0	0	0	0	C
* Peaches, plums, apricots (1 fruit)	0	0	0	0	0	0	0	0	C
• Strawberries, raspberries, kiwi fruit (medium serving)	0	0	0	0	0	0	0	0	C
Tinned fruit (medium serving)	0	0	0	0	0	0	0	0	(
Dried fruit, eg. raisins, prunes (medium serving)	0	0	0	0	0	0	0	0	C

0 0 0 0 0 0 0 0

greens, kale									
Brussels sprouts	0	0	0	0	0	0	0	0	С
Cabbage	0	0	0	0	0	0	0	0	С
Peas	0	0	0	0	0	0	0	0	С
Green beans, broad beans, runner beans	0	0	0	0	0	0	0	0	С
Marrow, courgettes	0	0	0	0	0	0	0	0	С
Cauliflower	0	0	0	0	0	0	0	0	C
Parsnips, turnips, swedes	0	0	0	0	0	0	0	0	С
Leeks	0	0	0	0	0	0	0	0	С
Onions	0	0	0	0	0	0	0	0	C
Garlic	0	0	0	0	0	0	0	0	С
Mushrooms	0	0	0	0	0	0	0	0	C
Sweet peppers	0	0	0	0	0	0	0	0	С
Beansprouts	0	0	0	0	0	0	0	0	C
Green salad, lettuce, cucumber, celery	0	0	0	0	0	0	0	0	С
Watercress	0	0	0	0	0	0	0	0	C
Tomatoes	0	0	0	0	0	0	0	0	C
Sweetcorn	0	0	0	0	0	0	0	0	C

0	0	eaten/week	0	5 I	
Food	0	Number of times eaten/week	O	al Serving Size	

How much milk did you drink each day, including milk with tea, coffee, cereals etc?

Did you usually eat breakfast cereal (excluding porridge and Ready Brek

If YES, which brand and type of breakfast cereal, including muesli, did

ocks/Ajax/GetSu _rvey/D=SV_db4s12m7UihsTPv&ContextLibraty/D+UR_cXReg9gOKCWvXsz Page 24 of 32

Usual Serving Size

15/09/2020, 08:37

Qualitrics Survey Software

15/09/2020, 06:37

https://betts.eu.qualtrice.com/QrEditSectlor/Blocks/Ajax/OetSu..rvey/D+SV_db4st2m2UiketPv&ContastLibraryID+UR_cXRegBpQKCWvXoz Page 25 of 32 https://herts.wu.duabrics.com/Q/EdiSection/Biocks/Ajax/GetSu.rveyID=SV_EbiAt2m7U/httPv&ContextLibraryID=UR_cXRepBpOKGWrXpz Page 28 of 32 Qualines Survey Software 15/09/2020, 08-37 Qualitics Survey Software during the Did you regularly use a salt substitute (egLoSalt)? past year? ++ 1 -If yes, which brand? If YES or SOMETIMES, please complete the tables below. If you have taken more than 8 types of supplement please put the most frequently consumed brands first. Example: If you take one tablet of vitamin C two times a day, please write '2' in the amount- column and cross the 'once a day' box. Most supplements mention a strength Average intakes value (in our example 500mg), please write this information in the table. Amount (Number of tablets, Strength (each tablet or capsule) 1 day) During the course of last year, on average, how many times a week did you eat the following foods? Brand Name Times/week 1 Vegetables (not including potatoes) - medium serving 2 3 Salads - medium serving 4 Fruit and fruit products (not including fruit juice) - medium serving or 1 fruit 5 Fish and fish products - medium serving 6 7 Meat, meat products and meat dishes (including bacon, ham and chicken) -medium serving 8 Average frequency for the past year Vitamins and Minerals INDICATE ONE box per line to show how often on average you took the amount consumed as mentioned in 'amount' column

How often did you eat food that was fried at home?

\$

If you used margarine, please give name or type eg. Flora, Stork

Have you taken any vitamins, minerals, fish oils, fibre or other food supplements

ncs.com/D/EditSection/Biocks/Alex/GetSu _rveviD=SV_db4x1Zm7UihsTPv&ContextUbraryiD=UR_cXReg9gQKCWvXpz Page 27 of 32

1 -1

1

What kind of fat did you most often use for baking cakes etc?

If you used vegetable oil, please give type eg. corn, sunflower

t -

What kind of fat did you most often use for frying, roasting, grilling etc?

O Type

O Type

FETA Fats and Frying

Qualines Survey Software

O Brand O Brand

ŧ 1

How often did you eat food away from home?

15/09/2020, 06:37

How often did you add salt to food while cooking?

÷

+

Salt

t

Qualitics Survey Software

15/09/2020, 08 37

1 4

How well cooked did you usually have grilled or roast meat?

How often did you add salt to any food at the table?

https://berts.eu.gualtrics.com/Q/EditSection/BiocksiAjaxiGetSu_rveyIDeSV_db4x1Zm7UihsTPv&CentextLibraryID=UR_cXReg9gQKCWvXpz Page 28 of 32

How often did you eat grilled or roast meat? (times a week)

+ +

What did you do with the visible fat on your meat?

15/09/2020, 06:37

Incs Survey Software											15/09/2020, 66:37	Qualitrics Survey Softwa	1.0										15/09/2020, 0
	Nevi or le											D											
	thar once mon	n Da	1-3 mor	per hth	Once wee	e a k	2-4 pe week	r 5	-6 per week	O	nce a Jay	E											
1	0		C)	0		0		0		0												
2	0	(C)	0		0		0		0	Milest po		monto un	*** ***	on fron	o diat		odifie	otion	~?		
3	0		C)	0		0		0		0	what pa	in improve	ments w	re se	entron	diet	ary m	lounic	auon	51		
4	0		C)	0		0		0		0		Very Much	Much	м	nimally	D	lo	Minin	nally	Much		Very Much
5	0		C)	0		0		0		0		Improved	Improve		proved	Cha		Wor	rse	Worse		Vorse
6	0		C)	0		0		0		0	A	0	0		0	(C	C)	0		0
7	0		C)	0		0		0	1	0	В	0	0		0	(C	C)	0		0
8	0		C)	0		0		0	2	0	С	0	0		0	(C	C)	0		0
												D	0	0		0	(C	C)	0		0
Distancionant	an nain											E	0	0		0	(C	C)	0		0
Dietary impact	on pain											F	0	0		0	(C	C)	0		0
Have you made	any dieta	ry ch	nange	es to i	impad	ct you	ir pain	leve	ls?			Refere th	ne dietary o	honocof		sh itom	how	would	duqu	done	iho ua		vorall
O Yes												levels of		nanges i	n ea	an itern	now	woun	u you	uesci	ine ao	ur o	verall
O No														0 1	2	3	4	5	6	7	8	9	10
												А											
Have you remove	ed or adde	ed a	ny ite	erns to	o you	r diet	?					в											
		F	Food	type			A	dded	/Remo	bwed		С											
A												D											
в												E			-								
в	etion/Blocks/Aiss/	(GetSu	rveyiD=t	Sv_db4x12	tm7UihaT	Py&Conte	etLibe arys	9+UR_cXI	teg5gQKC	WiXpz	Page 19 of 32	E	som√QrEditSection										
B C	ction/Blocks/Alex/	(GetSu	rveyiD∞t	Sv_db4x12	Em7 LiiksT	P+8Conte	atil de aryof	5+UR_c20	teg5gQKC		Page 28 of 32	E F										wvXez	Page 30 c
B C //write we qualifiest constrained in the res Survey Sufficience After changing sys	our diet for										6,009/2020, 66 37	E F Milips (Mette ex qualifier Goulines Burry Britiser What sour	* ces did you	Nijorita,Adax/Ge	l C) D	Contraction of the second seco	PubConte				wvXez	Page 30 ·
B C C tes survey settionre	our diet for										6,009/2020, 66 37	E F billpt://brits.ex.qualifics Coubies: Burry Estimat What sour	• ces did you al Media	USe to ma	l C) D	Contraction of the second seco	PubConte				wvXez	Page 30 c
B C //write we qualifiest constrained in the res Survey Sufficience After changing sys	our diet for Dain										6,009/2020, 66 37	E F billpt://brits.ex.qualifics Coubies: Burry Estimat What sour	• ces did you al Media ical Professi	USe to ma	l C) D	Contraction of the second seco	PubConte				wvXez	Page 30 ·
B C //write we qualifiest constrained in the res Survey Sufficience After changing sys	our diet for oain 0	r eac	ch of	the al	bove	items	: how	would	<u>i desc</u>	cribe	9.09/2026, 68 37 <u>YOUF</u>	E F Natura (Mette ex qualified Ovaliests Revery Ballware What sour - Soci - Diebi - Diebi	• ces did you al Media ical Professi iian d	USe to ma	l C) D	Contraction of the second seco	PubConte				wvXez	Page 30 ·
B C Varies on qualities constructions in a Soviety Settiment After, changing, ye overall levels, of p	our diet for pain 0	<u>r eac</u> 1	ch of	<u>the al</u> 3	bove 4	items 5	<u>how</u>	would 7	d desc 8	cribe 9	94,093,2028, 04 37 <u>YOUI</u> 10	E F billps://write as qualified Gouldees Borery Boffmar What sour - Soci - Medi - Diobli - Diobli - Frien - Supp	• al Media cal Professi lian d vort group	USe to ma	l C) D	Contraction of the second seco	PubConte				wvXez	Page 30 ·
B C C Marts are qualities constructions in a Soviety Settimene After, changeling, yyy overall levels, of p A	our diet for Dain 0 0	r eac 1 0	2 O	the al	bove 4	items 5 O	6 0	vouk 7 O	d desc 8 O	g O	Nonioni 2020, 64 37 Your 0	E F Natura (Mette ex qualified Ovaliests Revery Ballware What sour - Soci - Diebi - Diebi	• ces did you al Media ical Professi tian d cort group azine	USe to ma	l C) D	Contraction of the second seco	PubConte				wvXez	Page 30 ·
B C C Martin are qualities constructions ins Source Sufficience Affert changing us overall levels of r A B	our diet for pain 0 0 0	1 0	2 0	the all	4 O	5 O	6 0	7 0	8 0	g O	Novel2028. 64 97 VOULT	E F Subject, the expedition Coublect Browy Britner What sour - Soci - Mod - Diebi - Frien - Supp - Supp - Mage	• ces did you al Media ical Professi tian d cort group azine	USe to ma	l C) D	Contraction of the second seco	PubConte				wvXez	Page 30 ·
B C C Instruction qualities constructions instruction qualities constructions instruction qualities and the overall levels of p A B C	our diet for pain 0 0 0 0	1 0 0	2 0 0	3 O O	4 0 0	5 O O O	6 0 0	7 0 0	8 0 0	9 0 0	10 0	E F Coatnets is quartered What sour Particle Frien Supp Supp Supp Webs Webs	• ces did you al Media ical Professi tian d cort group azine	USe to ma	l C) D	Contraction of the second seco	PubConte				U vvXpz	
B C C Instruction qualities constructions res Sorvey Software Affer, changing, yr, overall levels of p A B C C D	our diet for pain 0 0 0 0	1 0 0 0	2 0 0 0	3 0 0 0	4 0 0 0	5 0 0 0	6 0 0	7 0 0 0	8 0 0	g O O O O		E F Output/Mats are qualified Output/Starsey Safeteer What sour - Soci - Oileti - Frien - Supp - Mag - Webs - Webs	• ces did you al Media ical Professi tian d cort group azine	use to ma	the rest	se dieta	contrulination	PrubConte	stLikranjO			U vvXpz	Page 30 c
B C C Instruction qualities constructions instruction of the second statement After changing yrs overall levels of r D E	our diet for pain 0 0 0 0 0	1 0 0 0 0	2 0 0 0 0	3 0 0 0 0	4 0 0 0	5 0 0 0	6 0 0 0 0	7 0 0 0 0	8 0 0 0 0	9 0 0 0	NOUT 10 0 0 0	E F Output/Mats are qualified Output/Starsey Safeteer What sour - Soci - Oileti - Frien - Supp - Mag - Webs - Webs	• al Media ical Professi lian d sort group zzine site	use to ma	the rest	se dieta	contrulination	PrubConte	stLikranjO			U vvXpz	Page 30 ·
B C C Inter Server Settlener After changing yy overall levels of p A B C D E F	our diel for pain 0 0 0 0 0	1 0 0 0 0	2 0 0 0 0	3 0 0 0 0	4 0 0 0	5 0 0 0	6 0 0 0 0	7 0 0 0 0	8 0 0 0 0	9 0 0 0	NOUT 10 0 0 0	E F Output/Mats are qualified Output/Starsey Safeteer What sour - Soci - Oileti - Frien - Supp - Mag - Webs - Webs	• al Media ical Professi lian d sort group zzine site	use to ma	the rest	se dieta	contrulination	PrubConte	stLikranjO			U vvXpz	Page 30 ·
B C C Inter Servery Settioner After: changing, sys overall levels of p A B C D E F How long after rm symptoms (if app	our diet for o o o o o o o o o o o o o o o o o o	1 0 0 0 0	2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	3 0 0 0 0	4 0 0 0 0	5 0 0 0	6 0 0 0 0 0 0	7 0 0 0 0	8 0 0 0 0 0 0 0	9 0 0 0	NOUT 10 0 0 0	E F Output/Mats are qualified Output/Starsey Safeteer What sour - Soci - Oileti - Frien - Supp - Mag - Webs - Webs	• al Media ical Professi lian d sort group zzine site	use to ma	the rest	se dieta	contrulination	PrubConte	stLikranjO			ther	Page 30 ·
B C C Institutes confluctions institutes confluctions Affer changing yr overall levels of r A B C D E F How long after m	our diet for o o o o o o o o o o o o o o o o o o		2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	3 0 0 0 0	4 0 0 0 0	5 0 0 0 0 0	6 0 0 0 0 0 0	7 0 0 0 0	8 0 0 0 0 0 0 0	9 0 0 0 0	NOUT 10 0 0 0	E F Coathres Barrey Bathan What sour - Socia - Medi - Diebli - Frien - Surgi - Swepe - Webe	• al Media ical Professi lian d sort group zzine site	use formation	ke the	se dieta	contrulination	PrubConte	stLikranjO			ther	Page 30 ·
B C C Inter Servery Settioner After: changing, sys overall levels of p A B C D E F How long after rm symptoms (if app	our diet for o o o o o o o o o o o o o o o o o o		2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	3 0 0 0 0	4 0 0 0 0	5 0 0 0 0 0	6 0 0 0 0 0 0	7 0 0 0 0	8 0 0 0 0 0 0 0	9 0 0 0 0	NOUT 10 0 0 0	E F Controls formy before What sour - Soci - Frien - Supp - Mage - Webs - Webs	es did you al Media ical Professi dian d port group azine site cult or easy cult or easy cult or easy	use to ma onal	ke the	se dieta	ry cho	I I I I I I I I I I I I I I I I I I I	ettikteranyi0		- O	ther	Pape 30 0

Impact of social media

s//herts su-qualitics:com/Qr(bitSection/Blocks/Ayas/GetSu..srveytDisSV_db4xtZm7UbtsTPv&ContextLibraryD+UB_cXReg8gDKCWvXpz Paga 31 of 32

E F

htt

Powered by Qualtrics

https://herts.Hu.gusftrics.com/Q/EditSection/Biocks/Ajac/GetSu ..rvey/D+SV/.cb4xt2m7U/hsTFv&ContextL/brary/D+UR_cxRegBgQKCWvXpz Page 32 of 32

A

Appendix B – Extract from The Fibromyalgia Magazine, with facebook group responses to dietary impact on fibromyalgia.

Which foods/drinks trigger your fibromyalgia? By Shel Bowden

We are often told that certain foods or drinks can make our Fibromyalgia worse so this month we asked our Facebook group members "Which foods/drinks trigger your fibromyalgia?" members were allowed to add their own options:

Aspartame (sweeteners)	64 votes
Refined Carbohydrates (white flour, white bread, white rice, pastries, biscuits etc)	56 votes
Alcohol	47 votes
Processed Foods	38 votes
Sugar	36 votes
Gluten	29 votes
Caffeine	23 votes
I don't know (member)	23 votes
Dairy	22 votes
Fizzy drinks	21 votes
Chocolate	18 votes
Red Meat	12 votes
Nightshade Vegetables (tomatoes, white potatoes, green peppers, goji berries)	9 votes
Eggs	6 votes
a variant of the above options (member)	5 votes
None (member)	4 votes
Energy drinks (Red Bull etc) (member)	3 votes
Bananas	1 votes

Most fibromyalgia diets recommend cutting out processed foods and sugars and increasing the number of vegetables and whole foods, doctors now seem to be recommending the FODMAP diet. But as each of us is very different what you need to do is work out which foods trigger you, a good way to do this is to keep a food and symptom diary which will help you see what foods you have eaten just before a flare in symptoms, this is best done over a long time as just because you had a take away one time and a flare in the next few days doesn't mean that, that takeaway was the trigger, but if you had the takeaway 3 or 4 times and had a flare after every time then you an definitely say that it is a trigger for you. It can be useful to add an activity part into your diary as sometimes an activity may be the trigger instead of food or drink.

Join us at:

https://www.facebook.com/groups/UKFibromyalgiaPrivate/

The Fibromyalgia Magazine. Year 19 Issue 8 June 2019 www.ukfibromyalgia.com